<?xml version="1.0" ?>
<document version="1.8" entity_encoding="single">
  <page number="1">
    <text>&lt;div align=&quot;center&quot;&gt;
&lt;h2&gt;HEAD &amp;amp; NECK CANCER:&lt;/h2&gt;
&lt;p&gt;THE PATIENT JOURNEY, MULTIDISCIPLINARY TEAM AND&lt;br&gt;MANAGING CHRONIC SIDE EFFECTS&lt;/p&gt;
&lt;/div&gt;

&lt;h3&gt;2026 DENT5311 DMD3&lt;/h3&gt;

&lt;h3&gt;Dr Jee-Yun Leung&lt;/h3&gt;

&lt;i&gt;BDSc(Hons) MSc(SCD) DSCD(RCSEng) DClinDent(SND) MRACDS(SND) FANZASND&lt;/i&gt;

Specialist in Special Needs Dentistry

Consultant, Maxillofacial &amp;amp; Dental Dept, Fiona Stanley Hospital

Senior Lecturer, The University of Western Australia</text>
    <formatted_text>2026 DENT5311 DMD3

**Dr Jee-Yun Leung**

*BDSc(Hons) MSc(SCD) DSCD(RCSEng) DClinDent(SND) MRACDS(SND) FANZASND*

- Specialist in Special Needs Dentistry
- Consultant, Maxillofacial &amp; Dental Dept, Fiona Stanley Hospital
- Senior Lecturer, The University of Western Australia</formatted_text>
  </page>
  <page number="2">
    <text>&lt;h2&gt;LECTURE OUTCOMES&lt;/h2&gt;

*   1. Outline cancer therapies and the interprofessional multidisciplinary team involved in providing management
*   2. Appreciate some of the surgical considerations for head and neck cancer resection and reconstruction
*   3. Describe the oral complications of head and neck cancer therapies and their management
*   4. Explain the importance of oral care for head and neck radiotherapy patients
*   5. Discuss the factors to be considered when performing a dental assessment for patients prior to commencing head and neck radiotherapy
*   6. Understand how treatment approaches may differ for palliative patients</text>
    <formatted_text>1. Outline cancer therapies and the interprofessional multidisciplinary team involved in providing management
2. Appreciate some of the surgical considerations for head and neck cancer resection and reconstruction
3. Describe the oral complications of head and neck cancer therapies and their management
4. Explain the importance of oral care for head and neck radiotherapy patients
5. Discuss the factors to be considered when performing a dental assessment for patients prior to commencing head and neck radiotherapy
6. Understand how treatment approaches may differ for palliative patients</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:05:24" confidence="8" anchor="6. Understand how treatment approaches may differ for palliative patients">

&gt; [!note] Lecturer — Patient Journey
&gt; The lecture focused on the practical, day-to-day patient journey through head and neck cancer care, particularly from a dental and multidisciplinary perspective.
&gt;
&gt; - The journey includes referral with suspected head and neck cancer and the role of the head and neck multidisciplinary team.
&gt; - Rehabilitation, chronic treatment effects and survivorship are important parts of care.
&gt; - There may be a substantial gap between a patient’s usual dental care and their return to general practice after cancer surgery or radiotherapy, when the oral cavity may have changed considerably.
</insert>
      <insert timestamp="00:03:47" confidence="14" anchor="6. Understand how treatment approaches may differ for palliative patients ## **G">
- ==Oral oncology guidelines from the Royal College of Surgeons of England==
- ==Restorative Dentistry UK guidelines, including input from affiliated associations==
- ==Joint guideline statements from the International Society of Oral Oncology, the Multinational Association for Supportive Care of Cancer and the American Society of Clinical Oncology==
- ==Guidance addressing oral care, dental management, mucositis, hypersalivation, osteoradionecrosis and other general problems in patients with advanced cancers==
- ==National Comprehensive Cancer Network guidelines for head and neck cancers, with the latest version referred to having been released in May 2016==</insert>
    </audio_inserts>
  </page>
  <page number="3">
    <text># GUIDELINES

![](W1 HNC Patient Journey_figures/img_8b908200672f1f7e.webp)
![](W1 HNC Patient Journey_figures/img_f962d85f9d8d1db2.webp)</text>
    <images>
      <img order="0" bbox="732,341,933,498" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="W1 HNC Patient Journey_figures/img_8b908200672f1f7e.webp">
        <description>No discernible content is present.</description>
      </img>
      <img order="1" bbox="616,811,651,834" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_f962d85f9d8d1db2.webp">
        <description>A QR code is displayed next to the text 'View Online Article', providing a scannable link to access the digital version of the content.</description>
      </img>
    </images>
  </page>
  <page number="4">
    <text># THE HEAD AND NECK CANCER PATIENT JOURNEY

```mermaid
flowchart LR
    A[Diagnosis] --&gt; B[&quot;H&amp;N MDT&lt;br&gt;Meeting&lt;br&gt;Discussion&quot;]
    B --&gt; C[&quot;Work-up to&lt;br&gt;Cancer&lt;br&gt;Treatment&quot;]
    C --&gt; D[Surgery]
    D --&gt; E[&quot;H&amp;N MDT&lt;br&gt;Meeting&lt;br&gt;Rediscussion&quot;]
    E --&gt; F[&quot;Radiotherapy&lt;br&gt;+/-&lt;br&gt;Chemotherapy&quot;]
    F --&gt; G[Rehabilitation]
    G --&gt; H[&quot;Chronic side&lt;br&gt;effects and&lt;br&gt;survivorship&quot;]
```</text>
    <formatted_text>Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery → H&amp;N MDT Meeting Rediscussion → Radiotherapy +/- Chemotherapy → Rehabilitation → Chronic side effects and survivorship</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:05:24" confidence="5" anchor="Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery →">

&gt; [!note] Lecturer — Long-Term Care
&gt; The patient journey also includes referral, immunotherapy in some cases, and long-term surveillance. Management of chronic side effects and survivorship care continue after rehabilitation.
</insert>
    </audio_inserts>
  </page>
  <page number="5">
    <text>WHAT ARE THE SIGNS &amp; SYMPTOMS THAT
ARE SUSPICIOUS FOR H&amp;N CANCER?

**Duration for longer than 2-3 weeks:**

*   Persistent &lt;u&gt;sore throat&lt;/u&gt;
*   &lt;u&gt;Foul breath&lt;/u&gt; unexplained by hygiene
*   &lt;u&gt;Hoarseness&lt;/u&gt; and changes in voice
*   &lt;u&gt;Swelling&lt;/u&gt; in throat
*   Persistent &lt;u&gt;ear ache&lt;/u&gt; and constant pain
*   Lump, bump or mass in the &lt;u&gt;neck&lt;/u&gt; without pain

*   &lt;u&gt;White or red patch&lt;/u&gt; in the mouth
*   Persistent &lt;u&gt;nasal&lt;/u&gt; obstruction or congestion
*   &lt;u&gt;Blocked nose on one side or bloody discharge&lt;/u&gt; from nose
*   Difficulty &lt;u&gt;swallowing&lt;/u&gt; (dysphagia)
*   Trouble &lt;u&gt;breathing&lt;/u&gt;
*   Unexplained &lt;u&gt;facial palsy&lt;/u&gt;, weakness or severe &lt;u&gt;facial pain/numbness&lt;/u&gt;</text>
    <formatted_text>Duration for longer than 2-3 weeks:

- Persistent sore throat
- Foul breath unexplained by hygiene
- Hoarseness and changes in voice
- Swelling in throat
- Persistent ear ache and constant pain
- Lump, bump or mass in the neck without pain
- White or red patch in the mouth
- Persistent nasal obstruction or congestion
- Blocked nose on one side or bloody discharge from nose
- Difficulty swallowing (dysphagia)
- Trouble breathing
- Unexplained facial palsy, weakness or severe facial pain/numbness</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:05:40" confidence="8" anchor="Unexplained facial palsy, weakness or severe facial pain/numbness">

&gt; [!note] Lecturer — Delayed Diagnosis
&gt; Head and neck cancers may produce relatively subtle symptoms, particularly when lesions involve the pharynx or oropharyngeal regions. Diagnosis may therefore occur only once disease is advanced.
&gt;
&gt; - Dentists may be the first clinicians to identify a suspicious lesion, including one of which the patient is unaware.
&gt; - Earlier diagnosis was associated with a better course and prognosis.
</insert>
      <insert timestamp="00:06:23" confidence="2" anchor="Unexplained facial palsy, weakness or severe facial pain/numbness">
- ==Persistent ulcers==</insert>
      <insert timestamp="00:06:54" confidence="11" anchor="Unexplained facial palsy, weakness or severe facial pain/numbness">

&gt; [!note] Lecturer — Referral Threshold
&gt; Suspicious signs or symptoms that remain unresolved for longer than two weeks should be investigated or referred. These features also have differential diagnoses, including infection, benign conditions and other non-head-and-neck-cancer causes, which can contribute to delayed diagnosis.
</insert>
    </audio_inserts>
  </page>
  <page number="6">
    <text>ANATOMIC SITES AND SUBSITES

Nasal antrum

Oral cavity
Lip
Buccal mucosa
Alveolar ridge and retromolar trigone
Floor of mouth
Hard palate
Oral tongue (anterior two thirds)

Nasopharynx
Pharynx

Oropharynx
Base of tongue
Soft palate
Tonsillar pillar and fossa

Hypopharynx

Larynx
Supraglottis
False cords
Arytenoids
Epiglottis
Arytenoepiglottic fold
Glottis
Subglottis

Esophagus

NCCN version 2.2026 – National Comprehensive Cancer Network

![](W1 HNC Patient Journey_figures/img_8259d99e5a1429c4.webp)</text>
    <formatted_text>- Nasal antrum
- Oral cavity
  - Lip
  - Buccal mucosa
  - Alveolar ridge and retromolar trigone
  - Floor of mouth
  - Hard palate
  - Oral tongue (anterior two thirds)
- Nasopharynx
- Pharynx
  - Oropharynx
    - Base of tongue
    - Soft palate
    - Tonsillar pillar and fossa
  - Hypopharynx
- Larynx
  - Supraglottis
    - False cords
    - Arytenoids
    - Epiglottis
    - Arytenoepiglottic fold
  - Glottis
  - Subglottis
- Esophagus

*NCCN version 2.2026 – National Comprehensive Cancer Network*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:08:14" confidence="10" anchor="Esophagus  *NCCN version 2.2026 – National Comprehensive Cancer Network*">

&gt; [!note] Lecturer — Head and Neck Spread
&gt; Head and neck squamous cell carcinomas may spread by local invasion, regional lymphatic dissemination or vascular dissemination. They tend to metastasise to regional lymph nodes rather than primarily through the bloodstream; distant metastases usually occur later, with the lungs the most common distant site.
&gt;
&gt; - Metastasis to the liver without lung metastases was described as unusual for head and neck squamous cell carcinoma.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="328,297,679,791" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_8259d99e5a1429c4.webp">
        <description>A labelled schematic diagram of the head and neck in sagittal view illustrating anatomic sites and subsites. The figure identifies regions including the nasal antrum, oral cavity (with lip, buccal mucosa, alveolar ridge, floor of mouth, hard palate, and tongue), pharynx (nasopharynx, oropharynx, hypopharynx), larynx (supraglottis, glottis, subglottis), and esophagus.</description>
      </img>
    </images>
  </page>
  <page number="7">
    <text>LEVEL DESIGNATION FOR CERVICAL LYMPHATICS

NCCN version 2.2026 – National Comprehensive Cancer Network

- use 1-2 kg of pressure when palpating

![](W1 HNC Patient Journey_figures/img_e5e7b0120ddb2ecc.webp)
![](W1 HNC Patient Journey_figures/img_f2216d53d3303374.webp)</text>
    <formatted_text>*NCCN version 2.2026 – National Comprehensive Cancer Network*

- Use 1-2 kg of pressure when palpating</formatted_text>
    <images>
      <img order="0" bbox="101,302,442,776" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_e5e7b0120ddb2ecc.webp">
        <description>A line drawing of a human head and neck in profile view, illustrating the anatomical boundaries of cervical lymph node levels. The image uses Roman numerals to designate specific regions: Level I is located under the chin/jaw area, Level II is positioned high in the neck near the angle of the jaw, Level III is situated lower on the side of the neck, Level IV is at the base of the neck near the collarbone, and Level V covers the posterior triangle of the neck.</description>
      </img>
      <img order="1" bbox="532,316,951,764" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_f2216d53d3303374.webp">
        <description>A reference table titled 'LEVEL DESIGNATION FOR CERVICAL LYMPHATICS' that categorizes lymph node levels I through VI. The columns define each level's anatomical location, specific anatomic borders, and the common primary tumor sites that metastasize to that region.</description>
      </img>
    </images>
  </page>
  <page number="8">
    <text>LEVEL DESIGNATION FOR CERVICAL LYMPHATICS

Fixation
Enlargement
Unilateral
Tenderness

NCCN version 2.2026 – National Comprehensive Cancer Network

![](W1 HNC Patient Journey_figures/img_18b004c24e003e0c.webp)</text>
    <formatted_text>- Fixation
- Enlargement
- Unilateral
- Tenderness

*NCCN version 2.2026 – National Comprehensive Cancer Network*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:09:40" confidence="7" anchor="Tenderness  *NCCN version 2.2026 – National Comprehensive Cancer Network*">

&gt; [!note] Lecturer — Cervical Node Examination
&gt; Concerning cervical lymph node features include hard consistency and enlargement greater than approximately 1 to 1.5 cm. Firm palpation is important because lightly touching or “bottle” palpation may not provide sufficient information; approximately 1 to 2 kg of pressure was described, with the node palpated against the underlying structure.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="104,310,441,775" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_18b004c24e003e0c.webp">
        <description>Anatomical line drawing of the lateral neck showing the cervical lymph node levels, with regions marked by Roman numerals I through V.</description>
      </img>
    </images>
  </page>
  <page number="9">
    <text>&lt;TABLE&gt;&lt;table&gt; &lt;tbody&gt; &lt;tr&gt; &lt;th colspan=&quot;2&quot;&gt; Primary tumour size (T) &lt;/th&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; Tx &lt;/td&gt; &lt;td&gt; No available information &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; T0 &lt;/td&gt; &lt;td&gt; No evidence of primary tumour &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; T1 &lt;/td&gt; &lt;td&gt; &amp;lt;2cm &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; T2 &lt;/td&gt; &lt;td&gt; 2-4cm &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; T3 &lt;/td&gt; &lt;td&gt; &amp;gt;4cm &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; T4 &lt;/td&gt; &lt;td&gt; Invades adjacent structures &lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;

&lt;table&gt;
 &lt;thead&gt; &lt;tr&gt; &lt;th colspan=&quot;2&quot;&gt; Regional lymph node involvement (N) &lt;/th&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr&gt; &lt;td&gt; Nx &lt;/td&gt; &lt;td&gt; Nodes cannot be / were not assessed &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; N0 &lt;/td&gt; &lt;td&gt; No regional nodes involved &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; N1 &lt;/td&gt; &lt;td&gt; Ipsilateral single node &amp;lt;3cm diameter &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; N2a &lt;/td&gt; &lt;td&gt; Ipsilateral single node 3-6cm &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; N2b &lt;/td&gt; &lt;td&gt; Ipsilateral multiple nodes &amp;lt;6cm &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; N2c &lt;/td&gt; &lt;td&gt; Bilateral or contralateral nodes &amp;lt;6cm &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; N3 &lt;/td&gt; &lt;td&gt; Any node &amp;gt;6cm &lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;

&lt;table&gt; &lt;tbody&gt; &lt;tr&gt; &lt;th colspan=&quot;2&quot;&gt; Involvement by distant metastases (M) &lt;/th&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; Mx &lt;/td&gt; &lt;td&gt; Distant metastasis not assessed &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; M0 &lt;/td&gt; &lt;td&gt; No evidence of distant metastasis &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; M1 &lt;/td&gt; &lt;td&gt; Distant metastasis is present &lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;

![TNM STAGING](W1 HNC Patient Journey_figures/img_0b1bb76b84e4957f.webp)</text>
    <formatted_text>#### Primary tumour size (T)

| Stage | Description |
| :--- | :--- |
| Tx | No available information |
| T0 | No evidence of primary tumour |
| T1 | &lt;2cm |
| T2 | 2-4cm |
| T3 | &gt;4cm |
| T4 | Invades adjacent structures |

#### Regional lymph node involvement (N)

| Stage | Description |
| :--- | :--- |
| Nx | Nodes cannot be / were not assessed |
| N0 | No regional nodes involved |
| N1 | Ipsilateral single node &lt;3cm diameter |
| N2a | Ipsilateral single node 3-6cm |
| N2b | Ipsilateral multiple nodes &lt;6cm |
| N2c | Bilateral or contralateral nodes &lt;6cm |
| N3 | Any node &gt;6cm |

#### Involvement by distant metastases (M)

| Stage | Description |
| :--- | :--- |
| Mx | Distant metastasis not assessed |
| M0 | No evidence of distant metastasis |
| M1 | Distant metastasis is present |</formatted_text>
    <images>
      <img order="0" bbox="51,418,305,733" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_0b1bb76b84e4957f.webp" caption="TNM STAGING">
        <description>A table titled 'Primary tumour size (T)' detailing the classification codes for the T component of cancer staging. It lists specific criteria for each stage, ranging from Tx (no available information) and T0 (no evidence) to T1 (&lt;2cm), T2 (2-4cm), T3 (&gt;4cm), and T4 (invades adjacent structures).</description>
      </img>
    </images>
  </page>
  <page number="10">
    <text>TNM STAGING

| Classification | Staging |
| :--- | :--- |
| • **Clinical** = cTNM | • **Stage 0** – carcinoma in situ |
| • **Pathological** = pTNM | • **Stage I and II** – tumours localised to organ of origin |
| | • **Stage III** – locally extensive spread, particularly to regional lymph nodes |
| | • **Stage IV** – distant metastasis |</text>
    <formatted_text>| Classification | Staging |
| :--- | :--- |
| Clinical = cTNM | Stage 0 – carcinoma in situ |
| Pathological = pTNM | Stage I and II – tumours localised to organ of origin |
| | Stage III – locally extensive spread, particularly to regional lymph nodes |
| | Stage IV – distant metastasis |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:10:09" confidence="12" anchor="Stage IV – distant metastasis">

&gt; [!note] Lecturer — TNM Classification
&gt; TNM staging is an anatomical classification system that represents the extent of cancer and functions as a shorthand system. It was initially conceived in the 1940s and has been adopted by the Union for International Cancer Control and the American Joint Committee on Cancer; the American system is used in Australia.
&gt;
&gt; - The exact T and N classifications differ according to the anatomical cancer site.
&gt; - Pathological TNM classification after surgery helps guide decisions about adjuvant therapy.
</insert>
    </audio_inserts>
  </page>
  <page number="11">
    <text>HPV +VE OROPHARYNGEAL CANCER

*   Rising incidence of oropharyngeal cancer due to increasing prevalence of Human papillomavirus (HPV)-induced cancers
    *   Incidence of HPV-associated tonsil and BOT cancers increasing 5% increase per year since 1990.
*   Younger, healthier individuals with little or no tobacco exposure
*   Viral aetiological factor: types 16 and 18
    *   Type 16 most prevalent subtype in 95% of cases
*   Preventable with vaccines
    *   Gardasil 9: HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58
*   Highly responsive to treatment and has excellent prognosis
*   Immunohistochemistry: **P16 biomarker** significantly correlated with HPV status

![Parts of the Oropharynx](W1 HNC Patient Journey_figures/img_dde728a0057cac59.webp)</text>
    <formatted_text>- Rising incidence of oropharyngeal cancer due to increasing prevalence of Human papillomavirus (HPV)-induced cancers
  - Incidence of HPV-associated tonsil and BOT cancers increasing 5% increase per year since 1990.
- Younger, healthier individuals with little or no tobacco exposure
- Viral aetiological factor: types 16 and 18
  - Type 16 most prevalent subtype in 95% of cases
- Preventable with vaccines
  - Gardasil 9: HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58
- Highly responsive to treatment and has excellent prognosis
- Immunohistochemistry: P16 biomarker significantly correlated with HPV status</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:13:04" confidence="7" anchor="Immunohistochemistry: P16 biomarker significantly correlated with HPV status">

&gt; [!note] Lecturer — HPV Vaccination
&gt; HPV vaccination was discussed as a way of reducing the incidence of HPV-associated cancers. Although vaccination had traditionally been directed towards females in relation to cervical cancer, males were also being included in the national immunisation program at approximately 12 to 13 years of age.
&gt;
&gt; - HPV-associated cancers generally have a better prognosis than HPV-negative cancers associated with smoking and alcohol.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="637,348,941,737" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_dde728a0057cac59.webp" caption="Parts of the Oropharynx">
        <description>A sagittal anatomical diagram of the human head and neck illustrating the boundaries of the oropharynx, which is highlighted in cyan. The image includes labels pointing to specific components within this region: 'Soft palate', 'Side and back wall of the throat', 'Tonsil', and 'Back 1/3 of the tongue'.</description>
      </img>
    </images>
  </page>
  <page number="12">
    <text>&lt;div style=&quot;text-align: center;&quot;&gt;&lt;b&gt;EVALUATION&lt;/b&gt;&lt;/div&gt;

Head and neck examination
Fiber-optic nasopharyngolaryngoscopy
EUA to assess tumour extent and obtain biopsy

Imaging:
• CT scan
• MRI
• PET/CT (if no obvious primary on imaging)
• FNA biopsy of metastatic or equivocal nodes
(US or CT guided needle biopsy)
• OPG (mandibultomy, mandibulectomy, radiotherapy)

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;Advantages of CT&lt;/th&gt;
    &lt;th&gt;Advantages of MRI&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Superior assessment of bone erosion / destruction or periosteal invasion&lt;/td&gt;
    &lt;td&gt;Better soft tissue delineation&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Ease of availability&lt;/td&gt;
    &lt;td&gt;Better perineural invasion delineation&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Less time-consuming&lt;/td&gt;
    &lt;td&gt;No radiation exposure&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Less costly&lt;/td&gt;
    &lt;td&gt;No contrast iodine required&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Dental artifacts do not affect image quality&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](W1 HNC Patient Journey_figures/img_f8ddc3439f8f325a.webp)</text>
    <formatted_text>#### Clinical Assessment

- Head and neck examination
- Fiber-optic nasopharyngolaryngoscopy
- EUA to assess tumour extent and obtain biopsy

#### Imaging

- CT scan
- MRI
- PET/CT (if no obvious primary on imaging)
- FNA biopsy of metastatic or equivocal nodes (US or CT guided needle biopsy)
- OPG (mandibultomy, mandibulectomy, radiotherapy)

#### Advantages of CT vs MRI

| Advantages of CT | Advantages of MRI |
| :--- | :--- |
| Superior assessment of bone erosion / destruction or periosteal invasion | Better soft tissue delineation |
| Ease of availability | Better perineural invasion delineation |
| Less time-consuming | No radiation exposure |
| Less costly | No contrast iodine required |
| | Dental artifacts do not affect image quality |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:14:03" confidence="11" anchor="OPG (mandibultomy, mandibulectomy, radiotherapy)">

&gt; [!note] Lecturer — Diagnostic Evaluation
&gt; Diagnostic evaluation identifies the tumour type, anatomical site, clinical stage and extent of disease, and these findings influence treatment planning. A detailed history, physical examination, blood tests and thorough examination for a primary disease site may be included.
&gt;
&gt; - Examination under anaesthesia is particularly important when metastatic carcinoma is present in the neck and the primary site has not been identified.
&gt; - An orthopantomogram is important from the dental perspective as part of the pre-radiotherapy dental assessment.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="491,486,962,670" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_f8ddc3439f8f325a.webp">
        <description>A two-column comparison table with an orange header row listing the advantages of CT scan versus MRI. The rows detail specific benefits such as bone erosion assessment and cost for CT, and soft tissue delineation or lack of radiation exposure for MRI.</description>
      </img>
    </images>
  </page>
  <page number="13">
    <text>THE HEAD AND NECK CANCER PATIENT JOURNEY

| Diagnosis | **H&amp;N MDT Meeting Discussion** | Work-up to Cancer Treatment | Surgery | H&amp;N MDT Meeting Rediscussion | Radiotherapy +/- Chemotherapy | Rehabilitation | Chronic side effects and survivorship |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |</text>
    <formatted_text>Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery → H&amp;N MDT Meeting Rediscussion → Radiotherapy +/- Chemotherapy → Rehabilitation → Chronic side effects and survivorship</formatted_text>
  </page>
  <page number="14">
    <text>COMPREHENSIVE CANCER CARE

&lt;table&gt;
  &lt;tr&gt;
    &lt;td&gt;Cancer treatment&lt;br&gt;General medical care&lt;br&gt;Pain and symptom management&lt;br&gt;Nutritional support (enteral feeding, oral nutrition)&lt;br&gt;Dental care&lt;br&gt;Speech and swallowing therapy&lt;/td&gt;
    &lt;td&gt;Smoking and alcohol cessation&lt;br&gt;Audiology&lt;br&gt;Tracheostomy care&lt;br&gt;Wound management&lt;br&gt;Depression and anxiety management&lt;br&gt;Social work and case management&lt;br&gt;Supportive care (palliative care)&lt;br&gt;Physical therapy (lymphoedema)&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](W1 HNC Patient Journey_figures/img_01973387e19213fd.webp)</text>
    <formatted_text>- Cancer treatment
- General medical care
- Pain and symptom management
- Nutritional support (enteral feeding, oral nutrition)
- Dental care
- Speech and swallowing therapy
- Smoking and alcohol cessation
- Audiology
- Tracheostomy care
- Wound management
- Depression and anxiety management
- Social work and case management
- Supportive care (palliative care)
- Physical therapy (lymphoedema)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:16:42" confidence="4" anchor="- Physical therapy (lymphoedema)">
- ==Health literacy and social circumstances==
- ==End-of-life care==
- ==Occupational therapy and lymphoedema management==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="168,405,830,788" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_01973387e19213fd.webp">
        <description>A two-column table listing various components of comprehensive cancer care, such as cancer treatment, general medical care, and pain management on the left, and smoking cessation, audiology, and wound management on the right.</description>
      </img>
    </images>
  </page>
  <page number="15">
    <text>H&amp;N Multidisciplinary Team Members

| | |
| :--- | :--- |
| Otolaryngologist (Ear Nose Throat) surgeon | Speech-language therapist |
| Plastic and reconstructive surgeon | Dietitian |
| Oral and maxillofacial surgeon | Social worker |
| Radiation Oncologist | **Adjunctive services:** |
| Medical Oncologist | Pain specialist |
| Dental: Special Needs Dentistry, Oral Medicine, Maxillofacial prosthodontist | Palliative care specialist |
| Radiologist | Neurosurgeon |
| Pathologist | Ophthalmologist |
| Anaesthetist | Psychologist/Psychiatrist |
| High risk assessment physician | Occupational therapist |
| Head and neck cancer coordinator | Addiction services |
| Clinical nurse specialist | Audiologist |

![](W1 HNC Patient Journey_figures/img_7b74972a946410df.webp)</text>
    <formatted_text>- Otolaryngologist (Ear Nose Throat) surgeon
- Plastic and reconstructive surgeon
- Oral and maxillofacial surgeon
- Radiation Oncologist
- Medical Oncologist
- Dental: Special Needs Dentistry, Oral Medicine, Maxillofacial prosthodontist
- Radiologist
- Pathologist
- Anaesthetist
- High risk assessment physician
- Head and neck cancer coordinator
- Clinical nurse specialist
- Speech-language therapist
- Dietitian
- Social worker
- Adjunctive services:
  - Pain specialist
  - Palliative care specialist
  - Neurosurgeon
  - Ophthalmologist
  - Psychologist/Psychiatrist
  - Occupational therapist
  - Addiction services
  - Audiologist</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:17:28" confidence="6" anchor="- Adjunctive services:   - Pain specialist   - Palliative care specialist   - Ne">

&gt; [!note] Lecturer — MDT Responsibilities
&gt; Head and neck cancer treatment requires multiple teams because treatment may be disfiguring and may substantially impair normal function.
&gt;
&gt; - The MDT assesses the patient, stages the cancer, develops and coordinates the treatment plan, and decides whether treatment is curative or palliative.
&gt; - It reviews progress, monitors for relapse, and liaises with community healthcare professionals after discharge.
&gt; - A designated home team generally coordinates the patient’s care and communicates the recommendations to the patient.
</insert>
      <insert timestamp="00:18:07" confidence="7" anchor="- Adjunctive services:   - Pain specialist   - Palliative care specialist   - Ne">

&gt; [!note] Lecturer — MDT Meetings
&gt; MDT meetings may include new patients, patients with recurrence, patients requiring review of new investigations, and patients requiring pathology review after surgery.
&gt;
&gt; - The team may review tumour histology and determine TNM staging.
&gt; - It agrees on the proposed treatment and develops a surveillance plan.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="112,235,889,807" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_7b74972a946410df.webp">
        <description>A two-column table listing the members of a Head and Neck (H&amp;N) Multidisciplinary Team, including surgeons, oncologists, therapists, and various adjunctive services.</description>
      </img>
    </images>
  </page>
  <page number="16">
    <text># FACTORS INFLUENCING
# RECOMMENDED TREATMENT

| Tumor Factors | Patient Factors | Physician Factors |
| :--- | :--- | :--- |
| Site | Medical condition and comorbidities | Expertise |
| Size | The impact of treatment on the quality of life of the patient | Availability of a comprehensive team: nursing, dental, speech therapy, dietitian, rehabilitation, and social support services |
| Depth of invasion | Performance status | Personal preferences of members of the team |
| Degree of spread | Treatment cost | Preferences of the institution |
| Location and proximity to critical structures | Patient compliance | |
| Previous treatment | Previous treatment | |
| Need for reconstructive surgery | Patient preference | |

Curative Intent
Palliative Intent

O'Sullivan B, Brierley J, D'Cruz A, et al. UICC Manual of Clinical Oncology. Chicester: John Wiley &amp; Sons, Incorporated, 2015

![Table 1–11. Factors Influencing Recommended Treatment for an Individual Patient With Head and Neck Cancer](W1 HNC Patient Journey_figures/img_7bebe68be33229ab.webp)</text>
    <formatted_text>| Tumor Factors | Patient Factors | Physician Factors |
| :--- | :--- | :--- |
| Site | Medical condition and comorbidities | Expertise |
| Size | The impact of treatment on the quality of life of the patient | Availability of a comprehensive team: nursing, dental, speech therapy, dietitian, rehabilitation, and social support services |
| Depth of invasion | Performance status | Personal preferences of members of the team |
| Degree of spread | Treatment cost | Preferences of the institution |
| Location and proximity to critical structures | Patient compliance | |
| Previous treatment | Previous treatment | |
| Need for reconstructive surgery | Patient preference | |

- Curative Intent
- Palliative Intent

*O'Sullivan B, Brierley J, D'Cruz A, et al. UICC Manual of Clinical Oncology. Chicester: John Wiley &amp; Sons, Incorporated, 2015.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:19:38" confidence="8" anchor="*O'Sullivan B, Brierley J, D'Cruz A, et al. UICC Manual of Clinical Oncology. Ch">

&gt; [!note] Lecturer — Treatment Decision Factors
&gt; Treatment is primarily determined by expected oncological outcomes, but functional and cosmetic outcomes are also important.
&gt;
&gt; - Potential treatment side effects and cost-effectiveness also influence the recommendation.
&gt; - These factors help determine whether treatment is delivered with curative or palliative intent.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="72,429,485,742" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_7bebe68be33229ab.webp" caption="Table 1–11. Factors Influencing Recommended Treatment for an Individual Patient With Head and Neck Cancer">
        <description>A three-column table categorizing factors that influence treatment recommendations for head and neck cancer patients into Tumor Factors, Patient Factors, and Physician Factors. The rows list specific considerations such as site, size, medical condition, performance status, expertise, and availability of a comprehensive team.</description>
      </img>
    </images>
  </page>
  <page number="17">
    <text>STANDARD CARE TREATMENTS

Neo-Adjuvant = Shrink tumour first

Surgery
Radiotherapy
Chemotherapy

*   **Surgery, unimodality**
*   **Neo-adjuvant radiotherapy**
*   **Primary radiotherapy, unimodality**
*   **Surgery + Adjuvant radiotherapy +/- chemotherapy**
*   **Primary chemoradiotherapy**
*   **Palliative radiotherapy / systemic therapy**</text>
    <formatted_text>Neo-Adjuvant = Shrink tumour first

- Surgery
- Radiotherapy
- Chemotherapy

Treatment modalities:

1. Surgery, unimodality
2. Neo-adjuvant radiotherapy
3. Primary radiotherapy, unimodality
4. Surgery + Adjuvant radiotherapy +/- chemotherapy
5. Primary chemoradiotherapy
6. Palliative radiotherapy / systemic therapy</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:20:15" confidence="8" anchor="6. Palliative radiotherapy / systemic therapy">

&gt; [!note] Lecturer — Treatment Morbidity
&gt; Surgery and radiotherapy were described as the proven curative modalities, while chemotherapy is commonly used as an adjunct. Generally, the greater the number of modalities used, the greater the associated morbidity.
</insert>
    </audio_inserts>
  </page>
  <page number="18">
    <text>NEOADJUVANT IMMUNOTHERAPY

• Standard of care in Australia in past 4 months
• Locally advanced HNSCC (stage III and IV)
• Enhances anti-tumour immunity
    • Primes T-cells to target cancer cells via PDL-1 pathway
• 3 weekly injections
    • 2 cycles pre-op (surgery after 1 week)
    • 15 cycles post-treatment (surgery + RT +/- CT)
• 12% increase in disease-free survival at 36 months
• Similar incidence of adverse events to control group

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Neoadjuvant and Adjuvant Pembrolizumab
in Locally Advanced Head and Neck Cancer

R. Uppaluri,1,2 R.I. Haddad,1,2 Y. Tao,3 C. Le Tourneau,4 N.Y. Lee,5 W. Westra,5
R. Chernock,7 M. Tahara,8 K.J. Harrington,9 A.L. Klochikhin,10 I. Braña,11
G. Vasconcelos Alves,12 B.G.M. Hughes,13 M. Oliva,14 I. Pinto Figueiredo Lima,15
T. Ueda,16 T. Rutkowski,17 U. Schroeder,18 P.S. Mauz,19 T. Fuereder,20 S. Laban,21
N. Oridate,22 A. Popovtzer,23 N. Mach,24 Y. Korobko,25 D.A. Costa,26
A. Hooda-Nehra,27,28 C.P. Rodriguez,29 R.B. Bell,30 C. Manschot,31 K. Benjamin,31
B. Gumuscu,31 and D. Adkins,32 for the KEYNOTE-689 Investigators*

ABSTRACT

BACKGROUND
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.

METHODS
In this phase 3, open-label trial, we randomly assigned participants with locally advanced HNSCC in a 1:1 ratio to receive 2 cycles of neoadjuvant pembrolizumab and 15 cycles of adjuvant pembrolizumab (both at a dose of 200 mg every 3 weeks) in addition to standard care (pembrolizumab group) or standard care alone (control group). Standard care was surgery and adjuvant radiotherapy with or without concomitant cisplatin. The primary end point was event-free survival, sequentially assessed in participants whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more (CPS-10 population), participants whose tumors expressed PD-L1 with a CPS of 1 or more (CPS-1 population), and all the participants. A higher CPS indicates a higher proportion of cells that express PD-L1.

The authors’ full names, academic degrees, and affiliations are listed at the end of the article. Dr. Uppaluri can be contacted at ravindra_uppaluri@dfci.harvard.edu or at Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115.

*A complete list of the principal investigators in the KEYNOTE-689 trial is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on June 18, 2025, at NEJM.org.

N Engl J Med 2025;393:37-50.
DOI: 10.1056/NEJMoa2415434
Copyright © 2025 Massachusetts Medical Society.

Percentage of Participants
100
80
60
40
20
0
Pembrolizumab
44.6
Control
42.9

Pembrolizumab
Control
Hazard ratio, 0.66
(95% CI, 0.49 to 0.88);
two-sided P=0.004
Hazard ratio, 0.70
(95% CI, 0.55 to 0.89);
two-sided P=0.003
Hazard ratio, 0.73
(95% CI, 0.58 to 0.92);
two-sided P=0.008
59.8
45.9
58.2
44.9
57.6
46.4
CPS-10
CPS-1
All participants
Percentage of Participants
100
80
60
40
20
0

![Grade ≥3 Treatment-Related Adverse Events](W1 HNC Patient Journey_figures/img_4b1b1494a633e0e1.webp)
![Event-free Survival at 36 Months](W1 HNC Patient Journey_figures/img_727dd9015b85eb28.webp)</text>
    <formatted_text>- Standard of care in Australia in past 4 months
- Locally advanced HNSCC (stage III and IV)
- Enhances anti-tumour immunity
  - Primes T-cells to target cancer cells via PDL-1 pathway
- 3 weekly injections
  - 2 cycles pre-op (surgery after 1 week)
  - 15 cycles post-treatment (surgery + RT +/- CT)
- 12% increase in disease-free survival at 36 months
- Similar incidence of adverse events to control group

#### Source Article

*The NEW ENGLAND JOURNAL of MEDICINE — ORIGINAL ARTICLE: &quot;Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer&quot; — R. Uppaluri, R.I. Haddad, Y. Tao, C. Le Tourneau, N.Y. Lee, W. Westra, R. Chernock, M. Tahara, K.J. Harrington, A.L. Klochikhin, I. Braña, G. Vasconcelos Alves, B.G.M. Hughes, M. Oliva, I. Pinto Figueiredo Lima, T. Ueda, T. Rutkowski, U. Schroeder, P.S. Mauz, T. Fuereder, S. Laban, N. Oridate, A. Popovtzer, N. Mach, Y. Korobko, D.A. Costa, A. Hooda-Nehra, C.P. Rodriguez, R.B. Bell, C. Manschot, K. Benjamin, B. Gumuscu, and D. Adkins, for the KEYNOTE-689 Investigators. N Engl J Med 2025;393:37-50. DOI: 10.1056/NEJMoa2415434. Copyright © 2025 Massachusetts Medical Society.*

#### Abstract

**Background** — The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.

**Methods** — In this phase 3, open-label trial, participants with locally advanced HNSCC were randomly assigned in a 1:1 ratio to receive 2 cycles of neoadjuvant pembrolizumab and 15 cycles of adjuvant pembrolizumab (both at a dose of 200 mg every 3 weeks) in addition to standard care (pembrolizumab group) or standard care alone (control group). Standard care was surgery and adjuvant radiotherapy with or without concomitant cisplatin. The primary end point was event-free survival, sequentially assessed in participants whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more (CPS-10 population), participants whose tumors expressed PD-L1 with a CPS of 1 or more (CPS-1 population), and all the participants. A higher CPS indicates a higher proportion of cells that express PD-L1.

#### Event-Free Survival Results (Figure)

Percentage of participants (axis: 100, 80, 60, 40, 20, 0):

- CPS-10: Pembrolizumab 59.8 vs Control 45.9; hazard ratio 0.66 (95% CI, 0.49 to 0.88); two-sided P=0.004
- CPS-1: Pembrolizumab 58.2 vs Control 44.9; hazard ratio 0.70 (95% CI, 0.55 to 0.89); two-sided P=0.003
- All participants: Pembrolizumab 57.6 vs Control 46.4; hazard ratio 0.73 (95% CI, 0.58 to 0.92); two-sided P=0.008

The article was published on June 18, 2025, at NEJM.org.</formatted_text>
    <images>
      <img order="0" bbox="173,651,457,825" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="W1 HNC Patient Journey_figures/img_4b1b1494a633e0e1.webp" caption="Grade ≥3 Treatment-Related Adverse Events">
        <description>A bar chart titled &quot;Grade ≥3 Treatment-Related Adverse Events&quot; comparing the incidence of severe adverse events between two groups. The y-axis represents the &quot;Percentage of Participants,&quot; and the x-axis lists the treatment arms, showing that 44.6% of participants in the Pembrolizumab group experienced Grade ≥3 treatment-related adverse events compared to 42.9% in the Control group.</description>
      </img>
      <img order="1" bbox="648,658,892,841" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="W1 HNC Patient Journey_figures/img_727dd9015b85eb28.webp" caption="Event-free Survival at 36 Months">
        <description>A grouped bar chart titled 'Event-free Survival at 36 Months' comparing outcomes between a Pembrolizumab group (blue bars) and a Control group (light purple bars). The x-axis categorizes participants into three groups: CPS-10, CPS-1, and All participants. Each category displays the percentage of event-free survival for both arms alongside statistical annotations for the hazard ratio, 95% confidence interval, and two-sided P-value.</description>
      </img>
    </images>
  </page>
  <page number="19">
    <text>MANAGEMENT
OF H&amp;N
CANCER

UICC 2015

Curative intent
Non-metastatic HNC (Stage I–IVB)
(except for those unable to tolerate standard
treatment due to co-morbidity or poor
performance status)

Palliative intent
Metastatic HNC (Stage IVC) or non-metastatic
but unable to tolerate standard treatment

Early stage (I/II)
• Single modality
(surgery/RT)
• Surgery preferred in
oral cavity,
paranasal sinuses
• Laser surgery is a
suitable alternative
in earl glottic cancers
• Robotic surgeries
have an emerging role
in early oropharyngeal
cancers
• RT preferred in
oropharynx,
nasopharynx larynx,
and hypopharynx
• Surgery/radiotherapy
in glottic cancers

Advanced stage
(III/IVA/IVB)
• Multimodality
• Oral cavity, paranasal
sinuses: surgery with PORT
with/without concurrent
chemotherapy
• Oropharynx, nasopharynx:
CCRT with/without salvage
surgery
• Larynx/hypopharynx: CCRT
or ICT followed by RT/CCRT
if deemed suitable for organ
preservation; alternatively
surgery with PORT
with/without concurrent
chemotherapy
• Bioradiotherapy with
cetuximab is another
treatment option

Metastatic with good
performance status
• Local treatment first
(RT/CCRT) for local
control, followed by
systemic therapy; or
systemic therapy first
followed by local
treatment, as indicated
• Chemotherapy
with/without targeted
therapy (cetuximab)
• Oligometastases can
be treated aggressively
as some may be
curable, especially in
HPV-related
oropharyngeal cancer
and EBV-related
nasopharyngeal cancer

Very frail/ very
poor
performance
status and
unable to
tolerate
treatment
• Supportive
care

HNC – head and neck cancer; RT – radiotherapy; PORT – postoperative radiotherapy; CCRT –
concurrent chemoradiotherapy; ICT – induction chemotherapy; EBV – Epstein-Barr virus; HPV –
human papillomavirus

![Curative intent Non-metastatic HNC (Stage I–IVB) (except for those unable to tolerate standard treatment due to co-morbidity or poor performance status); Palliative intent Metastatic HNC (Stage IVC) or non-metastatic but unable to tolerate standard treatment; Early stage (I/II); Advanced stage (III/IVA/IVB); Metastatic with good performance status; Very frail/ very poor performance status and unable to tolerate treatment; HNC – head and neck cancer; RT – radiotherapy; PORT – postoperative radiotherapy; CCRT – concurrent chemoradiotherapy; ICT – induction chemotherapy; EBV – Epstein-Barr virus; HPV – human papillomavirus](W1 HNC Patient Journey_figures/img_059ccbb81487fac3.webp)</text>
    <formatted_text>*UICC 2015*

#### Curative Intent

Non-metastatic HNC (Stage I–IVB) (except for those unable to tolerate standard treatment due to co-morbidity or poor performance status)

- **Early stage (I/II):** Single modality (surgery/RT)
  - Surgery preferred in oral cavity, paranasal sinuses
  - Laser surgery is a suitable alternative in early glottic cancers
  - Robotic surgeries have an emerging role in early oropharyngeal cancers
  - RT preferred in oropharynx, nasopharynx, larynx, and hypopharynx
  - Surgery/radiotherapy in glottic cancers
- **Advanced stage (III/IVA/IVB):** Multimodality
  - Oral cavity, paranasal sinuses: surgery with PORT with/without concurrent chemotherapy
  - Oropharynx, nasopharynx: CCRT with/without salvage surgery
  - Larynx/hypopharynx: CCRT or ICT followed by RT/CCRT if deemed suitable for organ preservation; alternatively surgery with PORT with/without concurrent chemotherapy
  - Bioradiotherapy with cetuximab is another treatment option

#### Palliative Intent

Metastatic HNC (Stage IVC) or non-metastatic but unable to tolerate standard treatment

- **Metastatic with good performance status:**
  - Local treatment first (RT/CCRT) for local control, followed by systemic therapy; or systemic therapy first followed by local treatment, as indicated
  - Chemotherapy with/without targeted therapy (cetuximab)
  - Oligometastases can be treated aggressively as some may be curable, especially in HPV-related oropharyngeal cancer and EBV-related nasopharyngeal cancer
- **Very frail/very poor performance status and unable to tolerate treatment:**
  - Supportive care

HNC – head and neck cancer; RT – radiotherapy; PORT – postoperative radiotherapy; CCRT – concurrent chemoradiotherapy; ICT – induction chemotherapy; EBV – Epstein-Barr virus; HPV – human papillomavirus</formatted_text>
    <audio_inserts count="5">
      <insert timestamp="00:20:44" confidence="7" anchor="- **Early stage (I/II):** Single modality (surgery/RT)   - Surgery preferred in ">

&gt; [!note] Lecturer — Choosing Surgery
&gt; Surgery alone may be preferred when the cancer is early stage, the lesion is accessible, or surgery is less morbid than radiotherapy.
&gt;
&gt; - Avoiding radiotherapy-related bone damage may be desirable.
&gt; - In a young patient, radiotherapy may be preserved for a possible second primary or recurrence.
</insert>
      <insert timestamp="00:22:03" confidence="6" anchor="- Bioradiotherapy with cetuximab is another treatment option">

&gt; [!note] Lecturer — Choosing Radiotherapy
&gt; Primary radiotherapy may be preferred when surgery would impair function or prosthetic rehabilitation, carry high morbidity, or produce a poor cosmetic outcome.
&gt;
&gt; - It may also be preferred when the tumour is particularly radiosensitive or surgical risk is high because of comorbidities.
</insert>
      <insert timestamp="00:22:45" confidence="12" anchor="- Supportive care">

&gt; [!note] Lecturer — Palliative Treatment
&gt; Palliative treatment is used to improve quality of life and reduce symptoms rather than aim for complete tumour eradication.
&gt;
&gt; - Treatment may reduce tumour size and relieve symptoms.
&gt; - Options include palliative radiotherapy, systemic chemotherapy, and immunotherapy.
</insert>
      <insert timestamp="00:23:45" confidence="5" anchor="- Note: All recommendations are category 2A unless otherwise indicated.">
- ==Students were not expected to memorise the detailed oral cavity treatment pathways; the diagrams demonstrate that defined pathways exist for particular cancer types and stages.==</insert>
      <insert timestamp="00:13:13" confidence="7" anchor="- Note: All recommendations are category 2A unless otherwise indicated.">

&gt; [!note] Lecturer — HPV Positive Disease
&gt; p16-positive tumours have separate treatment pathways because HPV-associated disease generally has a better prognosis and differs epidemiologically from HPV-negative disease.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="480,177,964,720" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_059ccbb81487fac3.webp" caption="Curative intent Non-metastatic HNC (Stage I–IVB) (except for those unable to tolerate standard treatment due to co-morbidity or poor performance status); Palliative intent Metastatic HNC (Stage IVC) or non-metastatic but unable to tolerate standard treatment; Early stage (I/II); Advanced stage (III/IVA/IVB); Metastatic with good performance status; Very frail/ very poor performance status and unable to tolerate treatment; HNC – head and neck cancer; RT – radiotherapy; PORT – postoperative radiotherapy; CCRT – concurrent chemoradiotherapy; ICT – induction chemotherapy; EBV – Epstein-Barr virus; HPV – human papillomavirus">
        <description>This flowchart outlines the management algorithms for head and neck cancer, bifurcating into curative intent (non-metastatic stages I–IVB) and palliative intent (metastatic stage IVC or patients unable to tolerate standard treatment). It categorizes specific treatment strategies—ranging from single-modality surgery or radiotherapy in early stages to multimodality chemoradiotherapy in advanced cases—and details protocols for metastatic disease versus supportive care for very frail patients.</description>
      </img>
    </images>
  </page>
  <page number="20">
    <text>DON'T HAVE TO KNOW

ORAL CAVITY MANAGEMENT

National Comprehensive Cancer Network®
NCCN Guidelines Version 2.2026
Cancer of the Oral Cavity (Including Mucosal Lip)
NCCN Guidelines Index
Table of Contents
Discussion

Buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, hard palateᵃ

WORKUP
• History and physical (H&amp;P)ᵇ,ᶜ including a complete head and neck exam; mirror and fiberoptic examination as clinically indicated
• Biopsyᵈ
• As clinically indicated:
» Chest CT (with or without contrast)ᵉ
» CT with contrast and/or MRI with and without contrast of primary and neck
» Consider FDG-PET/CT, ᵍ
» Examination under anesthesia (EUA) with endoscopy
» Preanesthesia studies
» Dental/prosthodontic evaluation,⁹ including Panorex or dental CT without contrastᵍ
» Nutrition, speech, and swallowing evaluation/therapyʰ
» Smoking cessation counselingʲ
» Fertility/reproductive counselingᵏ
» Screening for hepatitis B
» PD-L1 testing by immunohistochemistry (IHC) (combined positive score [CPS])ˡ
• Multidisciplinary consultation as clinically indicated
• Genetic testing in the context of early age of onset or family history

CLINICAL STAGING
T1–2,N0 → Treatment of Primary and Neck (OR-2)
T3,N0
T1–3,N1–3 → Treatment of Primary and Neck (OR-3)
T4a,N0–3
T4b,N0–3
or
Unresectable nodal disease → Treatment of Very Advanced Head and Neck Cancer (ADV-1)
or
Untfit for surgery
Metastatic (M1) disease at initial presentation → Treatment of Very Advanced Head and Neck Cancer (ADV-2)

Note: All recommendations are category 2A unless otherwise indicated.

ᵃ Cutaneous squamous cell carcinoma of the vermilion lip is not included in this guideline. See NCCN Guidelines for Squamous Cell Skin Cancer.
ᵇ H&amp;P should include documentation and quantification (pack years smoked) of tobacco use history, as well as alcohol use and counseling. All patients who currently smoke should be advised to quit smoking, and those who formerly smoked should be advised to remain abstinent from smoking. For additional cessation support, refer to the Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation.
ᶜ Screen for distress. Refer to the NCCN Distress Thermometer and Problem List, which includes social determinants of health. See NCCN Guidelines for Distress Management (DIS-A).
ᵈ Image-guided (ultrasound [US] or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than fine-needle aspiration (FNA) by palpation alone for initial diagnosis in this setting. For unresectable or metastatic disease where there is a plan for systemic therapy, a core biopsy would allow for biomarker testing.
ᵉ Principles of Imaging (IMG-A).
ᶠ Discussion.
ᵍ Principles of Oral/Dental Evaluation and Management (DENT-A).
ʰ Principles of Nutrition: Management and Supportive Care (NUTR-A).
ʲ See fertility and reproductive endocrine considerations in the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology.
ᵏ Discussion.
ˡ Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).

Version 2.2026, 09/12/2026 © 2026 National Comprehensive Cancer Network® (NCCN®). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.
OR-1

---

(FIGURE ON TOP RIGHT - BOX_B)
PLEASE NOTE: The use of this NCCN Content is governed by the End User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.
National Comprehensive Cancer Network®
NCCN Guidelines Version 2.2026
Cancer of the Oral Cavity (Including Mucosal Lip)
NCCN Guidelines Index
Table of Contents
Discussion

Buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, hard palateᵃ

CLINICAL STAGING | TREATMENT OF PRIMARY AND NECK | ADJUVANT TREATMENT | FOLLOW-UP
---|---|---|---
Surgery (preferred) | Resection of primary† Neck dissection* (guided by tumor location, depth of invasion, and imaging) | No positive nodes and No adverse pathologic featuresᵇ | Consider RTᶜ (category 1) | Follow-up (FOLL-A, 1 of 2)
or | | One positive node without adverse pathologic featuresᵇ | Systemic therapy/RTᶜ, ᵈ | Recurrent or persistent disease (ADV-3)
T1–2, N0 | Resection of primary + sentinel lymph node (SLN) biopsyᵉ | SLN pN0 | Re-resection if feasible and consider RTᶜ if negative margins |
or | Neck dissection† if SLN pN+ or SLN identification unsuccessful | Adverse pathologic featuresᵇ | or Consider systemic therapyᶜ |
| | Positive margin | RTᶜ or Consider systemic therapyᶜ |
| | Other risk features | RTᶜ or Consider systemic therapyᶜ |

Definitive RTᶜ → Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2) → Recurrent or persistent disease (ADV-3)

ᵃ Cutaneous squamous cell carcinoma of the vermilion lip is not included in this guideline. See NCCN Guidelines for Squamous Cell Skin Cancer.
ᵇ Principles of Surgery (SURG-A).
ᶜ Neck dissection is generally not indicated for T1–3,N0 mucosal lip.
ᵈ Data are limited on the efficacy of SLN biopsy for oral cavity cancer. See SentineL Lymph Node Biopsy in Principles of Surgery (SURG-A, 7 of 8).
ᵉ Adverse pathologic features: extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion (Discussion).
ᶜ Principles of Radiation Therapy (OR-A).
ᶠ Principles of Systems Therapy for Non-Nasopharyngeal Cancers (SYST-A).

Note: All recommendations are category 2A unless otherwise indicated.

Version 2.2026, 09/12/2026 © 2026 National Comprehensive Cancer Network® (NCCN®). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.
OR-2

---

(FIGURE ON BOTTOM RIGHT - BOX_C)
PLEASE NOTE: The use of this NCCN Content is governed by the End User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.
National Comprehensive Cancer Network®
NCCN Guidelines Version 2.2026
Cancer of the Oral Cavity (Including Mucosal Lip)
NCCN Guidelines Index
Table of Contents
Discussion

Buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, hard palateᵃ

CLINICAL STAGING | TREATMENT OF PRIMARY AND NECK | ADJUVANT TREATMENT | FOLLOW-UP
---|---|---|---
T3,N0; T1–3,N1–3; T4a,N0–3 | Surgery† (preferred) If PD-L1 positive (CPS ≥ 1): Neoadjuvant pembrolizumab (except for N3 disease)ᵇ or Clinical trials | N0,N1; N2a-b; N3 | Resection of primary (± ipsilateral, or bilateral neck dissection)* | If neoadjuvant pembrolizumab received | RT + pembrolizumab (with cisplatin if extranodal extension and/or positive margins followed by adjuvant pembrolizumab)ᶜ, ᵈ | Follow-up (FOLL-A, 1 of 2)
| | N2c (bilateral) | Resection of primary and bilateral neck dissection* | No adverse pathologic featuresᵇ | Consider RTᶜ | Recurrent or persistent disease (ADV-3)
| | | | Adverse pathologic featuresᵇ | Extranoadal extension + positive margin | Systemic therapy/ RTᶜ, ᶠ (category 1) |
| | | | | Positive margin | Systemic therapy/ RTᶜ, ᶠ (category 1) or Re-resection, if feasible and consider RTᶜ if negative margins |
| | | | | Other risk features | RTᶜ or Consider systemic therapy/RTᶜ |

Selected patients who decline surgery → Very Advanced Head and Neck Cancer (ADV-1)

ᵃ Cutaneous squamous cell carcinoma of the vermilion lip is not included in this guideline. See NCCN Guidelines for Squamous Cell Skin Cancer.
ᵇ Principles of Surgery (SURG-A).
ᶜ Neck dissection is generally not indicated for T1–3,N0 mucosal lip.
ᵈ Adverse pathologic features: extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion (Discussion).
ᶠ Principles of Radiation Therapy (OR-A).
ᶠ Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).

Note: All recommendations are category 2A unless otherwise indicated.

Version 2.2026, 09/12/2026 © 2026 National Comprehensive Cancer Network® (NCCN®). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.
OR-3

![](W1 HNC Patient Journey_figures/img_67d8244d64ee5dc2.webp)
![NCCN Guidelines Version 2.2026 Cancer of the Oral Cavity (Including Mucosal Lip) OR-2](W1 HNC Patient Journey_figures/img_cf179ce30fb8c56e.webp)
![NCCN Guidelines Version 2.2026 Cancer of the Oral Cavity (Including Mucosal Lip) OR-3](W1 HNC Patient Journey_figures/img_e3cda794bbf1b40a.webp)</text>
    <formatted_text>*Slide marked &quot;DON'T HAVE TO KNOW&quot;*

*NCCN Guidelines Version 2.2026 — Cancer of the Oral Cavity (Including Mucosal Lip) — OR-1*

Buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, hard palate

#### Workup (OR-1)

- History and physical (H&amp;P), including a complete head and neck exam; mirror and fiberoptic examination as clinically indicated
- Biopsy
- As clinically indicated:
  - Chest CT (with or without contrast)
  - CT with contrast and/or MRI with and without contrast of primary and neck
  - Consider FDG-PET/CT
  - Examination under anesthesia (EUA) with endoscopy
  - Preanesthesia studies
  - Dental/prosthodontic evaluation, including Panorex or dental CT without contrast
  - Nutrition, speech, and swallowing evaluation/therapy
  - Smoking cessation counseling
  - Fertility/reproductive counseling
  - Screening for hepatitis B
  - PD-L1 testing by immunohistochemistry (IHC) (combined positive score [CPS])
- Multidisciplinary consultation as clinically indicated
- Genetic testing in the context of early age of onset or family history

#### Clinical Staging (OR-1)

- T1–2,N0 → Treatment of Primary and Neck (OR-2)
- T3,N0; T1–3,N1–3; T4a,N0–3 → Treatment of Primary and Neck (OR-3)
- T4b,N0–3 or Unresectable nodal disease → Treatment of Very Advanced Head and Neck Cancer (ADV-1)
- Unfit for surgery; Metastatic (M1) disease at initial presentation → Treatment of Very Advanced Head and Neck Cancer (ADV-2)

#### Treatment of Primary and Neck (OR-2)

T1–2,N0:

- Surgery (preferred): Resection of primary; neck dissection (guided by tumor location, depth of invasion, and imaging)
- Adjuvant treatment:
  - No positive nodes and no adverse pathologic features → Consider RT (category 1)
  - One positive node without adverse pathologic features → Systemic therapy/RT
  - Adverse pathologic features:
    - Positive margin → RT or Consider systemic therapy
    - Other risk features → RT or Consider systemic therapy
- Or: Resection of primary + sentinel lymph node (SLN) biopsy
  - SLN pN0 → Re-resection if feasible and consider RT if negative margins
  - Neck dissection if SLN pN+ or SLN identification unsuccessful
- Or: Definitive RT → Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2) → Recurrent or persistent disease (ADV-3)

Follow-up (FOLL-A, 1 of 2) → Recurrent or persistent disease (ADV-3)

#### Treatment of Primary and Neck (OR-3)

T3,N0; T1–3,N1–3; T4a,N0–3:

- Surgery (preferred). If PD-L1 positive (CPS ≥ 1): Neoadjuvant pembrolizumab (except for N3 disease) or clinical trials
- Neck treatment:
  - N0,N1; N2a-b; N3 → Resection of primary (± ipsilateral, or bilateral neck dissection)
  - N2c (bilateral) → Resection of primary and bilateral neck dissection
- Adjuvant treatment:
  - If neoadjuvant pembrolizumab received → RT + pembrolizumab (with cisplatin if extranodal extension and/or positive margins) followed by adjuvant pembrolizumab
  - No adverse pathologic features → Consider RT
  - Adverse pathologic features:
    - Extranodal extension + positive margin → Systemic therapy/RT (category 1)
    - Positive margin → Systemic therapy/RT (category 1) or re-resection, if feasible and consider RT if negative margins
    - Other risk features → RT or Consider systemic therapy/RT
- Selected patients who decline surgery → Very Advanced Head and Neck Cancer (ADV-1)

Follow-up (FOLL-A, 1 of 2) → Recurrent or persistent disease (ADV-3)

#### Footnotes

- Cutaneous squamous cell carcinoma of the vermilion lip is not included in this guideline. See NCCN Guidelines for Squamous Cell Skin Cancer.
- H&amp;P should include documentation and quantification (pack years smoked) of tobacco use history, as well as alcohol use and counseling. All patients who currently smoke should be advised to quit smoking, and those who formerly smoked should be advised to remain abstinent from smoking. For additional cessation support, refer to the Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation.
- Screen for distress. Refer to the NCCN Distress Thermometer and Problem List, which includes social determinants of health. See NCCN Guidelines for Distress Management (DIS-A).
- Image-guided (ultrasound [US] or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than fine-needle aspiration (FNA) by palpation alone for initial diagnosis in this setting. For unresectable or metastatic disease where there is a plan for systemic therapy, a core biopsy would allow for biomarker testing.
- Principles of Imaging (IMG-A); Principles of Oral/Dental Evaluation and Management (DENT-A); Principles of Nutrition: Management and Supportive Care (NUTR-A); Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).
- Adverse pathologic features: extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion (Discussion).

Note: All recommendations are category 2A unless otherwise indicated.

*Version 2.2026, 09/12/2026 © 2026 National Comprehensive Cancer Network® (NCCN®). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.*</formatted_text>
    <images>
      <img order="0" bbox="205,375,483,605" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_67d8244d64ee5dc2.webp">
        <description>This flowchart illustrates the clinical staging and subsequent treatment pathways for oral cavity cancer. It categorizes patients by TNM stage (e.g., T1-2,N0; T3,N0) and directs them to specific management protocols such as 'Treatment of Primary and Neck' or 'Treatment of Very Advanced Head and Neck Cancer'.</description>
      </img>
      <img order="1" bbox="565,199,897,422" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_cf179ce30fb8c56e.webp" caption="NCCN Guidelines Version 2.2026 Cancer of the Oral Cavity (Including Mucosal Lip) OR-2">
        <description>A clinical flowchart from NCCN Guidelines detailing the management of T1-2, N0 oral cavity cancer. It maps decision pathways for surgery versus definitive radiation therapy, including resection and neck dissection options, criteria for adjuvant treatment based on pathologic features (such as extranodal extension or positive margins), and follow-up protocols.</description>
      </img>
      <img order="2" bbox="565,562,895,822" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_e3cda794bbf1b40a.webp" caption="NCCN Guidelines Version 2.2026 Cancer of the Oral Cavity (Including Mucosal Lip) OR-3">
        <description>This figure is a clinical flowchart outlining the NCCN Guidelines (Version 2.2026) for the management of oral cavity cancer, specifically detailing treatment pathways for patients with T3,N0; T1–3,N1–3; or T4a,N0–3 staging. The diagram illustrates decision trees starting from surgery (with potential neoadjuvant pembrolizumab), branching into various adjuvant treatments based on pathologic findings like extranodal extension and positive margins, and concluding with follow-up protocols.</description>
      </img>
    </images>
  </page>
  <page number="21">
    <text># OROPHARYNGEAL MANAGEMENT

**OROPHARYNGEAL MANAGEMENT**

[Image: NCCN Guidelines flowchart for Oropharynx cancer management]

PLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool. Printed by: Jai Leung on 11/8/2026 9:15:15 AM. Copyright © 2026 National Comprehensive Cancer Network, Inc. All Rights Reserved.

**NCCN**
National
Comprehensive
Cancer
Network*

**NCCN Guidelines Version 2.2026**
**Cancer of the Oropharynx**

NCCN Guidelines Index
Table of Contents
Discussion

**Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate**

**WORKUP**
• Tumor human papillomavirus (HPV) testing by p16 IHC required^a
• H&amp;P^b,c, including a complete head and neck exam; mirror and fiberoptic examination as clinically indicated
• Biopsy of primary site or fine-needle aspiration (FNA) of the neck^d
• CT with contrast and/or MRI with and without contrast of primary and neck^e
• As clinically indicated:
    ▸ EUA with endoscopy^f
    ▸ Preanesthesia studies
    ▸ FDG-PET/CT^g
    ▸ Chest CT^h (with or without contrast)
    ▸ Dental evaluation^i including Panorex
    ▸ Nutrition, speech, and swallowing evaluation/therapy, and audiogram^j
    ▸ Smoking cessation counseling^k
    ▸ Fertility/reproductive counseling^l
    ▸ Screening for hepatitis B
    ▸ PD-L1 testing by IHC (CPS)
• Multidisciplinary consultation as clinically indicated

**CLINICAL STAGING**

**TREATMENT**

p16-
negative

T1–2,N0–1 ➔ ORPH-2
T3–4a,N0–1 ➔ ORPH-3
T1–4a,N2–3 ➔ ORPH-4
T4b,N0–3 ➔ Treatment of Very Advanced Head and Neck Cancer (ADV-1)
Unresectable or unfit for surgery ➔ Treatment of Very Advanced Head and Neck Cancer (ADV-1)
Metastatic (M1) disease initial presentation ➔ Treatment of Very Advanced Head and Neck Cancer (ADV-2)

p16 (HPV)-
positive

T1–2,N0 ➔ ORHPV-1
T0–2,N1 (single node ≤3 cm) ➔ ORHPV-2
T0–2,N1 (single node &gt;3 cm, or 2 or more ipsilateral nodes ≤6 cm), or T1–2,N2 or T3,N0–2 ➔ ORHPV-3
T0–3,N3 or T4,N0–3 ➔ ORHPV-4

a Principles of p16 Testing for HPV-Mediated Oropharyngeal Cancer (ORPH-B).
b H&amp;P should include documentation and quantification (pack years smoked) of tobacco use history, as well as alcohol use and counseling. All patients who currently smoke should be advised to quit smoking, and those who formerly smoked should be advised to remain abstinent from smoking. For additional cessation support, refer to the Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation.
c Screen for distress. Refer to the NCCN Distress Thermometer and Problem List, which includes social determinants of health. See NCCN Guidelines for Distress Management (DIS-A).
d Image-guided (US or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting. For unresectable or metastatic disease where there is a plan for systemic therapy, a core biopsy would allow for biomarker testing.
e Principles of Imaging (IMG-A).
f Prior to treatment, EUA with biopsy confirmation of the oropharyngeal primary site is recommended for patients presenting with a p16+ cervical lymph node. See Principles of Surgical Management (SURG-A).
g Principles of Oral/Dental Evaluation and Management (DENT-A).
h Principles of Nutrition: Management and Supportive Care (NUTR-A).
i See fertility and reproductive endocrine considerations in the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology.
j The clinical staging definitions are based on the AJCC 8th edition for oropharynx cancer (see ST-4 for p16-, and see ST-7 for p16+). Definitions for nodal staging criteria previously used in clinical trials (AJCC 7th edition) for appropriate staging criteria are included.

Note: All recommendations are category 2A unless otherwise indicated.

ORPH-1

Version 2.2026, 09/12/2026 © 2026 National Comprehensive Cancer Network (“NCCN”). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

[Image: Flowchart showing treatment pathways for p16-negative oropharynx cancer]

PLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.
**NCCN**
National
Comprehensive
Cancer
Network*

**NCCN Guidelines Version 2.2026**
**Cancer of the Oropharynx (p16-negative)**

NCCN Guidelines Index
Table of Contents
Discussion

**Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate**

**CLINICAL STAGING**

**TREATMENT OF PRIMARY AND NECK**

p16-negative
T1–2,N0–1

Resection of primary and ipsilateral or bilateral neck dissection^j,k,m
If neoadjuvant pembrolizumab received
pN0 and no adverse pathologic features^o
➔ Adjuvant treatment
RT + pembrolizumab (with cisplatin if extranodal extension and/or positive margin) followed by adjuvant pembrolizumab^n,p

or

If PD-L1 positive (CPS ≥ 1)
Neoadjuvant pembrolizumab (except for N0 disease)^q
➔ Consider RT^m

or

Adverse pathologic features^r
➔ Extranodal extension ± positive margin ➔ Systemic therapy/RT^n,o
➔ Re-resection, if feasible or
➔ Systemic therapy/RT^n,o

or

Positive margin
➔ RT^n or
➔ Systemic therapy/RT^n,o

or

Other risk features
➔ RT^n or
➔ Consider systemic therapy/RT^n,o

Definitive RT^s
or
For T1–2,N1 only: Concurrent systemic therapy/RT^n,o (category 2B)
or
Clinical trials
➔ Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2)

ADJUVANT TREATMENT

Follow-up (FOLL-A, 1 of 2) ➔ Recurrent or persistent disease (ADV-3)

Recurrent or persistent disease (ADV-3)

a Principles of Surgery (SURG-A).
b Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment as do tumors of the tonsil invading the tongue base.
c For pN0-N1 and no poor pathologic risk features, single-modality treatment should be considered whenever possible. For T1-T2 primary tumors near midline and resected to adequate margins and with no adverse pathologic features, a staged contralateral neck dissection can be performed in order to avoid RT. Lateral tumors pN0-N1 resected with favorable pathologic features can be observed.
d Principles of Radiation Therapy (ORPH-A).
e Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).
f Adverse pathologic features: extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion (Discussion).

Note: All recommendations are category 2A unless otherwise indicated.

ORPH-2

Version 2.2026, 09/12/2026 © 2026 National Comprehensive Cancer Network (“NCCN”). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

[Image: Flowchart showing treatment pathways for p16-positive oropharynx cancer]

PLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.
**NCCN**
National
Comprehensive
Cancer
Network*

**NCCN Guidelines Version 2.2026**
**Cancer of the Oropharynx (p16 [HPV]-positive)**

NCCN Guidelines Index
Table of Contents
Discussion

**Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate**

**CLINICAL STAGING**

**TREATMENT OF PRIMARY AND NECK**

p16 (HPV)-positive
T1–2,N0

Resection of primary and ipsilateral or bilateral selective neck dissection^j,l
No adverse pathologic features^k,m
➔ Systemic therapy/RT^n,o,l or RT (category 2B)

or

Adverse pathologic features^k,m
➔ Extranodal extension ± positive margin ➔ Systemic therapy/RT^n,o,l or RT (category 2B)
➔ Re-resection, if feasible or Systemic therapy/RT^n,o,l

or

Positive margin
➔ RT^n or Systemic therapy/ RT^n,o,l

or

Other risk features^k
➔ RT^n or Systemic therapy/ RT^n,o,l (category 2B)

Definitive RT^n
or
Clinical trials
➔ Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2)

ADJUVANT TREATMENT

Follow-up (FOLL-A, 1 of 2) ➔ Recurrent or persistent disease (ADV-3)

a Principles of Surgery (SURG-A).
b Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment as do tumors of the tonsil invading the tongue base.
c Pathologic staging criteria differ from clinical staging criteria in HPV-mediated oropharyngeal cancer. For pathologic stage following resection, see AJCC 8th edition for appropriate staging criteria (ST-7).
d Adverse pathologic features: extranodal extension, positive margins, close margins (&lt;3 mm), pT3 or pT4 primary, one positive node &gt;3 cm or multiple positive nodes, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion (Discussion). The definition of an adverse pathologic feature in the context of HPV+ disease is an area of active research. This includes the presence and extent of extranodal extension, and the number of involved nodes.
e The recommendations for patients at high risk with extranodal extension + positive margins are based on randomized studies involving patients for whom the HPV status of their tumors was not specified.

Note: All recommendations are category 2A unless otherwise indicated.

ORHPV-1

Version 2.2026, 09/12/2026 © 2026 National Comprehensive Cancer Network (“NCCN”). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

![NCCN Guidelines Version 2.2026 Cancer of the Oropharynx (p16-negative) Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate CLINICAL STAGING TREATMENT OF PRIMARY AND NECK ADJUVANT TREATMENT ORPH-2](W1 HNC Patient Journey_figures/img_e8dcc5bcf2850c6e.webp)
![NCCN Guidelines Version 2.2026 Cancer of the Oropharynx (p16 HPV-positive) Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate CLINICAL STAGING TREATMENT OF PRIMARY AND NECK ADJUVANT TREATMENT ORHPV-1](W1 HNC Patient Journey_figures/img_2a2aae82f013f944.webp)</text>
    <formatted_text>*NCCN Guidelines Version 2.2026 — Cancer of the Oropharynx — Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate — ORPH-1, ORPH-2, ORHPV-1*

#### Workup (ORPH-1)

- Tumor human papillomavirus (HPV) testing by p16 IHC required
- H&amp;P, including a complete head and neck exam; mirror and fiberoptic examination as clinically indicated
- Biopsy of primary site or fine-needle aspiration (FNA) of the neck
- CT with contrast and/or MRI with and without contrast of primary and neck
- As clinically indicated:
  - EUA with endoscopy
  - Preanesthesia studies
  - FDG-PET/CT
  - Chest CT (with or without contrast)
  - Dental evaluation including Panorex
  - Nutrition, speech, and swallowing evaluation/therapy, and audiogram
  - Smoking cessation counseling
  - Fertility/reproductive counseling
  - Screening for hepatitis B
  - PD-L1 testing by IHC (CPS)
- Multidisciplinary consultation as clinically indicated

#### Clinical Staging (ORPH-1)

**p16-negative:**

- T1–2,N0–1 → ORPH-2
- T3–4a,N0–1 → ORPH-3
- T1–4a,N2–3 → ORPH-4
- T4b,N0–3, unresectable, or unfit for surgery → Treatment of Very Advanced Head and Neck Cancer (ADV-1)
- Metastatic (M1) disease at initial presentation → Treatment of Very Advanced Head and Neck Cancer (ADV-2)

**p16 (HPV)-positive:**

- T1–2,N0 → ORHPV-1
- T0–2,N1 (single node ≤3 cm) → ORHPV-2
- T0–2,N1 (single node &gt;3 cm, or 2 or more ipsilateral nodes ≤6 cm), or T1–2,N2 or T3,N0–2 → ORHPV-3
- T0–3,N3 or T4,N0–3 → ORHPV-4

#### p16-Negative: T1–2,N0–1 (ORPH-2)

- Resection of primary and ipsilateral or bilateral neck dissection
  - If neoadjuvant pembrolizumab received:
    - pN0 and no adverse pathologic features → RT + pembrolizumab (with cisplatin if extranodal extension and/or positive margin) followed by adjuvant pembrolizumab
    - Consider RT
  - Adverse pathologic features:
    - Extranodal extension ± positive margin → Systemic therapy/RT; or re-resection, if feasible; or systemic therapy/RT
    - Positive margin → RT or systemic therapy/RT
    - Other risk features → RT or Consider systemic therapy/RT
- Or: Definitive RT; or for T1–2,N1 only: concurrent systemic therapy/RT (category 2B); or clinical trials → Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2)
- Follow-up (FOLL-A, 1 of 2) → Recurrent or persistent disease (ADV-3)

#### p16 (HPV)-Positive: T1–2,N0 (ORHPV-1)

- Resection of primary and ipsilateral or bilateral selective neck dissection
  - No adverse pathologic features → Systemic therapy/RT or RT (category 2B)
  - Adverse pathologic features:
    - Extranodal extension ± positive margin → Systemic therapy/RT or RT (category 2B); or re-resection, if feasible, or systemic therapy/RT
    - Positive margin → RT or systemic therapy/RT
    - Other risk features → RT or systemic therapy/RT (category 2B)
- Or: Definitive RT; or clinical trials → Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2)
- Follow-up (FOLL-A, 1 of 2) → Recurrent or persistent disease (ADV-3)

#### Footnotes

- Principles of p16 Testing for HPV-Mediated Oropharyngeal Cancer (ORPH-B); Principles of Surgery (SURG-A); Principles of Imaging (IMG-A); Principles of Radiation Therapy (ORPH-A); Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).
- H&amp;P should include documentation and quantification (pack years smoked) of tobacco use history, as well as alcohol use and counseling. All patients who currently smoke should be advised to quit smoking, and those who formerly smoked should be advised to remain abstinent from smoking. For additional cessation support, refer to the Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation.
- Screen for distress. Refer to the NCCN Distress Thermometer and Problem List, which includes social determinants of health. See NCCN Guidelines for Distress Management (DIS-A).
- Image-guided (US or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting. For unresectable or metastatic disease where there is a plan for systemic therapy, a core biopsy would allow for biomarker testing.
- Prior to treatment, EUA with biopsy confirmation of the oropharyngeal primary site is recommended for patients presenting with a p16+ cervical lymph node. See Principles of Surgical Management (SURG-A).
- Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment as do tumors of the tonsil invading the tongue base.
- For pN0-N1 and no poor pathologic risk features, single-modality treatment should be considered whenever possible. For T1-T2 primary tumors near midline and resected to adequate margins and with no adverse pathologic features, a staged contralateral neck dissection can be performed in order to avoid RT. Lateral tumors pN0-N1 resected with favorable pathologic features can be observed.
- The clinical staging definitions are based on the AJCC 8th edition for oropharynx cancer (see ST-4 for p16-, and see ST-7 for p16+). Definitions for nodal staging criteria previously used in clinical trials (AJCC 7th edition) for appropriate staging criteria are included.
- Adverse pathologic features: extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion (Discussion). In the context of HPV+ disease, close margins are defined as &lt;3 mm; the definition of an adverse pathologic feature in HPV+ disease is an area of active research, including the presence and extent of extranodal extension and the number of involved nodes. The recommendations for patients at high risk with extranodal extension + positive margins are based on randomized studies involving patients for whom the HPV status of their tumors was not specified.

Note: All recommendations are category 2A unless otherwise indicated.

*Version 2.2026, 09/12/2026 © 2026 National Comprehensive Cancer Network® (NCCN®). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.*</formatted_text>
    <images>
      <img order="0" bbox="558,198,906,493" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_e8dcc5bcf2850c6e.webp" caption="NCCN Guidelines Version 2.2026 Cancer of the Oropharynx (p16-negative) Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate CLINICAL STAGING TREATMENT OF PRIMARY AND NECK ADJUVANT TREATMENT ORPH-2">
        <description>This image displays a clinical management flowchart from the NCCN Guidelines for p16-negative oropharynx cancer (specifically T1-2, N0-1 stage). The diagram outlines treatment pathways starting with surgery or definitive radiation therapy, branching into adjuvant treatment decisions based on pathological features such as extranodal extension, positive margins, and PD-L1 status. It concludes with follow-up recommendations or referral to advanced disease protocols.</description>
      </img>
      <img order="1" bbox="559,561,905,752" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="W1 HNC Patient Journey_figures/img_2a2aae82f013f944.webp" caption="NCCN Guidelines Version 2.2026 Cancer of the Oropharynx (p16 [HPV]-positive) Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate CLINICAL STAGING TREATMENT OF PRIMARY AND NECK ADJUVANT TREATMENT ORHPV-1">
        <description>A flowchart from the NCCN Guidelines illustrating the treatment pathway for p16 (HPV)-positive oropharyngeal cancer at clinical stage T1–2, N0. The diagram outlines decision points between resection of the primary tumor with neck dissection versus definitive radiation therapy, detailing subsequent adjuvant treatments based on adverse pathologic features such as extranodal extension or positive margins.</description>
      </img>
    </images>
  </page>
  <page number="22">
    <text>### THE HEAD AND NECK CANCER PATIENT JOURNEY

```mermaid
flowchart LR
    A[Diagnosis] --&gt; B[&quot;H&amp;N MDT&lt;br&gt;Meeting&lt;br&gt;Discussion&quot;]
    B --&gt; C[&quot;Work-up to&lt;br&gt;Cancer&lt;br&gt;Treatment&quot;]
    C --&gt; D[Surgery]
    D --&gt; E[&quot;H&amp;N MDT&lt;br&gt;Meeting&lt;br&gt;Rediscussion&quot;]
    E --&gt; F[&quot;Radiotherapy&lt;br&gt;+/-&lt;br&gt;Chemotherapy&quot;]
    F --&gt; G[Rehabilitation]
    G --&gt; H[&quot;Chronic side&lt;br&gt;effects and&lt;br&gt;survivorship&quot;]
```</text>
    <formatted_text>Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery → H&amp;N MDT Meeting Rediscussion → Radiotherapy +/- Chemotherapy → Rehabilitation → Chronic side effects and survivorship</formatted_text>
  </page>
  <page number="23">
    <text>MANY APPOINTMENTS!

• Anaesthetic assessment
• Dental assessment
• Nutrition assessment
• Speech and swallow evaluation
• Radiation oncology and medical oncology consults
• Audiogram
• Smoking cessation counselling
• Psychological counselling
• Any further investigations (e.g. incidental findings on imaging)

Cancer Nurse Coordinator</text>
    <formatted_text>Many appointments are required before treatment can begin.

- Anaesthetic assessment
- Dental assessment
- Nutrition assessment
- Speech and swallow evaluation
- Radiation oncology and medical oncology consults
- Audiogram
- Smoking cessation counselling
- Psychological counselling
- Any further investigations (e.g. incidental findings on imaging)

Contact: **Cancer Nurse Coordinator**</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:25:05" confidence="4" anchor="Any further investigations (e.g. incidental findings on imaging)  Contact: **Can">

&gt; [!note] Lecturer — Treatment Coordination
&gt; Although one surgical team may act as the main home team, substantial coordination is required between the various services.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="522,473,637,634" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A simple orange arrow pointing to the right, used as a decorative graphic element.</description>
      </img>
    </images>
  </page>
  <page number="24">
    <text>**Other support services**

**Cancer Council**
13 11 20 for information and support
(Monday to Friday, general office hours)

**Cancer Nurse Coordination Service**
(08) 6457 0855
(Monday to Friday, 8.30am–4.30pm)

**Crisis Care**
(08) 9223 1111
1800 199 008 (freecall STD)

**Lifeline**
13 11 14

**Mental Health Emergency Response Line**
Perth Metro 1300 555 788
Peel Region 1800 676 822
RuralLink WA 1800 552 002

The service is administered by the Cancer Network WA.

Government of Western Australia
North Metropolitan Health Service

[Icon: No Smoking] We are proud to be a smoke-free site.
Thank you for not smoking or vaping.

Ask a staff member about free nicotine therapy
to help your cravings during your hospital stay.

**Cancer Network WA**
Queen Elizabeth II Medical Centre.
Locked Bag 2012. Nedlands WA 6009
(08) 6457 0855
cnwa@health.wa.gov.au

This document can be made available
in alternative formats on request.

© North Metropolitan Health Service 2023

**WA**
**Psycho-Oncology**
**Service**

Clinical psychology care for
adults affected by cancer

![WA Psycho-Oncology Service](W1 HNC Patient Journey_figures/img_170dddfa11c274d5.webp)</text>
    <formatted_text>#### Cancer Council

13 11 20 for information and support (Monday to Friday, general office hours)

#### Cancer Nurse Coordination Service

(08) 6457 0855 (Monday to Friday, 8.30am–4.30pm)

#### Crisis Care

- (08) 9223 1111
- 1800 199 008 (freecall STD)

#### Lifeline

13 11 14

#### Mental Health Emergency Response Line

- Perth Metro: 1300 555 788
- Peel Region: 1800 676 822
- RuralLink WA: 1800 552 002

#### WA Psycho-Oncology Service

Clinical psychology care for adults affected by cancer.

The service is administered by the Cancer Network WA.

&gt; We are proud to be a smoke-free site. Thank you for not smoking or vaping. Ask a staff member about free nicotine therapy to help your cravings during your hospital stay.

#### Contact Details

* Cancer Network WA, Queen Elizabeth II Medical Centre, Locked Bag 2012, Nedlands WA 6009
* (08) 6457 0855
* cnwa@health.wa.gov.au

This document can be made available in alternative formats on request.

*© North Metropolitan Health Service 2023.*</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:25:20" confidence="14" anchor="Cancer Nurse Coordination Service  (08) 6457 0855 (Monday to Friday, 8.30am–4.30">

&gt; [!note] Lecturer — Nurse Coordination
&gt; The cancer nurse coordinator service acts as a valuable liaison service throughout the patient journey.
&gt;
&gt; - Acts as a central point of contact.
&gt; - Helps patients navigate the patient journey.
&gt; - Connects patients with hospital teams.
&gt; - Supports communication between patients and healthcare services.
</insert>
      <insert timestamp="00:25:38" confidence="5" anchor="Clinical psychology care for adults affected by cancer.  The service is administ">

&gt; [!note] Lecturer — Psycho-Oncology Support
&gt; The psycho-oncology service provides targeted psychological support so that patients do not have to rely solely on a general psychology waiting list.
&gt;
&gt; - It is particularly relevant to the depression, anxiety and psychosocial effects associated with cancer.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="593,260,835,603" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_170dddfa11c274d5.webp" caption="WA Psycho-Oncology Service">
        <description>A close-up photograph of a red and green Kangaroo Paw flower, set against a blurred green background. The image serves as decorative branding artwork on the slide.</description>
      </img>
    </images>
  </page>
  <page number="25">
    <text>ORAL SIDE-EFFECTS OF H&amp;N CANCER
RADIOTHERAPY

SHORT TERM
• Oral mucositis
• Altered taste

LONG TERM
• Altered saliva quality and quantity
• Oral thrush
• Dysphagia
• Trismus
• Periodontal susceptibility
• Radiation Caries
• *Osteoradionecrosis

![](W1 HNC Patient Journey_figures/img_6471e52273db226d.webp)
![](W1 HNC Patient Journey_figures/img_3fa03c8babf2bae5.webp)
![](W1 HNC Patient Journey_figures/img_91c2625339ea16b1.webp)
![](W1 HNC Patient Journey_figures/img_bd2e611bcc372f8a.webp)</text>
    <formatted_text>#### Short Term

- Oral mucositis
- Altered taste

#### Long Term

- Altered saliva quality and quantity
- Oral thrush
- Dysphagia
- Trismus
- Periodontal susceptibility
- Radiation caries
- *Osteoradionecrosis</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:04:09" confidence="2" anchor="- Altered taste">
- ==Oral soreness==
- ==Erythema==
- ==Ulceration==
- ==Changes in saliva==
- ==Difficulty eating==
- ==Increased mucus==
- ==Oral discomfort==
- ==Fungal infection==</insert>
      <insert timestamp="01:04:11" confidence="6" anchor="- *Osteoradionecrosis">
- ==Xerostomia==
- ==Dental erosion==
- ==Reduced healing capacity==
- ==Muscle fibrosis==
- ==Difficulties wearing dentures==
- ==Changes in oral flora==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="461,317,711,550" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_6471e52273db226d.webp">
        <description>Clinical photo: A close-up view of an open mouth showing severe oral mucositis, characterized by extensive redness and white ulcerative patches on the tongue and inner cheeks.</description>
      </img>
      <img order="1" bbox="728,354,974,516" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_3fa03c8babf2bae5.webp">
        <description>A close-up clinical photograph showing a dental instrument pressing down on the surface of a tongue, likely demonstrating an oral examination or assessing mucosal texture.</description>
      </img>
      <img order="2" bbox="458,580,711,778" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_91c2625339ea16b1.webp">
        <description>Clinical photo: showing severe dental decay with widespread blackened, eroded tooth structure and missing teeth.</description>
      </img>
      <img order="3" bbox="728,578,972,779" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_bd2e611bcc372f8a.webp">
        <description>Clinical photograph showing the lower anterior oral cavity with exposed, necrotic bone and severe tissue destruction characteristic of osteoradionecrosis. The image depicts non-vital teeth with significant decay and dark discoloration alongside inflamed gingival tissues.</description>
      </img>
    </images>
  </page>
  <page number="26">
    <text>ROLE OF DENTAL PRACTITIONER
PRE-RADIOTHERAPY

• Identify existing oral disease &amp; potential risk of oral disease
• Remove dental infections and teeth with poor long term prognosis prior to commencing cancer therapy
• Avoid unscheduled interruption to primary treatment due to dental issues
• Prepare the patient for expected side effects of cancer therapy
• Develop a plan for preventive care and follow up to meet the increasing challenges during cancer therapy
• Establish multidisciplinary collaboration within the cancer team</text>
    <formatted_text>- Identify existing oral disease &amp; potential risk of oral disease
- Remove dental infections and teeth with poor long term prognosis prior to commencing cancer therapy
- Avoid unscheduled interruption to primary treatment due to dental issues
- Prepare the patient for expected side effects of cancer therapy
- Develop a plan for preventive care and follow up to meet the increasing challenges during cancer therapy
- Establish multidisciplinary collaboration within the cancer team</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:28:02" confidence="19" anchor="- Establish multidisciplinary collaboration within the cancer team">

- ==Pay particular attention to teeth receiving high-dose radiation==
- ==Reduce the risk of osteoradionecrosis==

&gt; [!note] Lecturer — Patient Dental History
&gt; Many patients have poorly maintained dentitions, particularly because heavy smoking and alcohol use are common risk factors.
&gt;
&gt; - An Australian study from 2011 found that most head and neck cancer patients had not visited a dentist during the preceding 12 months.
&gt; - The mean time since the last dental visit was approximately five and a half years.
</insert>
      <insert timestamp="00:30:50" confidence="3" anchor="- Extractions during time of cancer surgery">
- ==The effect of mandibulotomy, segmental mandibulectomy or temporomandibular joint removal on later extraction access==</insert>
    </audio_inserts>
  </page>
  <page number="27">
    <text># MULTIDISCIPLINARY WORK UP

*   **Surgical teams** = altered anatomy affecting function and rehabilitation, teeth removed as part of resection, extractions due to impingement on healing flap, extractions to monitor cancer margins, extractions during time of cancer surgery
*   **Radiation Oncology** = urgency to commence radiotherapy, anticipated radiation fields, risks vs benefits of extractions
*   **Medical Oncology** = neo-adjuvant therapy affecting timings, patient factors
*   **Speech therapy and dietetics** = dysphagia, tube feeding, nutritional supplementation</text>
    <formatted_text>- **Surgical teams** — altered anatomy affecting function and rehabilitation, teeth removed as part of resection, extractions due to impingement on healing flap, extractions to monitor cancer margins, extractions during time of cancer surgery
- **Radiation Oncology** — urgency to commence radiotherapy, anticipated radiation fields, risks vs benefits of extractions
- **Medical Oncology** — neo-adjuvant therapy affecting timings, patient factors
- **Speech therapy and dietetics** — dysphagia, tube feeding, nutritional supplementation</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:30:34" confidence="3" anchor="- **Medical Oncology** — neo-adjuvant therapy affecting timings, patient factors">

- ==Potential effects on healing and the timing of dental treatment in relation to systemic therapy==

&gt; [!note] Lecturer — Dental Treatment Timing
&gt; In selected complex patients, dental treatment may be performed during the same general anaesthetic as cancer surgery.
&gt;
&gt; - This may be useful when the patient has significant comorbidities or would otherwise require two separate medical optimisations.
&gt; - Other indications include blood thinners, social or behavioural concerns, particularly difficult dental treatment, or access becoming more difficult after surgery.
&gt; - This approach is not used for every patient because of the logistical demands and additional time required.
</insert>
      <insert timestamp="00:28:19" confidence="2" anchor="- **Speech therapy and dietetics** — dysphagia, tube feeding, nutritional supple">
- ==Nutritional status and the implications of altered anatomy and dental treatment==</insert>
    </audio_inserts>
  </page>
  <page number="28">
    <text>FSH H&amp;N Cancer MDT - Provisional Radiotherapy Fields

Anticipated RT dose/#:

Ant max
□ high &gt;60Gy
□ mod &lt;45-60Gy
□ low &lt;45Gy

R post max
□ high &gt;60Gy
□ mod 45-60Gy
□ low &lt;45Gy

L post max
□ high &gt;60Gy
□ mod 45-60Gy
□ low &lt;45Gy

R post mand
□ high &gt;60Gy
□ mod 45-60Gy
□ low &lt;45Gy

L post mand
□ high &gt;60Gy
□ mod 45-60Gy
□ low &lt;45Gy

Ant mand
□ high &gt;60Gy
□ mod 45-60Gy
□ low &lt;45Gy

H&amp;N MDT Date:

Patient Name:

UR Number:

Cancer site / TNM:

New      Path Review      Known recurrence

Proposed treatment:

Rad Onc Consultant:

Comments:

Right Side      Left Side

Government of Western Australia
South Metropolitan Health Service
Fiona Stanley Fremantle Hospitals Group

![](W1 HNC Patient Journey_figures/img_4b4d248fda85f033.webp)
![](W1 HNC Patient Journey_figures/img_04768efc0fd496af.webp)</text>
    <formatted_text>**Anticipated RT dose/#:**

- **Ant max:** □ high &gt;60Gy □ mod 45–60Gy □ low &lt;45Gy
- **R post max:** □ high &gt;60Gy □ mod 45–60Gy □ low &lt;45Gy
- **L post max:** □ high &gt;60Gy □ mod 45–60Gy □ low &lt;45Gy
- **R post mand:** □ high &gt;60Gy □ mod 45–60Gy □ low &lt;45Gy
- **L post mand:** □ high &gt;60Gy □ mod 45–60Gy □ low &lt;45Gy
- **Ant mand:** □ high &gt;60Gy □ mod 45–60Gy □ low &lt;45Gy

**Form fields:**

- H&amp;N MDT Date:
- Patient Name:
- UR Number:
- Cancer site / TNM:
- New / Path Review / Known recurrence
- Proposed treatment:
- Rad Onc Consultant:
- Comments:
- Right Side / Left Side</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:26:34" confidence="6" anchor="- **Ant mand:** □ high &gt;60Gy □ mod 45–60Gy □ low &lt;45Gy">

&gt; [!note] Lecturer — Treatment Priorities
&gt; Dental treatment is prioritised according to the tooth’s relationship to the radiation field, anticipated dose, long-term prognosis, likelihood of future mucosal trauma, and urgency of cancer treatment.
&gt;
&gt; - Different health systems may have different arrangements.
&gt; - Some patients, particularly rural patients, may receive dental care in general practice rather than travelling to a major city.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="143,411,444,688" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_4b4d248fda85f033.webp">
        <description>A schematic dental arch diagram showing the maxillary (top) and mandibular (bottom) teeth, divided into posterior quadrants by diagonal lines. The illustration is surrounded by four labelled checkboxes corresponding to specific anatomical regions: 'R post max' (Right Posterior Maxilla), 'L post max' (Left Posterior Maxilla), 'R post mand' (Right Posterior Mandible), and 'L post mand' (Left Posterior Mandible). Each label includes radiotherapy dose options ('high &gt;60Gy', 'mod 45-60Gy', 'low &lt;45Gy') for marking provisional treatment fields.</description>
      </img>
      <img order="1" bbox="544,574,892,733" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_04768efc0fd496af.webp">
        <description>A schematic line drawing showing four views of a human head and neck (right profile, frontal, posterior, and left profile). It serves as a template for marking provisional radiotherapy fields on the corresponding anatomical surfaces.</description>
      </img>
    </images>
  </page>
  <page number="29">
    <text>THE HEAD AND NECK CANCER PATIENT
JOURNEY

| Diagnosis | H&amp;N MDT Meeting Discussion | Work-up to Cancer Treatment | **Surgery** | H&amp;N MDT Meeting Rediscussion | Radiotherapy +/- Chemotherapy | Rehabilitation | Chronic side effects and survivorship |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |</text>
    <formatted_text>Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → **Surgery** → H&amp;N MDT Meeting Rediscussion → Radiotherapy +/- Chemotherapy → Rehabilitation → Chronic side effects and survivorship</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:37:06" confidence="6" anchor="Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → **Surgery">
- ==After surgery, the pathology is reviewed to determine whether adjuvant treatment is required.==</insert>
    </audio_inserts>
  </page>
  <page number="30">
    <text>ANATOMICAL CHANGES OF RELEVANCE
TO DENTISTRY


![a Marginal mandibulectomy](W1 HNC Patient Journey_figures/img_3eb8a566cc793dbe.webp)
![b Segmental mandibulectomy](W1 HNC Patient Journey_figures/img_2d1aec8548168c0b.webp)</text>
    <formatted_text>Anatomical changes of relevance to dentistry.</formatted_text>
    <images>
      <img order="0" bbox="66,303,496,542" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_3eb8a566cc793dbe.webp" caption="a Marginal mandibulectomy">
        <description>The figure shows a lateral view of a human mandible (lower jaw) with a section of the alveolar ridge removed. Dashed lines indicate the excised segment, which is displayed separately below to illustrate the extent of bone resection.</description>
      </img>
      <img order="1" bbox="499,307,881,528" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_2d1aec8548168c0b.webp" caption="b Segmental mandibulectomy">
        <description>The figure presents two panels illustrating segmental mandibulectomy: on the left, a specimen of a resected mandible is shown with dashed lines indicating the removed segment containing teeth; on the right, an intraoperative diagram depicts the tongue and floor of mouth with red outlines marking the tumor extent and a blue line showing the surgical margin.</description>
      </img>
    </images>
  </page>
  <page number="31">
    <text>THE HEAD AND NECK CANCER PATIENT JOURNEY

Diagnosis
H&amp;N MDT Meeting Discussion
Work-up to Cancer Treatment
Surgery
**H&amp;N MDT Meeting Rediscussion**
Radiotherapy +/- Chemotherapy
Rehabilitation
Chronic side effects and survivorship</text>
    <formatted_text>Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery → **H&amp;N MDT Meeting Rediscussion** → Radiotherapy +/- Chemotherapy → Rehabilitation → Chronic side effects and survivorship</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:53:20" confidence="6" anchor="Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery →">

&gt; [!note] Lecturer — Surgical Changes
&gt; Cancer surgery and reconstruction can significantly alter oral and facial anatomy.
&gt;
&gt; - Loss of teeth during resection
&gt; - Mandibulotomy
&gt; - Segmental mandibulectomy
&gt; - Temporomandibular joint removal
&gt; - Partial maxillectomy
&gt; - Marginal mandibulectomy
&gt; - Tongue resection
&gt; - Neck dissection
&gt; - Tracheostomy
&gt; - Free flap reconstruction
&gt; - Hair-bearing free flaps placed into the oral cavity
&gt;
&gt; Hair-bearing flaps may cause tickling, hygiene difficulties, gagging, nausea, and saliva collecting in the hair, which can make the area difficult to clean. An eyebrow plucker may be used to remove hair from an intraoral flap when required. Surgical changes may also make later dental extractions more difficult, especially when mandibular mobility is reduced.
</insert>
    </audio_inserts>
  </page>
  <page number="32">
    <text>ADJUVANT RADIOTHERAPY REQUIRED?
ORAL CANCERS

| Definitive Factors for Adjuvant Radiotherapy | Definitive Factors for Adjuvant Chemoradiotherapy | Other Factors that may influence receipt of Adjuvant Radiotherapy |
| :--- | :--- | :--- |
| • pT3/T4&lt;br&gt;• pN2/N3&lt;br&gt;• Close margins &lt;5mm&lt;br&gt;• Depth of invasion &gt;10mm | • Lymph node extracapsular spread (ECS)&lt;br&gt;• Positive margin &lt;1mm | • Perineural invasion (PNI)&lt;br&gt;• Lymphovascular invasion (LVI)&lt;br&gt;• Grade&lt;br&gt;• Single node positive &gt;3cm or multiple positive nodes&lt;br&gt;• Worst pattern of invasion |

D'Cruz A, Vaish R, Dhar H. Oral cancers: current status. Oral Oncol. 2018;87:64-9
Chen et al. Surgical margins in head and neck squamous cell carcinoma: A narrative review. Int J Surg. 2024; 110: 3680-3700

![Classification of Tumor-associated Margins](W1 HNC Patient Journey_figures/img_77e442d7dd95dd50.webp)
![](W1 HNC Patient Journey_figures/img_6fce2e14bc711f91.webp)</text>
    <formatted_text>#### Definitive Factors for Adjuvant Radiotherapy

- pT3/T4
- pN2/N3
- Close margins &lt;5mm
- Depth of invasion &gt;10mm

#### Definitive Factors for Adjuvant Chemoradiotherapy

- Lymph node extracapsular spread (ECS)
- Positive margin &lt;1mm

#### Other Factors that may influence receipt of Adjuvant Radiotherapy

- Perineural invasion (PNI)
- Lymphovascular invasion (LVI)
- Grade
- Single node positive &gt;3cm or multiple positive nodes
- Worst pattern of invasion

*D'Cruz A, Vaish R, Dhar H. Oral cancers: current status. Oral Oncol. 2018;87:64-9*

*Chen et al. Surgical margins in head and neck squamous cell carcinoma: A narrative review. Int J Surg. 2024; 110: 3680-3700*</formatted_text>
    <audio_inserts count="4">
      <insert timestamp="00:22:29" confidence="6" anchor="- Positive margin &lt;1mm">

&gt; [!note] Lecturer — Chemoradiotherapy
&gt; Adjuvant chemoradiotherapy is used when adverse pathological features indicate the need for additional systemic treatment alongside radiotherapy. Radio-sensitising chemotherapy may augment the effect of radiotherapy.
</insert>
      <insert timestamp="00:19:16" confidence="5" anchor="- Worst pattern of invasion">

&gt; [!note] Lecturer — Treatment Selection
&gt; The final decision is influenced by more than the pathological findings.
&gt;
&gt; - Expected oncological benefit
&gt; - Patient comorbidities
&gt; - Functional outcomes
&gt; - Cosmetic outcomes
&gt; - Previous treatment
&gt; - The patient’s ability to tolerate further treatment
&gt; - Overall treatment intent
</insert>
      <insert timestamp="00:38:27" confidence="10" anchor="### **Radiotherapy Fundamentals**  - Used to treat approximately 50-60% of patie">

&gt; [!note] Lecturer — Radiation Mechanism
&gt; Radiotherapy uses ionising radiation to induce loss of reproductive potential through DNA damage.
&gt;
&gt; - The relevant damage particularly includes double-stranded DNA breaks.
&gt; - The matter absorbing radiation may be water or human tissue.
</insert>
      <insert timestamp="00:38:46" confidence="2" anchor="### **Radiotherapy Fundamentals**  - Used to treat approximately 50-60% of patie">
- ==For example, 70 Gy in 35 fractions means 70 Gy delivered over 35 treatment sessions==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="52,315,920,758" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_77e442d7dd95dd50.webp" caption="Classification of Tumor-associated Margins">
        <description>This is a labelled schematic diagram illustrating the classification of tumor-associated margins in relation to tissue layers. It depicts a central tumor mass surrounded by concentric colored lines representing distinct boundaries, including the 'Histological margin', 'Molecular margin', and 'Surgical incision/Surgical margin'. The diagram also indicates vertical measurements such as 'CSD' and 'HSD' alongside labels for the 'Clinical margin/Gross margin'.</description>
      </img>
      <img order="1" bbox="383,581,564,799" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_6fce2e14bc711f91.webp">
        <description>Labelled schematic diagram illustrating the spatial relationships between different types of surgical and clinical margins in tissue. The figure depicts a central tumor mass surrounded by concentric zones, with labels identifying: Surgical incision/Surgical margin (red line), Molecular margin (green line), Histological margin (purple dashed line), Clinical margin/Gross margin (blue arrow), HSD (High-Grade Squamous Dysplasia or similar acronym context-dependent, black bracket), and CSD (Consecutive/Continuous Squamous Dysplasia or similar, blue bracket). A legend at the bottom identifies pink circles as 'Cells with morphological changes' and lighter pink circles as 'Cells with genetic changes'.</description>
      </img>
    </images>
  </page>
  <page number="33">
    <text>THE HEAD AND NECK CANCER PATIENT JOURNEY

| Diagnosis | H&amp;N MDT Meeting Discussion | Work-up to Cancer Treatment | Surgery | H&amp;N MDT Meeting Rediscussion | **Radiotherapy +/- Chemotherapy** | Rehabilitation | Chronic side effects and survivorship |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |</text>
    <formatted_text>Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery → H&amp;N MDT Meeting Rediscussion → **Radiotherapy +/- Chemotherapy** → Rehabilitation → Chronic side effects and survivorship</formatted_text>
  </page>
  <page number="34">
    <text>RADIOTHERAPY

*   Used to treat approximately 50-60% of patients with HNC
*   Aims: destroy cancer cells, reduce size of tumours
*   Unit of measurement: Gray (Gy) = absorption of 1 joule of energy per kilogram of matter
*   Delivered in *fractions* (# = treatment sessions)
*   Gold standard = commence within 6 weeks of MDT discussion or surgery

![](W1 HNC Patient Journey_figures/img_7660daa281084755.webp)</text>
    <formatted_text>- Used to treat approximately 50-60% of patients with HNC
- Aims: destroy cancer cells, reduce size of tumours
- Unit of measurement: Gray (Gy) = absorption of 1 joule of energy per kilogram of matter
- Delivered in *fractions* (# = treatment sessions)
- Gold standard = commence within 6 weeks of MDT discussion or surgery</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:39:06" confidence="8" anchor="Gold standard = commence within 6 weeks of MDT discussion or surgery">

&gt; [!note] Lecturer — Treatment Coordination
&gt; Postoperative radiotherapy should ideally commence as soon as possible, with a goal of approximately six weeks after surgery. Achieving this requires careful planning and coordination.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="670,382,964,762" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_7660daa281084755.webp">
        <description>Clinical photo: A patient lying supine on a radiotherapy treatment table, secured with a mesh immobilization mask over the head and neck. Green laser alignment lines are projected across the patient's face and body to guide positioning relative to the large, curved gantry of the radiation machine.</description>
      </img>
    </images>
  </page>
  <page number="35">
    <text>RADIATION SCHEDULE

**Curative Radiotherapy (complete eradication)**
• Definitive Radiotherapy: 60-72 Gy in 25-40 fractions over 6-7 weeks
• Adjuvant Radiotherapy:
• Primary and involved nodes: 56-60Gy in 28-30 fractions (2Gy) over 6 weeks
• High risk sites (e.g. ECS, residual disease, positive tumour margins): 4-10 Gy dose augmentation (up to 66-70Gy)

**Palliative Radiotherapy (symptom control)**
• 30-50Gy, in 5-20 fractions

**Prophylactic Radiotherapy (prevent growth in high-risk sites)**</text>
    <formatted_text>#### Curative Radiotherapy (complete eradication)

- **Definitive Radiotherapy:** 60-72 Gy in 25-40 fractions over 6-7 weeks
- **Adjuvant Radiotherapy:**
  - Primary and involved nodes: 56-60 Gy in 28-30 fractions (2 Gy) over 6 weeks
  - High risk sites (e.g. ECS, residual disease, positive tumour margins): 4-10 Gy dose augmentation (up to 66-70 Gy)

#### Palliative Radiotherapy (symptom control)

- 30-50 Gy, in 5-20 fractions

#### Prophylactic Radiotherapy (prevent growth in high-risk sites)</formatted_text>
    <audio_inserts count="3">
      <insert confidence="1" anchor="- 30-50 Gy, in 5-20 fractions">
- ==Its purpose is symptom control and reduction of tumour burden rather than complete eradication==</insert>
      <insert timestamp="00:40:44" confidence="8" anchor="### **Challenges Of Treatment Planning Before Radiotherapy**  Most medical proce">

&gt; [!note] Lecturer — Radiotherapy Trajectory
&gt; Head and neck radiotherapy creates a complex oral health trajectory because the risk of dental disease increases after treatment, but the extent of oral deterioration varies.
&gt;
&gt; - Radiation affects salivary glands and oral tissues.
&gt; - The patient’s previous dental trajectory may not predict the post-radiotherapy trajectory.
&gt; - Dental treatment timing must be balanced against the urgency of cancer treatment.
</insert>
      <insert timestamp="00:40:44" confidence="8" anchor="### **Radiation Field Plans**  ### **Osteoradionecrosis Prevention Guidelines**">

&gt; [!note] Lecturer — Radiation Field Planning
&gt; Modern radiation field plans are highly contoured to maximise the dose to the cancer site while minimising the dose to healthy tissues.
&gt;
&gt; - Earlier three-dimensional conformal radiotherapy produced broader fields and exposed more healthy tissue.
&gt; - Intensity-modulated radiotherapy allows more precise contouring of the treatment site.
&gt; - Dental planning should identify teeth receiving more than 60 Gy, areas receiving approximately 50 Gy or more, and whether the posterior mandible receives high-dose radiation.
&gt; - Dental treatment may need to be more aggressive for teeth receiving high doses.
</insert>
    </audio_inserts>
  </page>
  <page number="36">
    <text>Why is treatment planning before H&amp;N Radiotherapy
so challenging?

Most medical procedures have a modest effect on oral
health risk factors.

Predicting the patient’s future oral health trajectory is
often fairly straightforward: we examine their past
trajectory.

*But here’s where it gets tricky…*

For Head &amp; Neck radiotherapy patients, their risk of dental
disease almost always increases after treatment… but the
extent can vary from mild to catastrophic.

Predicting their future oral health trajectory is more
complex because there are many more variables.

Historical oral
health trajectory
Post-treatment oral
health trajectory

Historical oral
health trajectory
Post-radiotherapy oral
health trajectory

![Post-radiotherapy oral health trajectory](W1 HNC Patient Journey_figures/img_4afaa6d59b01a3bd.webp)</text>
    <formatted_text>Most medical procedures have a modest effect on oral health risk factors. Predicting the patient's future oral health trajectory is often fairly straightforward: we examine their past trajectory.

*But here's where it gets tricky…*

For Head &amp; Neck radiotherapy patients, their risk of dental disease almost always increases after treatment… but the extent can vary from mild to catastrophic. Predicting their future oral health trajectory is more complex because there are many more variables.

- Historical oral health trajectory → Post-treatment oral health trajectory
- Historical oral health trajectory → Post-radiotherapy oral health trajectory</formatted_text>
    <images>
      <img order="0" bbox="720,540,824,634" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_4afaa6d59b01a3bd.webp" caption="Post-radiotherapy oral health trajectory">
        <description>An illustration of a patient undergoing radiotherapy, showing a head model secured in a positioning mask beneath the gantry of a radiation machine.</description>
      </img>
    </images>
  </page>
  <page number="37">
    <text>RADIATION FIELDS PLANS

![](W1 HNC Patient Journey_figures/img_00ac8246fe6d1833.webp)
![](W1 HNC Patient Journey_figures/img_25ecbd06afdd3c76.webp)
![](W1 HNC Patient Journey_figures/img_08eb31f0d879ea63.webp)
![](W1 HNC Patient Journey_figures/img_e1cb6d44d346dde5.webp)</text>
    <formatted_text>Radiation field plans</formatted_text>
    <images>
      <img order="0" bbox="88,361,430,704" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_00ac8246fe6d1833.webp">
        <description>Clinical photo showing a patient in supine position fitted with a custom mesh immobilization mask covering the head and neck, extending to the shoulders. The device is attached to a base plate on the treatment table.</description>
      </img>
      <img order="1" bbox="479,325,839,547" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="W1 HNC Patient Journey_figures/img_25ecbd06afdd3c76.webp">
        <description>This image is a radiation dose distribution plan (isodose chart) overlaid on an axial CT slice of the head and neck region. It displays multiple colored contour lines representing different radiation dose levels, which are quantified by the vertical color scale bar on the right side ranging from 7.00 Gy to 77.00 Gy.</description>
      </img>
      <img order="2" bbox="478,551,655,771" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_08eb31f0d879ea63.webp">
        <description>A sagittal CT scan from a radiation therapy planning system showing the head and neck region with overlaid isodose curves (colored contours) indicating dose distribution. The image includes text annotations such as 'MaxDose 74.81 Gy' and a color-coded legend on the right mapping specific colors to absorbed dose levels in Gray (Gy).</description>
      </img>
      <img order="3" bbox="657,552,838,769" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_e1cb6d44d346dde5.webp">
        <description>A medical radiation treatment planning image displaying a coronal CT slice of the head and neck overlaid with color-coded isodose lines. A vertical scale on the right indicates radiation dose levels in Gray (Gy), ranging from 77.00 down to 28.00, illustrating the distribution of radiation intensity within the anatomical structures.</description>
      </img>
    </images>
  </page>
  <page number="38">
    <text>PREVENTION AND
MANAGEMENT OF
ORN GUIDELINES
2024

International Society of Oral Oncology
Multinational Association for Supportive Care
in Cancer
American Society of Clinical Oncology

ASCO Special Articles
Check for u

Prevention and Management of Osteoradionecrosis in
Patients With Head and Neck Cancer Treated With Radiation
Therapy: ISOO-MASCC-ASCO Guideline

Douglas E. Peterson, DMD, PhD, FDS RCSED, FASCO¹; Shlomo A. Koyfman, MD²; Noam Yarom, DMD, MPH³⁴;
Charlotte Duch Lynggaard, MD, PhD⁵; Nofisat Ismaila, MD, MSc⁶; Lone E. Forner, DDS, PhD⁷; Clifton David Fuller, MD, PhD⁸;
Yvonne M. Mowery, MD, PhD⁹¹⁰; Barbara A. Murphy, MD¹¹; Erin Watson, DMD, MHSc¹²; David H. Yang, DDS, FRCD(C)¹³;
Ivan Alajbeg, DMD, MSc, PhD¹⁴¹⁵; Paolo Bossi, MD¹⁵¹⁶; Michael Fritz, MD²; Neal D. Futran, MD, DMD¹⁷; Daphna Y. Gelblum, MD¹⁸;
Edward King, JD¹⁹; Salvatore Ruggiero, DMD, MD, FACS²⁰; Derek K. Smith, DDS, PhD, MPH²¹; Alessandro Villa, DDS, MPH, PhD²²;
Jonn S. Wu, BMSc, MD, FRCPC¹³; and Deborah Saunders, DMD²³

DOI https://doi.org/10.1200/JCO.23.02750

ABSTRACT
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant
literature for each recommendation, following the guideline development process as outlined in the
ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy
for Clinical Practice Guidelines.

Clinical Practice Guidelines and other guidance (&quot;Guidance&quot;) provided by ASCO is not a comprehensive
or definitive guide to treatment options. It is intended for voluntary use by providers and should be used
in conjunction with independent professional judgment. Guidance may not be applicable to all patients,
interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant
literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party
drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related
to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only)
for more.

PURPOSE To provide evidence-based recommendations for prevention and man-
agement of osteoradionecrosis (ORN) of the jaw secondary to head and
neck radiation therapy in patients with cancer.

METHODS The International Society of Oral Oncology–Multinational Association for
Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidis-
ciplinary Expert Panel to evaluate the evidence and formulate recommen-
dations. PubMed, EMBASE, and Cochrane Library databases were searched
for randomized controlled trials and observational studies, published be-
tween January 1, 2009, and December 1, 2023. The guideline also incorpo-
rated systematic reviews conducted by ISOO-MASCC, which included studies
published from January 1, 1990, through December 31, 2008.

RESULTS A total of 1,539 publications were initially identified. There were 487
duplicate publications, resulting in 1,052 studies screened by abstract, 104
screened by full text, and 80 included for systematic review evaluation.

RECOMMENDATIONS Due to limitations of available evidence, the guideline relied on informal
consensus for some recommendations. Recommendations that were
deemed evidence-based with strong evidence by the Expert Panel were those

ACCOMPANYING CONTENT
Appendix
Data Supplement

Accepted January 22, 2024
Published May 1, 2024

Evidence Based Medicine
Committee approval:
December 15, 2023
ISOO-MASCC approval:
November 9, 2023

J Clin Oncol 00:1-22
© 2024 by American Society of
Clinical Oncology

View Online
Article

38</text>
    <formatted_text>*Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline*

Douglas E. Peterson, DMD, PhD, FDS RCSED, FASCO; Shlomo A. Koyfman, MD; Noam Yarom, DMD, MPH; Charlotte Duch Lynggaard, MD, PhD; Nofisat Ismaila, MD, MSc; Lone E. Forner, DDS, PhD; Clifton David Fuller, MD, PhD; Yvonne M. Mowery, MD, PhD; Barbara A. Murphy, MD; Erin Watson, DMD, MHSc; David H. Yang, DDS, FRCD(C); Ivan Alajbeg, DMD, MSc, PhD; Paolo Bossi, MD; Michael Fritz, MD; Neal D. Futran, MD, DMD; Daphna Y. Gelblum, MD; Edward King, JD; Salvatore Ruggiero, DMD, MD, FACS; Derek K. Smith, DDS, PhD, MPH; Alessandro Villa, DDS, MPH, PhD; Jonn S. Wu, BMSc, MD, FRCPC; and Deborah Saunders, DMD

DOI: https://doi.org/10.1200/JCO.23.02750

#### Purpose

To provide evidence-based recommendations for prevention and management of osteoradionecrosis (ORN) of the jaw secondary to head and neck radiation therapy in patients with cancer.

#### Methods

The International Society of Oral Oncology–Multinational Association for Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library databases were searched for randomized controlled trials and observational studies, published between January 1, 2009, and December 1, 2023. The guideline also incorporated systematic reviews conducted by ISOO-MASCC, which included studies published from January 1, 1990, through December 31, 2008.

#### Results

A total of 1,539 publications were initially identified. There were 487 duplicate publications, resulting in 1,052 studies screened by abstract, 104 screened by full text, and 80 included for systematic review evaluation.

#### Recommendations

Due to limitations of available evidence, the guideline relied on informal consensus for some recommendations. Recommendations that were deemed evidence-based with strong evidence by the Expert Panel were those…

*J Clin Oncol 00:1-22. © 2024 by American Society of Clinical Oncology. Accepted January 22, 2024; published May 1, 2024. ISOO-MASCC approval: November 9, 2023; Evidence Based Medicine Committee approval: December 15, 2023.*</formatted_text>
    <images>
      <img order="0" bbox="898,637,938,688" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A black-and-white QR code is visible in the crop.</description>
      </img>
    </images>
  </page>
  <page number="39">
    <text>PRE-THERAPY DENTAL MANAGEMENT

• **Extract teeth** with doubtful long-term prognosis (especially mandibular teeth planned for &gt;60Gy) at least 10-14 days prior to RT
   • Balance against the risks of delaying RT (e.g. OAC, co-morbidities that may contribute to delayed healing, MRONJ)
• **Recontour/restore sharp teeth**, failing restorations, carious cavities with potential to traumatise soft tissues or flap
• **Assess dentures** = modify ill-fitting dentures if possible
• Joint planning with **surgical team** if surgery will alter oral cavity (e.g. maxillectomy requiring obturator construction, dental extractions as part of resection or cancer margin monitoring)


![From: Brandão, T.B., Migliorati, C.A., Vechiato-Filho, A.J. et al. Strategic use of obturator prostheses for the rehabilitation of oral cancer patients during the COVID-19 pandemic. Support Care Cancer 29, 11–15 (2021).](W1 HNC Patient Journey_figures/img_9a04e3e77bc2add8.webp)</text>
    <formatted_text>- **Extract teeth** with doubtful long-term prognosis (especially mandibular teeth planned for &gt;60 Gy) at least 10-14 days prior to RT
  - Balance against the risks of delaying RT (e.g. OAC, co-morbidities that may contribute to delayed healing, MRONJ)
- **Recontour/restore sharp teeth**, failing restorations, carious cavities with potential to traumatise soft tissues or flap
- **Assess dentures** = modify ill-fitting dentures if possible
- Joint planning with the **surgical team** if surgery will alter the oral cavity (e.g. maxillectomy requiring obturator construction, dental extractions as part of resection or cancer margin monitoring)</formatted_text>
    <images>
      <img order="0" bbox="610,400,965,621" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_9a04e3e77bc2add8.webp" caption="From: Brandão, T.B., Migliorati, C.A., Vechiato-Filho, A.J. et al. Strategic use of obturator prostheses for the rehabilitation of oral cancer patients during the COVID-19 pandemic. Support Care Cancer 29, 11–15 (2021).">
        <description>A composite figure containing six clinical photographs and views of dental prostheses, illustrating the fabrication and placement of an obturator for a patient following maxillectomy. The sequence shows the pre-operative dentition (a), post-surgical defect with exposed hardware (b), the resulting open communication between oral and nasal cavities (c), the fabricated acrylic obturator prosthesis (d, e), and the final rehabilitation with the obturator in place closing the defect (f).</description>
      </img>
    </images>
  </page>
  <page number="40">
    <text>&lt;h2&gt;KEY FACTORS TO DETERMINE TREATMENT APPROACH&lt;/h2&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;Cancer-related factors&lt;/th&gt;
    &lt;th&gt;Patient-related factors&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Cancer prognosis&lt;/td&gt;
    &lt;td&gt;• Other co-morbidities&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Urgency to commence radiotherapy&lt;/td&gt;
    &lt;td&gt;• Physiological tolerance / risks of dental tx&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Irradiation dose &amp;gt;50Gy (risk ↑ 11x if &amp;gt;66Gy)&lt;/td&gt;
    &lt;td&gt;• Patient prognosis&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Site&lt;/td&gt;
    &lt;td&gt;• Patient function (e.g. morbidity of surgery, dysphagia, QOL, wishes)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&amp;nbsp;&amp;nbsp;• Posterior &amp;gt; anterior&lt;/td&gt;
    &lt;td&gt;• Patient motivation and psychology&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&amp;nbsp;&amp;nbsp;• Mandible &amp;gt; maxilla 24:1&lt;/td&gt;
    &lt;td&gt;• Maintenance (motivation, access, ability)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Tooth extraction timing (&amp;lt;21 days pre-RT)&lt;/td&gt;
    &lt;td&gt;• Risks of extraction (OAC, IAN, MRONJ)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Cancer-related trismus&lt;/td&gt;
    &lt;td&gt;• Periodontal health and oral hygiene&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;• Alcohol/tobacco use&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;• Nutritional status&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;• Dentate &amp;gt; edentate&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;• Poor prosthetic adjustment&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

Peterson DE, et al. Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: ISOO-MASCC-ASOC Guideline. J Clin Oncol. 2024;42(16):1975-1996
Nabil S, Samman N. Risk factors for osteoradionecrosis after head and neck radiation: a systematic review. Oral Surg Oral Med Oral Path Oral Radiol. 2012;113(1):54-69.
Frankart AJ, et al. Osteoradionecrosis: Exposing the evidence not the bone. Int J Radiat Oncol Biol Phys. 2021;109(5):1206-18.
Beadle B, et al. Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER–Medicare analysis. Head Neck. 2012;35:1599-605
Raguse J-D, et al. Patient and treatment-related risk factors for osteoradionecrosis of the jaw in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(3):215-21</text>
    <formatted_text>#### Cancer-Related Factors

- Cancer prognosis
- Urgency to commence radiotherapy
- Irradiation dose &gt;50 Gy (risk ↑ 11x if &gt;66 Gy)
- Site:
  - Posterior &gt; anterior
  - Mandible &gt; maxilla 24:1
- Tooth extraction timing (&lt;21 days pre-RT)
- Cancer-related trismus

#### Patient-Related Factors

- Other co-morbidities
- Physiological tolerance / risks of dental tx
- Patient prognosis
- Patient function (e.g. morbidity of surgery, dysphagia, QOL, wishes)
- Patient motivation and psychology
- Maintenance (motivation, access, ability)
- Risks of extraction (OAC, IAN, MRONJ)
- Periodontal health and oral hygiene
- Alcohol/tobacco use
- Nutritional status
- Dentate &gt; edentate
- Poor prosthetic adjustment

*Peterson DE, et al. Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: ISOO-MASCC-ASOC Guideline. J Clin Oncol. 2024;42(16):1975-1996.*

*Nabil S, Samman N. Risk factors for osteoradionecrosis after head and neck radiation: a systematic review. Oral Surg Oral Med Oral Path Oral Radiol. 2012;113(1):54-69.*

*Frankart AJ, et al. Osteoradionecrosis: Exposing the evidence not the bone. Int J Radiat Oncol Biol Phys. 2021;109(5):1206-18.*

*Beadle B, et al. Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER–Medicare analysis. Head Neck. 2012;35:1599-605.*

*Raguse J-D, et al. Patient and treatment-related risk factors for osteoradionecrosis of the jaw in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(3):215-21.*</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:17:28" confidence="4" anchor="- Tooth extraction timing (&lt;21 days pre-RT) - Cancer-related trismus">
- ==Whether the patient is being treated with curative or palliative intent==</insert>
      <insert timestamp="00:24:48" confidence="2" anchor="- Dentate &gt; edentate - Poor prosthetic adjustment">
- ==Willingness to attend regular dental appointments==</insert>
    </audio_inserts>
  </page>
  <page number="41">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
&lt;h1&gt;PRE-RT EXTRACTIONS&lt;/h1&gt;
&lt;/div&gt;

*   Teeth with &lt;span style=&quot;color: red;&quot;&gt;doubtful prognosis should be extracted as early as possible&lt;/span&gt; in the patient journey before RT.
    *   Ideally allow 3 weeks healing before RT, minimum 10-14 days

*   Pre-RT extractions still pose a &lt;span style=&quot;color: red;&quot;&gt;risk of developing ORN&lt;/span&gt;
    *   Irradiation of healing bone
    *   2017 Moon et al: pre-RT tooth extractions independent risk factor for ORN (hazard ratio 4.52)
    *   2013 Cochrane review: no evidence from RCTs to support or refute extraction of healthy or diseased teeth prior to ORN
    *   1986 – 2006: ORN pooled incidence after pre-RT extraction 3.0-3.2%, post-RT extraction 3.1 – 3.5%
    *   Prophylactic extractions of healthy/restorable molars within the anticipated RT field $\rightarrow$ no longer considered appropriate

*   Most established guidelines still argue for pre-RT extraction of teeth with &lt;span style=&quot;color: red;&quot;&gt;poor to hopeless long-term prognoses&lt;/span&gt;
    *   Majority of studies report higher rate of ORN post-RT extractions
    *   Beumer et al: ORN more often requires radical resection with post-RT extraction (45.4%) than pre-RT (11.7%)

Kumar N, et al. The oral management of oncology patients requiring radiotherapy, chemotherapy and/or bone marrow transplantation. London: Royal College of Surgeons and British Society for Disability &amp; Oral Health; 2018. Available from: https://www.rcseng.ac.uk/dentalfaculties/fds/publications-guidelines/clinical-guidelines/
McCaul LK, et al. Predicting and managing oral and dental complications of surgical and non-surgical treatment for head and neck cancer - A clinical guideline. United Kingdom: Restorative Dentistry UK, British Association of Head and Neck Oncology Nurses, British Association of Head and Neck Oncologists, Royal College of Speech &amp; Language Therapists, ENT UK, British Dieticians Association, British Association of Oral and Maxillofacial Surgeons; 2016.
Eliyas S, Al-Khayatt A, Porter RWJ, Briggs P. Dental extractions prior to radiotherapy to the jaws for reducing post-radiotherapy dental complications. The Cochrane database of systematic reviews. 2013;2013(2):CD008857
Moon DH, et al. Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. Oral Oncol. 2017;72:98-103.
Beech NM, Porceddu S, Batstone MD. Radiotherapy-associated dental extractions and osteoradionecrosis. Head Neck. 2017;39(1):128-32.
Chang DT, et al. Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? Head Neck. 2007;29(6):528.
Beumer 3rd J, et al. Osteoradionecrosis: Predisposing factors and outcomes of therapy. Head Neck Surg. 1984;64:819-27</text>
    <formatted_text>- **Teeth with doubtful prognosis should be extracted as early as possible** in the patient journey before RT.
  - Ideally allow 3 weeks healing before RT, minimum 10-14 days

- **Pre-RT extractions still pose a risk of developing ORN**
  - Irradiation of healing bone
  - 2017 Moon et al: pre-RT tooth extractions an independent risk factor for ORN (hazard ratio 4.52)
  - 2013 Cochrane review: no evidence from RCTs to support or refute extraction of healthy or diseased teeth prior to ORN
  - 1986–2006: ORN pooled incidence after pre-RT extraction 3.0-3.2%, post-RT extraction 3.1-3.5%
  - Prophylactic extractions of healthy/restorable molars within the anticipated RT field → no longer considered appropriate

- **Most established guidelines still argue for pre-RT extraction of teeth with poor to hopeless long-term prognoses**
  - Majority of studies report higher rate of ORN post-RT extractions
  - Beumer et al: ORN more often requires radical resection with post-RT extraction (45.4%) than pre-RT (11.7%)

*Kumar N, et al. The oral management of oncology patients requiring radiotherapy, chemotherapy and/or bone marrow transplantation. London: Royal College of Surgeons and British Society for Disability &amp; Oral Health; 2018. Available from: https://www.rcseng.ac.uk/dentalfaculties/fds/publications-guidelines/clinical-guidelines/.*

*McCaul LK, et al. Predicting and managing oral and dental complications of surgical and non-surgical treatment for head and neck cancer - A clinical guideline. United Kingdom: Restorative Dentistry UK, British Association of Head and Neck Oncology Nurses, British Association of Head and Neck Oncologists, Royal College of Speech &amp; Language Therapists, ENT UK, British Dieticians Association, British Association of Oral and Maxillofacial Surgeons; 2016.*

*Eliyas S, Al-Khayatt A, Porter RWJ, Briggs P. Dental extractions prior to radiotherapy to the jaws for reducing post-radiotherapy dental complications. The Cochrane database of systematic reviews. 2013;2013(2):CD008857.*

*Moon DH, et al. Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. Oral Oncol. 2017;72:98-103.*

*Beech NM, Porceddu S, Batstone MD. Radiotherapy-associated dental extractions and osteoradionecrosis. Head Neck. 2017;39(1):128-32.*

*Chang DT, et al. Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? Head Neck. 2007;29(6):528.*

*Beumer 3rd J, et al. Osteoradionecrosis: Predisposing factors and outcomes of therapy. Head Neck Surg. 1984;64:819-27.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:46:21" confidence="9" anchor="- **Pre-RT extractions still pose a risk of developing ORN**   - Irradiation of ">

&gt; [!note] Lecturer — Healing After Extraction
&gt; Extraction before radiotherapy does not eliminate the risk of osteoradionecrosis because the healing socket may still receive high-dose radiation.
&gt;
&gt; - Bone turnover remains rapid in the healing socket.
&gt; - Oncological treatment often cannot be delayed until complete healing.
&gt; - Full resolution of the extraction site may take up to a year.
</insert>
    </audio_inserts>
  </page>
  <page number="42">
    <text>DENTAL TREATMENT PROTOCOLS PRIOR TO H&amp;N RT

ORN Prevention and Management in Head and Neck Cancer

| Dental Pathology | Complete Dental Clearance | Partial Dental Clearance | Limited Dental Clearance |
| :--- | :--- | :--- | :--- |
| Caries | Restore all teeth | Restore deep caries; mild/moderate caries restored if time permits | Intervention only if symptomatic |
| Severe caries/pulp involvement/ dental abscess | Extraction | Extraction | Intervention only if symptomatic |
| Apical periodontitis—previous endodontic treatment | Extraction of symptomatic lesions and lesions ≥5 mm | Extraction of symptomatic lesions and lesions ≥5 mm | Intervention only if symptomatic |
| | Surveillance of asymptomatic lesions &lt;5 mm | Surveillance of asymptomatic lesions &lt;5 mm | Intervention only if symptomatic |
| Apical periodontitis—no previous endodontic treatment | Extraction or endodontic therapy for restorable, periodontally sound teeth | Extraction or endodontic therapy of restorable, periodontally sound teeth | Intervention only if symptomatic |
| Advanced periodontal disease | Extract teeth with | Extract teeth with | Intervention only if symptomatic |
| | Probing depth ≥5 mm | Probing depth ≥5 mm | |
| | Furcation II, III; Mobility II, III | Furcation II, III; Mobility II, III | |
| | Severe inflammation | Severe inflammation | |
| Partially erupted third molars | Extract | Extraction of symptomatic teeth; consider requesting radiation delay | Intervention only if symptomatic |

NOTE. The proper protocol should be selected by the oncologist and dentist according to the patient's medical status. Limited clearance would be indicated for patients treated with noncurative intent. Partial and complete clearance protocols are based on patients being treated with curative-intent radiotherapy and appropriate access to care. In general, patients with at least 2 weeks of healing available before radiation can be treated with complete clearance and those with less than 2 weeks of time can be treated with partial clearance.
*Clearance protocols should be applied to teeth that will receive a therapeutic dose of radiation. For teeth that will receive below a therapeutic dose, minimal clearance protocols can be applied.

Peterson DE, et al. Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: ISOO-MASCC-ASOC Guideline. J Clin Oncol. 2024;42(16):1975-1996
• Lalla RV, Hodges JS, Treister NS, et al: Tooth-level predictors of tooth loss and exposed bone after radiation therapy for head and neck cancer. J Am Dent Assoc. 2023;154:519-528.e4
• Watson E, Dorna Mojdami Z, Oladega A, et al: Clinical practice guidelines for dental management prior to radiation for head and neck cancer. Oral Oncol . 123:105604, 2021

![TABLE A3. Descriptions of Complete, Partial, and Minimal Dental Evaluation Protocols on the Basis of the Type of Dental and/or Periodontal Pathology*†,‡](W1 HNC Patient Journey_figures/img_65543008123a4255.webp)</text>
    <formatted_text>ORN Prevention and Management in Head and Neck Cancer

| Dental Pathology | Complete Dental Clearance | Partial Dental Clearance | Limited Dental Clearance |
| :--- | :--- | :--- | :--- |
| Caries | Restore all teeth | Restore deep caries; mild/moderate caries restored if time permits | Intervention only if symptomatic |
| Severe caries/pulp involvement/dental abscess | Extraction | Extraction | Intervention only if symptomatic |
| Apical periodontitis—previous endodontic treatment | Extraction of symptomatic lesions and lesions ≥5 mm; surveillance of asymptomatic lesions &lt;5 mm | Extraction of symptomatic lesions and lesions ≥5 mm; surveillance of asymptomatic lesions &lt;5 mm | Intervention only if symptomatic |
| Apical periodontitis—no previous endodontic treatment | Extraction or endodontic therapy for restorable, periodontally sound teeth | Extraction or endodontic therapy of restorable, periodontally sound teeth | Intervention only if symptomatic |
| Advanced periodontal disease | Extract teeth with: probing depth ≥5 mm; furcation II, III; mobility II, III; severe inflammation | Extract teeth with: probing depth ≥5 mm; furcation II, III; mobility II, III; severe inflammation | Intervention only if symptomatic |
| Partially erupted third molars | Extract | Extraction of symptomatic teeth; consider requesting radiation delay | Intervention only if symptomatic |

**NOTE.** The proper protocol should be selected by the oncologist and dentist according to the patient's medical status. Limited clearance would be indicated for patients treated with noncurative intent. Partial and complete clearance protocols are based on patients being treated with curative-intent radiotherapy and appropriate access to care. In general, patients with at least 2 weeks of healing available before radiation can be treated with complete clearance and those with less than 2 weeks of time can be treated with partial clearance.

*Clearance protocols should be applied to teeth that will receive a therapeutic dose of radiation. For teeth that will receive below a therapeutic dose, minimal clearance protocols can be applied.*

*Peterson DE, et al. Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: ISOO-MASCC-ASOC Guideline. J Clin Oncol. 2024;42(16):1975-1996.*

*Lalla RV, Hodges JS, Treister NS, et al. Tooth-level predictors of tooth loss and exposed bone after radiation therapy for head and neck cancer. J Am Dent Assoc. 2023;154:519-528.e4.*

*Watson E, Dorna Mojdami Z, Oladega A, et al. Clinical practice guidelines for dental management prior to radiation for head and neck cancer. Oral Oncol. 123:105604, 2021.*</formatted_text>
    <images>
      <img order="0" bbox="232,320,766,612" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_65543008123a4255.webp" caption="TABLE A3. Descriptions of Complete, Partial, and Minimal Dental Evaluation Protocols on the Basis of the Type of Dental and/or Periodontal Pathology*†,‡">
        <description>Table: This grid outlines dental evaluation protocols, categorized by specific pathologies such as caries, apical periodontitis, and advanced periodontal disease. It details the required interventions for three levels of clearance: Complete, Partial, and Limited, ranging from full restorations to symptom-based management.</description>
      </img>
    </images>
  </page>
  <page number="43">
    <text>**THINKING IT THROUGH… H&amp;N RADIOTHERAPY**

**Rationale**
*   Reducing initiating factors for ORN within an irradiated site
*   Curative-intent radiotherapy

**Medical, Dental and Social Considerations**
*   Long-term prognosis of tooth
*   Ability to tolerate extractions (pain, cancer-induced trismus)
*   Risks of extraction (other medical co-morbidities, OAC, IAN, MRONJ)
*   Ability for tooth to be maintained post-surgery &amp; RT (restricted mouth opening, surgical flaps/grafts)
*   Compliance with ongoing preventive oral care
*   Ongoing alcohol and tobacco use
*   Concomitant oral disease (periodontal disease, periapical pathology) = infection risk factor for ORN
*   Focus on preventive oral hygiene measures
*   Education about life-long risks of ORN
*   Tooth location

**Entire or localised areas of the mouth**
*   Anticipated radiation fields &gt;50-60Gy
*   Maxilla vs mandible
*   Anterior vs posterior
*   Mucosal trauma during period of mucositis

**Optimal Timeframes**
*   Ideally future-proof for life-long foreseeable future
*   Urgency to commence RT vs time available for healing (min 14 days healing, ideally 2-3 wks)
*   Prioritise care that reduces mucosal trauma or need for future oral surgery impacting on bone (e.g. poor prognosis tooth extraction, poorly fitting dentures)
*   If extractions will alter VDO, perform prior to immobilisation mask fabrication
*   Rapidly progressing tumours: defer extractions, do not delay RT initiation

**Treatment Approaches**
*   Curative intent tx: Typically aggressive pre-RT, then conservative post-RT
*   Long-term medical prognosis, physiological tolerance
*   Resulting QOL (# appts, functionality)</text>
    <formatted_text>#### Rationale

- Reducing initiating factors for ORN within an irradiated site
- Curative-intent radiotherapy

#### Medical, Dental and Social Considerations

- Long-term prognosis of tooth
- Ability to tolerate extractions (pain, cancer-induced trismus)
- Risks of extraction (other medical co-morbidities, OAC, IAN, MRONJ)
- Ability for tooth to be maintained post-surgery &amp; RT (restricted mouth opening, surgical flaps/grafts)
- Compliance with ongoing preventive oral care
- Ongoing alcohol and tobacco use
- Concomitant oral disease (periodontal disease, periapical pathology) = infection risk factor for ORN
- Focus on preventive oral hygiene measures
- Education about life-long risks of ORN
- Tooth location

#### Entire or Localised Areas of the Mouth

- Anticipated radiation fields &gt;50-60 Gy
- Maxilla vs mandible
- Anterior vs posterior
- Mucosal trauma during period of mucositis

#### Optimal Timeframes

- Ideally future-proof for life-long foreseeable future
- Urgency to commence RT vs time available for healing (min 14 days healing, ideally 2-3 wks)
- Prioritise care that reduces mucosal trauma or need for future oral surgery impacting on bone (e.g. poor prognosis tooth extraction, poorly fitting dentures)
- If extractions will alter VDO, perform prior to immobilisation mask fabrication
- Rapidly progressing tumours: defer extractions, do not delay RT initiation

#### Treatment Approaches

- Curative intent tx: typically aggressive pre-RT, then conservative post-RT
- Long-term medical prognosis, physiological tolerance
- Resulting QOL (# appts, functionality)</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:49:14" confidence="5" anchor="- If extractions will alter VDO, perform prior to immobilisation mask fabricatio">
- ==If extractions alter the occlusal vertical dimension after the mask is made, the radiotherapy plan may require remaking==</insert>
      <insert timestamp="00:50:48" confidence="8" anchor="- Resulting QOL (# appts, functionality)">

&gt; [!note] Lecturer — Lower Dentures
&gt; Retaining lower teeth where possible may avoid a full lower denture in a dry mouth. A full lower denture may be difficult to retain in a dry mouth and may increase the risk of thrush.
</insert>
      <insert timestamp="00:22:29" confidence="4" anchor="Contexts: Induction (neo-adjuvant) chemotherapy Primary chemoradiotherapy Adjuva">
- ==Chemotherapy may also be used as a radio-sensitising treatment.==</insert>
    </audio_inserts>
  </page>
  <page number="44">
    <text>&lt;div align=&quot;center&quot;&gt;&lt;b&gt;CHEMOTHERAPY&lt;/b&gt;&lt;/div&gt;

*   &lt;b&gt;Not a curative treatment for HNC alone&lt;/b&gt;
*   Contexts:
    *   Induction (neo-adjuvant) chemotherapy
    *   Primary chemoradiotherapy
    *   Adjuvant chemoradiotherapy
    *   Palliation
*   Typical chemotherapy drugs: *cisplatin, carboplatin, docetaxel, 5-fluorouracil and hydroxyurea
*   Typical schedule: 3 doses, 3 weekly during RT (start, middle, end)</text>
    <formatted_text>- **Not a curative treatment for HNC alone**
- Contexts:
  - Induction (neo-adjuvant) chemotherapy
  - Primary chemoradiotherapy
  - Adjuvant chemoradiotherapy
  - Palliation
- Typical chemotherapy drugs: *cisplatin, carboplatin, docetaxel, 5-fluorouracil and hydroxyurea*
- Typical schedule: 3 doses, 3 weekly during RT (start, middle, end)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:55:22" confidence="2" anchor="Typical schedule: 3 doses, 3 weekly during RT (start, middle, end)">
- ==Cisplatin is administered intravenously in the cancer centre, with the infusion taking approximately four hours.==</insert>
    </audio_inserts>
  </page>
  <page number="45">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
&lt;h2&gt;IMMUNOTHERAPY&lt;/h2&gt;
&lt;/div&gt;

*   **Immunotherapy**: form of biological therapy that stimulates the body’s immune system to detect and act against cancer cells
*   Examples in H&amp;N cancer context: cetixumab, nivolumab
*   Growing field
*   Advantages:
    *   higher specificity against malignant cells thus fewer side-effects
    *   ability to target both microscopic disease and widespread metastases
    *   increased efficacy against cancer cells that are slowly dividing or quiescent (do not preferentially attack dividing cells c.f. radiation and chemotherapy)
    *   potential to provide long-term control (immune system’s ability to develop “memory” cells)</text>
    <formatted_text>- **Immunotherapy**: form of biological therapy that stimulates the body's immune system to detect and act against cancer cells
- Examples in H&amp;N cancer context: cetuximab, nivolumab
- Growing field
- Advantages:
  - Higher specificity against malignant cells thus fewer side-effects
  - Ability to target both microscopic disease and widespread metastases
  - Increased efficacy against cancer cells that are slowly dividing or quiescent (do not preferentially attack dividing cells c.f. radiation and chemotherapy)
  - Potential to provide long-term control (immune system's ability to develop &quot;memory&quot; cells)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:23:23" confidence="4" anchor="Potential to provide long-term control (immune system's ability to develop &quot;memo">
- ==Neoadjuvant immunotherapy may be administered before surgery, followed by further cycles afterwards.==</insert>
    </audio_inserts>
  </page>
  <page number="46">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 30px;&quot;&gt;
  IMPACTS OF CANCER&lt;br&gt;TREATMENT ON THE MOUTH
&lt;/div&gt;

&lt;h3 style=&quot;color: #607D8B;&quot;&gt;SHORT-TERM EFFECTS&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Mouth Lining&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Increased inflammation, damage to cell layering &amp;rarr; mucositis&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Tastebuds&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Altered taste sensation; loss of taste sensation&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 style=&quot;color: #607D8B;&quot;&gt;LONG-TERM EFFECTS&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Salivary Glands&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Decreased saliva volume; change in quality&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Oral Flora&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Changed environment &amp;rarr; changed organism profile&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Jaw Joints &amp;amp; Facial Musculature&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Fibrosis &amp;rarr; limited mouth opening, tightness on opening&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Bone of the Jaws&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Decreased blood/oxygen supply &amp;rarr; reduced healing capacity&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;</text>
    <formatted_text>#### Short-Term Effects

- **Mouth lining**
  - Increased inflammation, damage to cell layering → mucositis
- **Tastebuds**
  - Altered taste sensation; loss of taste sensation

#### Long-Term Effects

- **Salivary glands**
  - Decreased saliva volume; change in quality
- **Oral flora**
  - Changed environment → changed organism profile
- **Jaw joints &amp; facial musculature**
  - Fibrosis → limited mouth opening, tightness on opening
- **Bone of the jaws**
  - Decreased blood/oxygen supply → reduced healing capacity</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:26:50" confidence="4" anchor="- **Bone of the jaws**   - Decreased blood/oxygen supply → reduced healing capac">
- ==Osteoradionecrosis and periodontal susceptibility may occur as long-term effects.==</insert>
    </audio_inserts>
  </page>
  <page number="47">
    <text>MUCOSITIS

• Radiotherapy and chemotherapy damages cells → inflammation of the mouth lining (mucosa).
• Initially erythema → progress to painful ulcers with white/yellow fibrinous slough
• Onset ~2 weeks into treatment
• Effects generally short term:
    • Usually resolves at 2 to 6 weeks after completion of therapy.

Normal epithelium
Phase I Initiation
Radiation
Basal cell
Chemotherapy
Phase II/III Messaging, signaling, and amplification
Blood vessel
Phase IV Ulceration (mucositis)
Bacteria
Inflammatory cell
Phase V Healing
Fibroblast
Epithelial layer
Submucosa

Sonis S.A biological approach to mucositis. J Support Oncol. 2005;2(1):21-36.

![](W1 HNC Patient Journey_figures/img_1f9285314c9069bf.webp)
![](W1 HNC Patient Journey_figures/img_2893f8d89f986a3d.webp)
![Normal epithelium Phase I Initiation Phase II/III Messaging, signaling, and amplification Phase IV Ulceration (mucositis) Phase V Healing Epithelial layer Submucosa Basal cell Chemotherapy Blood vessel Inflammatory cell Fibroblast Sonis S.A biological approach to mucositis. J Support Oncol. 2005;2(1):21-36.](W1 HNC Patient Journey_figures/img_dd3830eacef7cca1.webp)</text>
    <formatted_text>- Radiotherapy and chemotherapy damages cells → inflammation of the mouth lining (mucosa).
- Initially erythema → progresses to painful ulcers with white/yellow fibrinous slough
- Onset ~2 weeks into treatment
- Effects generally short term:
  - Usually resolves at 2 to 6 weeks after completion of therapy.

*Phases of mucositis (figure content):* Normal epithelium; Phase I Initiation (radiation, basal cell, chemotherapy); Phase II/III Messaging, signaling, and amplification (blood vessel); Phase IV Ulceration – mucositis (bacteria, inflammatory cell); Phase V Healing (fibroblast); epithelial layer; submucosa.

*Sonis S. A biological approach to mucositis. J Support Oncol. 2005;2(1):21-36.*</formatted_text>
    <images>
      <img order="0" bbox="30,603,203,799" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_1f9285314c9069bf.webp">
        <description>Clinical photo: An intraoral photograph showing the buccal mucosa with patchy, bright erythematous areas surrounded by pale tissue, consistent with the initial stage of radiation-induced mucositis.</description>
      </img>
      <img order="1" bbox="222,603,413,802" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_2893f8d89f986a3d.webp">
        <description>Clinical photo: An intraoral view showing the tongue and surrounding oral mucosa affected by severe mucositis. The tissue exhibits diffuse erythema (redness) and is covered with white/yellowish fibrinous sloughs or pseudomembranes, indicative of ulceration and inflammation.</description>
      </img>
      <img order="2" bbox="531,610,826,794" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_dd3830eacef7cca1.webp" caption="Normal epithelium Phase I Initiation Phase II/III Messaging, signaling, and amplification Phase IV Ulceration (mucositis) Phase V Healing Epithelial layer Submucosa Basal cell Chemotherapy Blood vessel Inflammatory cell Fibroblast Sonis S.A biological approach to mucositis. J Support Oncol. 2005;2(1):21-36.">
        <description>This labelled diagram illustrates the five biological phases of oral mucositis, progressing from normal epithelium through initiation, messaging/signaling, ulceration, and healing. It depicts cross-sections of the epithelial layer and submucosa, showing cellular damage caused by radiation and chemotherapy, followed by amplification via blood vessels, bacterial invasion during ulceration, and fibroblast activity during the healing phase.</description>
      </img>
    </images>
  </page>
  <page number="48">
    <text>MUCOSITIS

• Complications:
• Painful to speak, eat, swallow
• Infection, sepsis
• Nutritional deficiencies, weight loss
• Dose-limiting factor, necessitating dose reduction or treatment delay

• Severity / healing determined by:
• Radiotherapy dose
• Radiation field size
• Fractionation schedules (hyperfractionated)
• Saliva volume
• Combination of chemo and radiotherapy
• Host immune and genomic factors
• Hepatic and renal impairment
• Tobacco smoking

Severe Mucositis
Grade 1
Soreness ± erythema
Grade 2
Erythema, ulcers; patient can swallow solid food
Grade 3
Ulcers with extensive erythema; patient cannot swallow food
Grade 4
Mucositis to the extent that alimentation is not possible

![WHO Mucositis Scale](W1 HNC Patient Journey_figures/img_e8ba7a0a4ff13e4f.webp)</text>
    <formatted_text>#### Complications

- Painful to speak, eat, swallow
- Infection, sepsis
- Nutritional deficiencies, weight loss
- Dose-limiting factor, necessitating dose reduction or treatment delay

#### Severity / Healing Determined By

- Radiotherapy dose
- Radiation field size
- Fractionation schedules (hyperfractionated)
- Saliva volume
- Combination of chemo and radiotherapy
- Host immune and genomic factors
- Hepatic and renal impairment
- Tobacco smoking

#### Severe Mucositis — Grading

- **Grade 1:** Soreness ± erythema
- **Grade 2:** Erythema, ulcers; patient can swallow solid food
- **Grade 3:** Ulcers with extensive erythema; patient cannot swallow food
- **Grade 4:** Mucositis to the extent that alimentation is not possible</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:57:31" confidence="3" anchor="- Dose-limiting factor, necessitating dose reduction or treatment delay">

&gt; [!note] Lecturer — Severe Mucositis
&gt; Severe mucositis can make solid food intolerable and may require nutritional support.
&gt;
&gt; - Patients may require nasogastric tube feeding.
&gt; - Difficulty maintaining oral hygiene and treatment-related weight loss may also complicate severe mucositis.
</insert>
      <insert timestamp="00:59:57" confidence="5" anchor="- Dose-limiting factor, necessitating dose reduction or treatment delay">

&gt; [!note] Lecturer — Mucositis Management
&gt; Management should be tailored to the patient’s presentation and reviewed regularly during radiotherapy.
&gt;
&gt; - Chlorhexidine may be used when appropriate, including 0.12% or 0.2% formulations; a 0.2% formulation may be diluted 50:50 with water if too strong while retaining some substantivity.
&gt; - A preventive fluoride rinse may be started before radiotherapy and continued until soreness develops, although ethanol-containing products may irritate the mucosa.
&gt; - Ice chips may be sucked for approximately 30 minutes before chemotherapy sessions.
</insert>
      <insert timestamp="00:57:17" confidence="2" anchor="- Tobacco smoking">
- ==The patient’s oral condition, nutritional status, infection, degree of ulceration, and ability to tolerate food and fluids also influence severity and healing.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="132,544,498,785" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_e8ba7a0a4ff13e4f.webp" caption="WHO Mucositis Scale">
        <description>This figure illustrates the WHO Mucositis Scale using a flowchart of text boxes paired with corresponding clinical photographs. It displays four grades ranging from Grade 1 (soreness ± erythema) to Grade 4 (mucositis preventing alimentation), visually depicting the progression of oral tissue damage.</description>
      </img>
    </images>
  </page>
  <page number="49">
    <text># MANAGEMENT OF MUCOSITIS

![](W1 HNC Patient Journey_figures/img_b86ddb87b8c72e83.webp)
![](W1 HNC Patient Journey_figures/img_e97f184301e0bd50.webp)
![](W1 HNC Patient Journey_figures/img_114e5e47edabb8b7.webp)
![](W1 HNC Patient Journey_figures/img_7d0b80c3bc562485.webp)
![](W1 HNC Patient Journey_figures/img_d9198416382981f2.webp)
![](W1 HNC Patient Journey_figures/img_fe46d8aceb9ca8ba.webp)
![](W1 HNC Patient Journey_figures/img_63286db322114a48.webp)
![](W1 HNC Patient Journey_figures/img_43dd943c4fe40c49.webp)
![](W1 HNC Patient Journey_figures/img_e1939dd401555e17.webp)
![](W1 HNC Patient Journey_figures/img_945370dbc9e84fc2.webp)</text>
    <images>
      <img order="0" bbox="97,336,196,513" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_b86ddb87b8c72e83.webp">
        <description>Product photo of a bottle and box of Difflam Anti-Inflammatory Solution, a pharmacy medicine providing fast relief of painful conditions of the throat and mouth.</description>
      </img>
      <img order="1" bbox="243,338,421,517" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_e97f184301e0bd50.webp">
        <description>A product photograph showing a bottle of green liquid alongside two boxes of Curasept Oral-Rinse mouthwash. The packaging identifies the solution as containing chlorhexidine, with one box specifying 'Extended Action 0.12' and the other 'Intensive treatment 0.30'.</description>
      </img>
      <img order="2" bbox="690,336,737,534" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_114e5e47edabb8b7.webp">
        <description>A product image of a tube of Oral7 Active Enzymes toothpaste, featuring branding and text highlighting 'Real Dry Mouth Relief' and the inclusion of enzymes.</description>
      </img>
      <img order="3" bbox="21,647,187,717" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_7d0b80c3bc562485.webp">
        <description>A cropped image of a tube of Orabase Protective Paste, showing the brand name and indication text.</description>
      </img>
      <img order="4" bbox="228,561,312,806" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_d9198416382981f2.webp">
        <description>A product photograph of a plastic bottle containing pink liquid, labeled as Xylocaine Viscous (lidocaine hydrochloride). The label indicates it is pharmacy medicine for topical anesthesia of the mouth and upper gastrointestinal tract.</description>
      </img>
      <img order="5" bbox="349,565,500,802" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_fe46d8aceb9ca8ba.webp">
        <description>Product photo of a bottle and box of Sedalotion, a pharmacy medicine in raspberry flavour. The packaging indicates it contains Lignocaine 2.5% w/v and is used to relieve pain from mouth ulcers, toothache, and sore gums.</description>
      </img>
      <img order="6" bbox="552,565,635,803" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_63286db322114a48.webp">
        <description>A product photograph of a blue bottle of Mylanta Antacid Original, featuring a green cap and label with text indicating relief for indigestion and heartburn.</description>
      </img>
      <img order="7" bbox="787,350,857,787" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_43dd943c4fe40c49.webp">
        <description>A photograph of a packaged surgical interdental brush, featuring a red handle and bristles in a blister pack labeled &quot;CURAPROX&quot;.</description>
      </img>
      <img order="8" bbox="665,570,741,801" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_e1939dd401555e17.webp">
        <description>A photograph of a bottle of Gaviscon Cool Liquid antacid. The label features the brand name 'GAVISCON' and the variety 'Cool Liquid', along with an icon of a flame, suggesting it is used for heartburn relief.</description>
      </img>
      <img order="9" bbox="880,402,965,729" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_945370dbc9e84fc2.webp">
        <description>A photograph of a packaged oral care product alongside its applicator. The packaging is labeled 'Coulident Care' and 'Oraswab', identifying it as a sterile foam swab used for mouth care.</description>
      </img>
    </images>
  </page>
  <page number="50">
    <text>&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;Diet that is typically acceptable&lt;/th&gt;
    &lt;th&gt;Food to Avoid&lt;/th&gt;
    &lt;th&gt;Lifestyle Habits to Avoid&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;
      &lt;ul&gt;
        &lt;li&gt;Liquids&lt;/li&gt;
        &lt;li&gt;Purees&lt;/li&gt;
        &lt;li&gt;Ice&lt;/li&gt;
        &lt;li&gt;Custards&lt;/li&gt;
        &lt;li&gt;Non-acidic fruits (banana, mango, melon, peach)&lt;/li&gt;
        &lt;li&gt;Soft cheese&lt;/li&gt;
        &lt;li&gt;Eggs&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
    &lt;td&gt;
      &lt;ul&gt;
        &lt;li&gt;Rough foods (potato crisps, toast)&lt;/li&gt;
        &lt;li&gt;Spicy foods&lt;/li&gt;
        &lt;li&gt;Salt&lt;/li&gt;
        &lt;li&gt;Acidic fruit (grapefruit, lemon, orange)&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
    &lt;td&gt;
      &lt;ul&gt;
        &lt;li&gt;Smoking&lt;/li&gt;
        &lt;li&gt;Alcohol&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>#### Diet Typically Acceptable

- Liquids
- Purees
- Ice
- Custards
- Non-acidic fruits (banana, mango, melon, peach)
- Soft cheese
- Eggs

#### Food to Avoid

- Rough foods (potato crisps, toast)
- Spicy foods
- Salt
- Acidic fruit (grapefruit, lemon, orange)

#### Lifestyle Habits to Avoid

- Smoking
- Alcohol</formatted_text>
    <audio_inserts count="3">
      <insert confidence="1" anchor="- Salt">
- ==Foods that irritate ulcerated mucosa==</insert>
      <insert timestamp="01:00:14" confidence="4" anchor="- Alcohol">

&gt; [!note] Lecturer — Plaque Removal
&gt; A very soft toothbrush, including a Curaprox surgical toothbrush, may help patients continue removing plaque when conventional bristles are too painful. If brushing is not tolerated, sponge sticks are preferable to doing nothing, although mechanical plaque removal remains preferable.
</insert>
      <insert timestamp="01:01:13" confidence="5" anchor="- Alcohol">

&gt; [!note] Lecturer — Topical Pain Relief
&gt; Topical pain relief may include 2% viscous lignocaine, known as “pink lady,” held in the mouth and swallowed approximately 30 minutes before meals. It may also be diluted or mixed with Mylanta or Gaviscon to create a thicker coating that helps food pass more comfortably.
</insert>
    </audio_inserts>
  </page>
  <page number="51">
    <text>LOSS OF TASTE

• Onsets at start of cancer treatment
• Related to dry mouth and direct damage to taste buds
• May start to recover within 2 to 4 months
• Taste often returns with an unpleasant interim period of altered taste
• Typically restored by 6 months
• If radiation dose &gt;60 Gy, loss of taste may be permanent

![](W1 HNC Patient Journey_figures/img_ced61aa265339d82.webp)</text>
    <formatted_text>- Onset at start of cancer treatment
- Related to dry mouth and direct damage to taste buds
- May start to recover within 2 to 4 months
- Taste often returns with an unpleasant interim period of altered taste
- Typically restored by 6 months
- If radiation dose &gt;60 Gy, loss of taste may be permanent</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:02:53" confidence="4" anchor="- Onset at start of cancer treatment - Related to dry mouth and direct damage to">

&gt; [!note] Lecturer — Altered Taste
&gt; Altered taste may begin approximately two weeks into radiotherapy.
&gt;
&gt; - Patients may experience a metallic taste.
&gt; - Sugar may taste unpleasant, salty foods may taste bland, and enjoyment of food may be reduced.
</insert>
      <insert timestamp="01:13:48" confidence="2" anchor="- If radiation dose &gt;60 Gy, loss of taste may be permanent">
- ==Taste commonly begins to recover after treatment, although the timing varies.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="707,428,828,638" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_ced61aa265339d82.webp">
        <description>A schematic diagram of a tongue illustrating the classic 'taste map' theory, with specific zones labeled for different taste sensations. The visible labels are 'BITTER', 'SALT', 'SOUR', and 'SWEET', corresponding to different regions of the tongue.</description>
      </img>
    </images>
  </page>
  <page number="52">
    <text>SALIVARY CHANGES AND THE SECONDARY COMPLICATIONS

Viscous, acidic, reduced pH &amp; buffering capacity, reduced quantity

• Difficulty with speech, eating (mastication) and swallowing (dysphagia)
• Mouth soreness
• Difficulty/discomfort wearing dentures
• Taste alteration/loss
• Reduced food clearance
• Changes in oral flora → fungal, viral, bacterial infections (e.g. oral thrush, salivary gland infections, gingival/periodontal disease progression)
• Radiation caries
• Dental erosion
• Increased risk of tooth wear and gingival recession (hyposalivation important contributor) → Tooth sensitivity
• ➔ QUALITY OF LIFE

![Parotid gland Sublingual gland Submandibular gland © Healthwise, Incorporated](W1 HNC Patient Journey_figures/img_dc8441a4eb35ac03.webp)
![](W1 HNC Patient Journey_figures/img_9a28b8eb08c055ab.webp)</text>
    <formatted_text>Saliva becomes viscous and acidic, with reduced pH and buffering capacity, and reduced quantity.

- Difficulty with speech, eating (mastication) and swallowing (dysphagia)
- Mouth soreness
- Difficulty/discomfort wearing dentures
- Taste alteration/loss
- Reduced food clearance
- Changes in oral flora → fungal, viral, bacterial infections (e.g. oral thrush, salivary gland infections, gingival/periodontal disease progression)
- Radiation caries
- Dental erosion
- Increased risk of tooth wear and gingival recession (hyposalivation important contributor) → tooth sensitivity
- → Quality of life</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="01:03:25" confidence="4" anchor="- → Quality of life">

&gt; [!note] Lecturer — Salivary Dose Effects
&gt; Radiation doses of approximately 10 grays may temporarily alter salivary flow and composition, while permanent damage may occur at approximately 30 grays.
</insert>
      <insert timestamp="01:06:18" confidence="6" anchor="#### **Managing Dry Mouth Symptoms**">

&gt; [!note] Lecturer — Dry Mouth Management
&gt; Dry-mouth management may include frequent sips of water, saliva substitutes, oral moisturising products, fluoride-containing products, and regular preventive dental care.
&gt;
&gt; - Sugar-free chewing gum may help where functional salivary tissue remains, but is less effective when salivary tissue has been significantly damaged.
&gt; - Saliva substitutes mentioned included Biotene, Oral7, and products incorporating some enzymes found in natural saliva.
&gt; - Lips may be kept moist with plant- or animal-based products such as lanolin or beeswax; petroleum-based products such as Vaseline act mainly as a barrier rather than moisturising the lips.
</insert>
      <insert timestamp="01:08:07" confidence="8" anchor="- Everyday use: For dry mouth, use more as needed throughout the day.">

&gt; [!note] Lecturer — XyliMelts Duration
&gt; XyliMelts may be particularly useful overnight when dry mouth is worse and causes repeated waking.
&gt;
&gt; - Adhesion strengthens over several minutes.
&gt; - A disc may last approximately four to six hours at night and one to three hours during the day, depending on dry-mouth severity.
&gt; - The discs may be used while eating or drinking and should not interfere with speaking or appearance.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="676,326,956,563" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_dc8441a4eb35ac03.webp" caption="Parotid gland Sublingual gland Submandibular gland © Healthwise, Incorporated">
        <description>Labelled anatomical diagram showing a profile view of the human head with the three major salivary glands highlighted in pink. The labels indicate the Parotid gland located near the ear, and the Sublingual and Submandibular glands located under the jaw.</description>
      </img>
      <img order="1" bbox="677,582,953,830" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_9a28b8eb08c055ab.webp">
        <description>A composite of four clinical intraoral photographs (labeled a, b, c, and d) displaying severe dental complications. The images illustrate extensive tooth wear, enamel erosion, and rampant caries with significant black staining and structural breakdown, particularly visible in the mandibular arches.</description>
      </img>
    </images>
  </page>
  <page number="53">
    <text>MANAGING THE SYMPTOMS OF DRY
MOUTH

![](W1 HNC Patient Journey_figures/img_62481ff013d8ddee.webp)
![](W1 HNC Patient Journey_figures/img_9a0dfc7c6858632f.webp)
![](W1 HNC Patient Journey_figures/img_cf6e87caea816e1c.webp)
![](W1 HNC Patient Journey_figures/img_86848eb5786d43c7.webp)
![](W1 HNC Patient Journey_figures/img_4f34cd79078e9fd9.webp)
![](W1 HNC Patient Journey_figures/img_dafd173bb6f79bbb.webp)
![](W1 HNC Patient Journey_figures/img_1fd9d39f7897300d.webp)</text>
    <images>
      <img order="0" bbox="128,361,218,519" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_62481ff013d8ddee.webp">
        <description>A close-up photograph of a clear glass filled with water, capturing the dynamic motion of splashing liquid rising above the rim.</description>
      </img>
      <img order="1" bbox="502,365,658,530" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_9a0dfc7c6858632f.webp">
        <description>Product photograph showing a bottle of Biotène PBF Oral Rinse alongside its packaging boxes, which are labeled with claims such as 'Gentle Formula', 'Essential Fluoride', and 'Designed to Relieve Dry Mouth'.</description>
      </img>
      <img order="2" bbox="705,345,848,529" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_cf6e87caea816e1c.webp">
        <description>A product photograph displaying a range of Oral7 brand items, including bottles of moisturising mouthwash and spray, tubes of gel or toothpaste, and sachets.</description>
      </img>
      <img order="3" bbox="163,592,205,788" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_86848eb5786d43c7.webp">
        <description>A product photograph of a Hamilton Aquae Dry Mouth Spray bottle. The container features a white spray nozzle and cap, with a label displaying the brand name and text indicating it is an ultra-mild mint flavour relief solution.</description>
      </img>
      <img order="4" bbox="310,594,368,829" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_4f34cd79078e9fd9.webp">
        <description>A product shot of a tube of Lip-eze Ointment, specifically the Oralife Peppermint flavor. The packaging indicates it is for the treatment and prevention of dry lips, which aligns with the slide's topic of managing dry mouth symptoms.</description>
      </img>
      <img order="5" bbox="416,633,472,809" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_dafd173bb6f79bbb.webp">
        <description>A photograph of a tube of Denta-Med oral health gel. The packaging lists benefits such as 'Whole Mouth Care' and states that it helps to relieve dry mouth.</description>
      </img>
      <img order="6" bbox="471,671,606,806" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_1fd9d39f7897300d.webp">
        <description>A product box for Denta-Med Gel, a whole mouth oral care treatment. The packaging lists conditions it addresses, including xerostomia (dry mouth), bad breath, and mouth ulcers.</description>
      </img>
    </images>
  </page>
  <page number="54">
    <text>XYLIMELTS

Xylitol in long-lasting adhering discs
to temporarily relieve dry mouth*

All-natural

OraCoat
XyliMelts
for Dry Mouth
For use while sleeping and daytime
Coats, moisturizes and lubricates*
Increases saliva*
May reduce risk of tooth decay
Freshens breath

40
DISCS

Place the tan adhesive side of disc on the outside of a molar and/or adjoining gums, upper or lower, white
side touching cheek. Use your tongue to push the disc to a comfortable spot. Once there, do not touch it
with your tongue for 10 seconds, as this movement will disrupt the adhesion.

Before bedtime: Use two (2) discs, placing one on each side of the mouth.

Everyday use: For dry mouth, use more as needed throughout the day.

![OraCoat XyliMelts for Dry Mouth](W1 HNC Patient Journey_figures/img_3500fb3f85b3f862.webp)</text>
    <formatted_text>*XyliMelts — OraCoat, for dry mouth. 40 discs.*

Xylitol in long-lasting adhering discs to temporarily relieve dry mouth\*. All-natural.

- For use while sleeping and daytime
- Coats, moisturizes and lubricates\*
- Increases saliva\*
- May reduce risk of tooth decay
- Freshens breath

#### Instructions For Use

Place the tan adhesive side of disc on the outside of a molar and/or adjoining gums, upper or lower, white side touching cheek. Use your tongue to push the disc to a comfortable spot. Once there, do not touch it with your tongue for 10 seconds, as this movement will disrupt the adhesion.

- **Before bedtime:** Use two (2) discs, placing one on each side of the mouth.
- **Everyday use:** For dry mouth, use more as needed throughout the day.</formatted_text>
    <images>
      <img order="0" bbox="434,378,607,655" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_3500fb3f85b3f862.webp" caption="OraCoat XyliMelts for Dry Mouth">
        <description>A product photograph of the packaging for OraCoat XyliMelts, an oral adhering disc. The box features a stylized illustration of a human head in profile and green leaves, with text indicating it is for dry mouth relief and contains 40 discs.</description>
      </img>
    </images>
  </page>
  <page number="55">
    <text>DIFFICULTIES WITH DENTURES

• Susceptibility to oral thrush
  • Denture hygiene
  • Well-fitting denture
• Ill-fitting dentures
  • Post-surgical change
  • Weight loss
  • Changes in sensation
• Dry mouth

![The only waterproof Denture Adhesive fitty dent super](W1 HNC Patient Journey_figures/img_306a1a2a52d638b0.webp)
![ORAL7 MOISTURISING MOUTH GEL ORALSEVEN](W1 HNC Patient Journey_figures/img_588d73918e23a579.webp)
![POLIDENT POLIDENT](W1 HNC Patient Journey_figures/img_5ff95ecd71c2d499.webp)</text>
    <formatted_text>- Susceptibility to oral thrush
  - Denture hygiene
  - Well-fitting denture
- Ill-fitting dentures
  - Post-surgical change
  - Weight loss
  - Changes in sensation
- Dry mouth</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:09:14" confidence="6" anchor="- Dry mouth">

&gt; [!note] Lecturer — Denture Retention
&gt; Mucositis, oral ulcers, reduced denture retention, and altered oral structures may contribute to denture problems.
&gt;
&gt; - Denture adhesives may be painful on mucositis or ulcerated mucosa.
&gt; - Oral moisturising gel may sometimes improve retention by providing a more suitable surface for suction and capillary action.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="739,349,858,471" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_306a1a2a52d638b0.webp" caption="The only waterproof Denture Adhesive fitty dent super">
        <description>A close-up photograph of a green and white box for 'fitty dent super' waterproof denture adhesive. The packaging prominently displays a circular badge reading '24h HOLD', an image of green olives on a branch, the size designation 'XL', and text indicating 'Swiss Made 75g'.</description>
      </img>
      <img order="1" bbox="735,504,896,651" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_588d73918e23a579.webp" caption="ORAL7 MOISTURISING MOUTH GEL ORALSEVEN">
        <description>Product photograph showing a box and tube of Fittydent Super Denture Adhesive. The packaging highlights features such as being 'The only waterproof Denture Adhesive' and providing 'Long-lasting extra firm hold'.</description>
      </img>
      <img order="2" bbox="752,704,872,790" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_5ff95ecd71c2d499.webp" caption="POLIDENT POLIDENT">
        <description>A product photograph showing a tube and packaging box of Polident denture adhesive cream. The green and white branding highlights the text 'Complete Comfort' and 'Fresh'.</description>
      </img>
    </images>
  </page>
  <page number="56">
    <text>![](W1 HNC Patient Journey_figures/img_ba4c958be18280aa.webp)
![](W1 HNC Patient Journey_figures/img_3790d763a0fa7f84.webp)
![](W1 HNC Patient Journey_figures/img_ffe6c25db6a08cca.webp)
![](W1 HNC Patient Journey_figures/img_b8b0cfdd230bd716.webp)
![MCKENZIE'S Bi-Carb Soda Baking Soda](W1 HNC Patient Journey_figures/img_2b433f8693c89332.webp)
![CURASEPT ADS 220](W1 HNC Patient Journey_figures/img_9b6fa3e175128d4f.webp)
![Confidential Care Product Oraswab with Sodium Bicarbonate](W1 HNC Patient Journey_figures/img_66e49c374e466eb2.webp)</text>
    <images>
      <img order="0" bbox="40,295,291,558" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_ba4c958be18280aa.webp">
        <description>Clinical photograph showing an intraoral view of the tongue, which exhibits a large, raised mass with distinct red and white patches on its surface.</description>
      </img>
      <img order="1" bbox="308,295,606,558" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_3790d763a0fa7f84.webp">
        <description>Clinical intraoral photograph showing the maxillary arch and hard palate. The image reveals extensive brownish-yellow necrotic tissue and plaque accumulation along the gingival margins and covering the anterior palate, with visible teeth exhibiting significant staining.</description>
      </img>
      <img order="2" bbox="633,306,739,540" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_ffe6c25db6a08cca.webp">
        <description>Clinical photo: A gloved hand holding a long-handled cotton swab, likely an applicator used for oral examination or treatment.</description>
      </img>
      <img order="3" bbox="315,579,598,836" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_b8b0cfdd230bd716.webp">
        <description>Clinical intraoral photograph showing the maxillary arch and palate. The image reveals extensive dark brown to black staining or decay on the cervical margins of the teeth, particularly affecting the anterior incisors and premolars.</description>
      </img>
      <img order="4" bbox="757,281,842,425" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_2b433f8693c89332.webp" caption="MCKENZIE'S Bi-Carb Soda Baking Soda">
        <description>Product photo of a white and blue cardboard box for McKenzie's Bi-Carb Soda, identified as baking soda with a net weight of 1kg. The packaging features the brand logo at the top, a central label describing the product contents, and a red circular badge on the lower right stating 'Natural Product'.</description>
      </img>
      <img order="5" bbox="759,452,839,649" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_9b6fa3e175128d4f.webp" caption="CURASEPT ADS 220">
        <description>Product photo of a bottle of Curasept ADS 220 mouthwash, showing the label with branding and product details.</description>
      </img>
      <img order="6" bbox="863,271,957,635" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_66e49c374e466eb2.webp" caption="Confidential Care Product Oraswab with Sodium Bicarbonate">
        <description>A photograph of a packaged oral care swab product alongside the unpackaged applicator. The packaging features branding for 'Confident Care products' and identifies the item as an 'Oraswab with Sodium Bicarbonate', while the separate item shows a long handle attached to a blue foam sponge tip.</description>
      </img>
    </images>
  </page>
  <page number="57">
    <text># FUNGAL INFECTIONS (ORAL THRUSH)

• Candida albicans: harmless organism that inhabits the mouths of up to 50% of the population.
• ‘Opportunistic’ fungal infection
• Symptoms are variable, and not always specific. They may include:
    • White spots on the palate
    • Central red patch on tongue (can be “kissing” a red spot on the palate)
    • Thickly coated tongue
    • Red patch delineated by a denture-breing area
    • Cracked corners of the mouth
    • Burning sensation in the mouth

Images: Contemporary Oral Medicine 2018 (Farah, Balasubramaniam, McCullough)

![](W1 HNC Patient Journey_figures/img_0d49ab5acce16a10.webp)
![](W1 HNC Patient Journey_figures/img_331e25655420d048.webp)
![](W1 HNC Patient Journey_figures/img_0574d906a4723728.webp)
![](W1 HNC Patient Journey_figures/img_00a4be79425c0036.webp)
![](W1 HNC Patient Journey_figures/img_aa978549d31c003c.webp)</text>
    <formatted_text>- *Candida albicans:* harmless organism that inhabits the mouths of up to 50% of the population.
- 'Opportunistic' fungal infection
- Symptoms are variable, and not always specific. They may include:
  - White spots on the palate
  - Central red patch on tongue (can be &quot;kissing&quot; a red spot on the palate)
  - Thickly coated tongue
  - Red patch delineated by a denture-bearing area
  - Cracked corners of the mouth
  - Burning sensation in the mouth

*Images: Contemporary Oral Medicine 2018 (Farah, Balasubramaniam, McCullough)*</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:04:11" confidence="6" anchor="*Images: Contemporary Oral Medicine 2018 (Farah, Balasubramaniam, McCullough)*">
- ==More acidic saliva, reduced salivary flow, moist altered oral environments, denture use, and changes in oral flora increase susceptibility to oral thrush.==</insert>
      <insert timestamp="01:11:37" confidence="8" anchor="#### **Management Of Fungal Infections**">

&gt; [!note] Lecturer — Thrush Management
&gt; Management may include antifungal medication, sodium bicarbonate rinses, good denture hygiene, avoiding smoking, natural yoghurt particularly containing probiotics, and maintaining oral hygiene.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="628,343,789,486" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_0d49ab5acce16a10.webp">
        <description>Clinical photo: showing the posterior palate and soft tissue of the oral cavity with multiple white, raised spots scattered across the surface.</description>
      </img>
      <img order="1" bbox="625,501,791,623" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_331e25655420d048.webp">
        <description>Clinical photo: An intraoral view of the left buccal mucosa (cheek) and lateral tongue, both exhibiting raised, curvilinear white plaques with erythematous borders. These lesions represent characteristic features of oral candidiasis (thrush).</description>
      </img>
      <img order="2" bbox="805,368,940,561" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_0574d906a4723728.webp">
        <description>Clinical photo showing the hard palate and anterior tongue. A distinct red patch is visible on the midline of the hard palate, corresponding to a matching red area on the dorsal surface of the tongue tip.</description>
      </img>
      <img order="3" bbox="641,659,780,788" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_00a4be79425c0036.webp">
        <description>Clinical photo showing an open mouth with the tongue protruded, exhibiting a red patch on the dorsal surface. The corners of the lips display erythema and cracking, consistent with angular cheilitis.</description>
      </img>
      <img order="4" bbox="805,594,944,724" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_aa978549d31c003c.webp">
        <description>Clinical photo: An intraoral view of the hard palate showing a central red patch surrounded by white spots, illustrating symptoms of oral thrush.</description>
      </img>
    </images>
  </page>
  <page number="58">
    <text># MANAGEMENT OF FUNGAL INFECTIONS

![](W1 HNC Patient Journey_figures/img_e05ecf299e2d5824.webp)
![](W1 HNC Patient Journey_figures/img_b229ba8f2f8916a8.webp)
![](W1 HNC Patient Journey_figures/img_c2f132dc9f7556fe.webp)</text>
    <images>
      <img order="0" bbox="181,355,362,584" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_e05ecf299e2d5824.webp">
        <description>Product photograph of Nilstat Oral drops, a cherry-flavoured antifungal suspension containing Nystatin. The image displays the retail packaging box, an amber glass bottle with a white cap, and a plastic measuring syringe.</description>
      </img>
      <img order="1" bbox="457,454,603,716" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_b229ba8f2f8916a8.webp">
        <description>A product photograph showing a white plastic jar with a blue lid, labeled 'Jalna Pot Set Greek Yoghourt Natural'. The label includes marketing text such as 'Award Winning Creamy Taste' and lists attributes like 'Naturally Probiotic', 'No Gluten or Additives', and 'Australian Made &amp; Owned'.</description>
      </img>
      <img order="2" bbox="671,369,820,593" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_c2f132dc9f7556fe.webp">
        <description>A product photograph showing a white and blue cardboard box of McKenzie's Bi-Carb Soda baking soda. The packaging features the brand logo at the top, with text indicating '1kg NET' and '100% Australian family owned', along with a red circular seal stating it is a 'Natural Product'.</description>
      </img>
    </images>
  </page>
  <page number="59">
    <text>WEIGHT
MAINTENANCE

• Dietician advice during chemo-radiotherapy
  • High calorie foods and drinks
  • Nutritional supplements (contain sugar)
  • Moisten foods, thickened liquids
  • PEG feeding
  • Soda water (effervescent)

• After chemo-radiotherapy
  • Weight stabilisation may still be a priority
  • Taste alterations (John lost sweet and salty sensations)
  • Taste aversions
  • Risk assessment for dental caries

![](W1 HNC Patient Journey_figures/img_5f1e3a3bd9ca20b4.webp)
![](W1 HNC Patient Journey_figures/img_bfc1a469526f827b.webp)
![](W1 HNC Patient Journey_figures/img_73a261b70b8d611a.webp)</text>
    <formatted_text>#### During Chemo-Radiotherapy

- Dietician advice
  - High calorie foods and drinks
  - Nutritional supplements (contain sugar)
  - Moisten foods, thickened liquids
  - PEG feeding
  - Soda water (effervescent)

#### After Chemo-Radiotherapy

- Weight stabilisation may still be a priority
- Taste alterations (John lost sweet and salty sensations)
- Taste aversions
- Risk assessment for dental caries</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:12:14" confidence="8" anchor="- PEG feeding - Soda water (effervescent)">

&gt; [!note] Lecturer — Nutrition Priority
&gt; During treatment, maintaining nutrition and body weight is an immediate priority even when some high-energy foods contain sugar and may increase the risk of dental decay.
&gt;
&gt; - Dietitians may recommend custard, doughnuts, ice cream, jelly, and other foods that help maintain weight.
&gt; - Dental and dietetic advice must be coordinated so oral-health recommendations do not conflict with nutritional requirements.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="712,325,789,542" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_5f1e3a3bd9ca20b4.webp">
        <description>A photograph of a bottle of Nutricia Fortisip, which is labeled as high energy and nutritionally complete with strawberry flavour.</description>
      </img>
      <img order="1" bbox="839,216,967,448" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_bfc1a469526f827b.webp">
        <description>A product photograph of a gold and white tin of Nestlé Health Science Sustagen Optimum Complete Nutrition powder. The label highlights key nutritional features such as '10g of protein', 'Immune support Vitamin C &amp; Zinc', and 'Probiotics &amp; Prebiotics' alongside an image of the prepared vanilla-flavoured drink.</description>
      </img>
      <img order="2" bbox="775,594,940,809" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_73a261b70b8d611a.webp">
        <description>A product photograph showing a four-pack of Ensure Vanilla flavour ready-to-drink nutritional supplements. This image illustrates the slide's point regarding the use of nutritional supplements during weight maintenance.</description>
      </img>
    </images>
  </page>
  <page number="60">
    <text>HOW WOULD
THIS IMPACT ON
THE DIETARY
ADVICE YOU
WOULD
ROUTINELY
PROVIDE
PATIENTS WITH
FOR THE
PREVENTION OF
DENTAL CARIES?

*   Liaise with dietician: Ensure our advice does not conflict with theirs!

*   Focus on prevention:
    *   Sip water or bicarbonate rinses after meals
    *   Fluoride / CPP-ACP
    *   Oral hygiene
    *   Use of straws</text>
    <formatted_text>&gt; How would this impact on the dietary advice you would routinely provide patients with for the prevention of dental caries?

- Liaise with dietician: ensure our advice does not conflict with theirs!
- Focus on prevention:
  - Sip water or bicarbonate rinses after meals
  - Fluoride / CPP-ACP
  - Oral hygiene
  - Use of straws</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:12:53" confidence="6" anchor="- Use of straws">
- ==Weight loss may result from pain, nausea, altered taste, reduced appetite, reflux, difficulty eating, reduced enjoyment of food, or mucositis.==</insert>
    </audio_inserts>
  </page>
  <page number="61">
    <text>FOLLOW-UP

• 4-8 week clinical assessment
• *3 month post-treatment FDG-PET/CT
• (3-4 month post-surgical CT and/or MRI)

![FOLL-A 2 OF 2](W1 HNC Patient Journey_figures/img_a18ea4ed9518da63.webp)</text>
    <formatted_text>- 4–8 week clinical assessment
- 3 month post-treatment FDG-PET/CT
- (3–4 month post-surgical CT and/or MRI)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:13:41" confidence="7" anchor="- (3–4 month post-surgical CT and/or MRI)">
- ==Dental review around the three-month post-radiotherapy period, ongoing cancer surveillance, assessment of oral complications, and review of rehabilitation needs.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="422,320,940,819" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_a18ea4ed9518da63.webp" caption="FOLL-A 2 OF 2">
        <description>A flowchart illustrating follow-up recommendations for head and neck cancers after systemic therapy or radiation, detailing the decision pathway based on clinical assessment and imaging results (FDG-PET/CT, CT, MRI) to determine whether observation, biopsy, or resection is required.</description>
      </img>
    </images>
  </page>
  <page number="62">
    <text>THE HEAD AND NECK CANCER PATIENT JOURNEY

| Diagnosis | H&amp;N MDT Meeting Discussion | Work-up to Cancer Treatment | Surgery | H&amp;N MDT Meeting Rediscussion | Radiotherapy +/- Chemotherapy | **Rehabilitation** | Chronic side effects and survivorship |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |</text>
    <formatted_text>Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery → H&amp;N MDT Meeting Rediscussion → Radiotherapy +/- Chemotherapy → **Rehabilitation** → Chronic side effects and survivorship</formatted_text>
  </page>
  <page number="63">
    <text>## THE HEAD AND NECK CANCER PATIENT JOURNEY

```mermaid
flowchart LR
    A[Diagnosis] --&gt; B[H&amp;N MDT&lt;br&gt;Meeting&lt;br&gt;Discussion]
    B --&gt; C[Work-up to&lt;br&gt;Cancer&lt;br&gt;Treatment]
    C --&gt; D[Surgery]
    D --&gt; E[H&amp;N MDT&lt;br&gt;Meeting&lt;br&gt;Rediscussion]
    E --&gt; F[Radiotherapy&lt;br&gt;+/-&lt;br&gt;Chemotherapy]
    F --&gt; G[Rehabilitation]
    G --&gt; H[Chronic side&lt;br&gt;effects and&lt;br&gt;survivorship]
```</text>
    <formatted_text>Diagnosis → H&amp;N MDT Meeting Discussion → Work-up to Cancer Treatment → Surgery → H&amp;N MDT Meeting Rediscussion → Radiotherapy +/- Chemotherapy → Rehabilitation → Chronic side effects and survivorship</formatted_text>
  </page>
  <page number="64">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
ONGOING DENTAL ISSUES POST-RADIOTHERAPY
&lt;/div&gt;

*   Salivary changes and their long-term impacts
*   Muscle fibrosis and limited mouth opening (trismus)
*   Difficulties with dentures
    *   Trismus, surgery, hyposalivation
*   Osteoradionecrosis
    *   Spontaneous, trauma-induced (extractions, dentures)
*   Risk of recurrence
    *   Oral surveillance
    *   Lymph node assessment
    *   Smoking cessation and counselling regarding alcohol intake</text>
    <formatted_text>- Salivary changes and their long-term impacts
- Muscle fibrosis and limited mouth opening (trismus)
- Difficulties with dentures
  - Trismus, surgery, hyposalivation
- Osteoradionecrosis
  - Spontaneous, trauma-induced (extractions, dentures)
- Risk of recurrence
  - Oral surveillance
  - Lymph node assessment
  - Smoking cessation and counselling regarding alcohol intake</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:28:19" confidence="2" anchor="Risk of recurrence   - Oral surveillance   - Lymph node assessment   - Smoking c">
- ==Altered oral anatomy==</insert>
    </audio_inserts>
  </page>
  <page number="65">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
&lt;b&gt;ROLE OF DENTAL PRACTITIONER POST-RADIOTHERAPY&lt;/b&gt;
&lt;/div&gt;

*   Management of hyposalivation
*   Prevention and minimisation of trismus
*   Prevention and management of dental caries, periodontal disease, ORN and oral candidiasis
*   Performing dental work deferred during RT
*   Consultation with the treating radiation oncologist if extractions or implants are to be considered.
*   Continued monitoring for local recurrence, metastatic lesions in the head and neck region, and second cancers</text>
    <formatted_text>- Management of hyposalivation
- Prevention and minimisation of trismus
- Prevention and management of dental caries, periodontal disease, ORN and oral candidiasis
- Performing dental work deferred during RT
- Consultation with the treating radiation oncologist if extractions or implants are to be considered
- Continued monitoring for local recurrence, metastatic lesions in the head and neck region, and second cancers</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:04:01" confidence="4" anchor="Continued monitoring for local recurrence, metastatic lesions in the head and ne">
- ==Maintain oral hygiene==
- ==Monitor teeth exposed to high-dose radiation==
- ==Manage denture problems==
- ==Support rehabilitation==
- ==Coordinate with specialist services==
- ==Provide regular surveillance after the patient returns to community care==
- ==Patients may eventually be discharged back to community dental services, so general dentists need to understand the treatment history and chronic effects==</insert>
      <insert timestamp="01:05:14" confidence="2" anchor="##### **Saliva Testing Products**  - Dental Saliva pH Indicator - Saliva-Check B">
- ==Biotene==
- ==Oral7==
- ==Other saliva substitutes and moisturising products==</insert>
    </audio_inserts>
  </page>
  <page number="66">
    <text>SALIVARY CHANGES AND THE SECONDARY COMPLICATIONS

Viscous, acidic, reduced buffering capacity, reduced quantity

* Difficulty with speech, eating (mastication) and swallowing (dysphagia)
* Mouth soreness
* Difficulty/discomfort wearing dentures
* Taste alteration/loss
* Reduced food clearance
* Changes in oral flora $\rightarrow$ fungal, viral, bacterial infections (e.g. oral thrush, salivary gland infections, gingival/periodontal disease progression)
* Radiation caries
* Dental erosion
* Increased risk of tooth wear and gingival recession (hyposalivation important contributor) $\rightarrow$ Tooth sensitivity
* $\rightarrow$ QUALITY OF LIFE

![Parotid gland Sublingual gland Submandibular gland © Healthwise, Incorporated](W1 HNC Patient Journey_figures/img_ddedf4474fc8275a.webp)
![](W1 HNC Patient Journey_figures/img_9a28b8eb08c055ab.webp)</text>
    <formatted_text>Viscous, acidic, reduced buffering capacity, reduced quantity

- Difficulty with speech, eating (mastication) and swallowing (dysphagia)
- Mouth soreness
- Difficulty/discomfort wearing dentures
- Taste alteration/loss
- Reduced food clearance
- Changes in oral flora → fungal, viral, bacterial infections (e.g. oral thrush, salivary gland infections, gingival/periodontal disease progression)
- Radiation caries
- Dental erosion
- Increased risk of tooth wear and gingival recession (hyposalivation important contributor) → tooth sensitivity
- → QUALITY OF LIFE</formatted_text>
    <images>
      <img order="0" bbox="676,326,956,564" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_ddedf4474fc8275a.webp" caption="Parotid gland Sublingual gland Submandibular gland © Healthwise, Incorporated">
        <description>This is an anatomical diagram showing a profile view of a human head and neck, illustrating the locations of the major salivary glands. The image features pink, textured glandular structures positioned in front of the ear and under the jaw, with lines connecting them to specific text labels.</description>
      </img>
      <img order="1" bbox="677,582,953,830" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_9a28b8eb08c055ab.webp">
        <description>A composite of four clinical intraoral photographs labelled a, b, c, and d. The images depict severe dental decay and tooth structure loss, characterized by extensive dark carious lesions on the lower anterior teeth (visible in views c and d) and significant erosion or wear affecting the upper dentition.</description>
      </img>
    </images>
  </page>
  <page number="67">
    <text>WILL IT RECOVER?

• Usually yes, to some degree
• Timing varies between individuals
• Gains usually start within 4 weeks to 6 months
• Can be last up to 2 years post-radiotherapy, but is often permanent</text>
    <formatted_text>- Usually yes, to some degree
- Timing varies between individuals
- Gains usually start within 4 weeks to 6 months
- Can be last up to 2 years post-radiotherapy, but is often permanent</formatted_text>
  </page>
  <page number="68">
    <text>SALIVA
TESTING

Dental Saliva pH Indicator
Saliva-Check
BUFFER
Saliva-Check BUFFER

The Challacombe Scale
of Clinical Oral Dryness
KING'S College LONDON

The Challacombe Scale was developed from research conducted at King's College London Dental Institute under the supervision of Professor Stephen Challacombe*. The purpose of this scale is to be able to visually identify and quantify whether your patient has xerostomia (dry mouth) and if so, how it changes over time and the most appropriate therapy options. This scale is applicable whatever your profession.

The Challacombe Scale works as an additive score of 1 to 10 : 1 being the least and 10 being the most severe. Each feature scores 1 and symptoms will not necessarily progress in the order shown, but summed scores indicate likely patient needs. Score changes over time can be used to monitor symptom progression or regression.

1
Mirror sticks to buccal mucosa
An additive score of 1 - 3 indicates mild dryness. May not need treatment or management. Sugar-free chewing gum for 15 mins, twice daily and attention to hydration is needed. Many drugs will cause mild dryness. Routine checkup monitoring required.

2
Mirror sticks to tongue

3
Saliva frothy

4
No saliva pooling in floor of mouth
An additive score of 4 - 6 indicates moderate dryness. Sugar-free chewing gum or simple salagogues may be required. Needs to be investigated further if reasons for dryness are not clear. Saliva substitutes and topical fluoride may be helpful. Monitor at regular intervals especially for early decay and symptom change.

5
Tongue shows generalised shortened papillae (mild depapillation)

6
Altered gingival architecture (ie. smooth)

7
Glassy appearance of oral mucosa, especially palate
An additive score of 7 - 10 indicates severe dryness. Saliva substitutes and topical fluoride usually needed. Cause of hyposalivation needs to be ascertained and Sjögrens Syndrome excluded. Refer for investigation and diagnosis. Patients then need to be monitored for changing symptoms and signs, with possible further specialist input if worsening.

8
Tongue lobulated / fissured

9
Cervical caries (more than two teeth)

10
Debris on palate or sticking to teeth

![Dental Saliva pH Indicator, Saliva-Check BUFFER](W1 HNC Patient Journey_figures/img_15229bbfe94e34e9.webp)</text>
    <formatted_text>#### Saliva Testing Products

- Dental Saliva pH Indicator
- Saliva-Check BUFFER

#### The Challacombe Scale of Clinical Oral Dryness

*King's College London*

The Challacombe Scale was developed from research conducted at King's College London Dental Institute under the supervision of Professor Stephen Challacombe. The purpose of this scale is to be able to visually identify and quantify whether your patient has xerostomia (dry mouth) and if so, how it changes over time and the most appropriate therapy options. This scale is applicable whatever your profession.

The Challacombe Scale works as an additive score of 1 to 10: 1 being the least and 10 being the most severe. Each feature scores 1 and symptoms will not necessarily progress in the order shown, but summed scores indicate likely patient needs. Score changes over time can be used to monitor symptom progression or regression.

| Score | Feature | Interpretation |
| :--- | :--- | :--- |
| 1 | Mirror sticks to buccal mucosa | Score 1–3 = mild dryness. May not need treatment or management. Sugar-free chewing gum for 15 mins, twice daily and attention to hydration is needed. Many drugs will cause mild dryness. Routine checkup monitoring required. |
| 2 | Mirror sticks to tongue | |
| 3 | Saliva frothy | |
| 4 | No saliva pooling in floor of mouth | Score 4–6 = moderate dryness. Sugar-free chewing gum or simple sialagogues may be required. Needs to be investigated further if reasons for dryness are not clear. Saliva substitutes and topical fluoride may be helpful. Monitor at regular intervals especially for early decay and symptom change. |
| 5 | Tongue shows generalised shortened papillae (mild depapillation) | |
| 6 | Altered gingival architecture (i.e. smooth) | |
| 7 | Glassy appearance of oral mucosa, especially palate | Score 7–10 = severe dryness. Saliva substitutes and topical fluoride usually needed. Cause of hyposalivation needs to be ascertained and Sjögren's Syndrome excluded. Refer for investigation and diagnosis. Patients then need to be monitored for changing symptoms and signs, with possible further specialist input if worsening. |
| 8 | Tongue lobulated / fissured | |
| 9 | Cervical caries (more than two teeth) | |
| 10 | Debris on palate or sticking to teeth | |</formatted_text>
    <images>
      <img order="0" bbox="252,391,537,582" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_15229bbfe94e34e9.webp" caption="Dental Saliva pH Indicator, Saliva-Check BUFFER">
        <description>A product photograph showing the packaging and components of a Saliva-Check Buffer kit. The items include a box labeled 'Saliva-Check BUFFER', a foil packet, a plastic measuring cup, a pH indicator strip, and a color-coded chart titled 'Dental Saliva pH Indicator' displaying values from 5.0 to 8.0.</description>
      </img>
    </images>
  </page>
  <page number="69">
    <text>PREVENTION OF DENTAL DECAY

PHARMACIST ONLY MEDICINE
KEEP OUT OF REACH OF CHILDREN
Colgate
NeutraFluor® 5000 Plus FRESHMINT
5000ppm Fluoride Professional Toothpaste
Contains 1.23% w/w Neutral Sodium Fluoride
For individuals at high risk of caries
NET 56g e

NUPRO

GC
Tooth
Mousse
GC
Tooth
Mousse
Strawberry
GC
Tooth
Mousse
Plus
Mint

CPP-ACP 2倍配合
Re
CAL
DENT
リカルデント 歯科医院専用
 CPP-ACP 2倍配合

Clinpro 5000
1.1% Sodium Fluoride
Anti-Cavity Toothpaste

McKENZIE'S
Bi-Carb
Soda
Baking Soda
1kg NET

XYLITOL

![](W1 HNC Patient Journey_figures/img_cdf1cb6bbfca2827.webp)
![](W1 HNC Patient Journey_figures/img_11a9648b75b49f7a.webp)
![](W1 HNC Patient Journey_figures/img_761f3ec1a750dbca.webp)
![](W1 HNC Patient Journey_figures/img_dfc1c461e566c715.webp)
![](W1 HNC Patient Journey_figures/img_21e2860caa3551ec.webp)
![](W1 HNC Patient Journey_figures/img_d6c42c62e615eca1.webp)
![](W1 HNC Patient Journey_figures/img_4aaca459f2360d4b.webp)
![](W1 HNC Patient Journey_figures/img_9f12b1cd37429f8d.webp)
![](W1 HNC Patient Journey_figures/img_3862cb8d4c5ba334.webp)</text>
    <formatted_text>- Colgate NeutraFluor® 5000 Plus Freshmint — 5000ppm fluoride professional toothpaste, contains 1.23% w/w neutral sodium fluoride, for individuals at high risk of caries (pharmacist only medicine; keep out of reach of children)
- GC Tooth Mousse (original, Strawberry, and Plus Mint — CPP-ACP)
- ReCalDent (リカルデント, dental-practice use, CPP-ACP 2倍配合)
- Clinpro 5000 — 1.1% sodium fluoride anti-cavity toothpaste
- McKenzie's Bi-Carb Soda (baking soda)
- Xylitol</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:16:54" confidence="6" anchor="- Xylitol">
- ==Adequate fluoride==
- ==Regular dental review==
- ==Mechanical plaque removal==
- ==Avoidance of unnecessary dietary sugar once nutritional priorities permit==
- ==Maintaining calcium and phosphate availability in saliva or through topical products==
- ==Use of modified toothbrushes when mouth opening or anatomy is restricted==
  - ==End-tufted toothbrushes for posterior teeth==
  - ==Curved toothbrushes that can contact buccal, lingual and occlusal surfaces==
  - ==Other adaptations when the patient cannot open the mouth normally==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="46,380,242,473" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_cdf1cb6bbfca2827.webp">
        <description>A product photograph showing a box of Colgate NeutraFluor 5000 Plus Freshmint toothpaste. The packaging displays text indicating it is 'Pharmacist Only Medicine', contains 1.23% w/w Neutral Sodium Fluoride, and is for individuals at high risk of caries.</description>
      </img>
      <img order="1" bbox="367,324,405,520" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_11a9648b75b49f7a.webp">
        <description>Product photograph of a green and white bottle of Nupro Neutral Sodium Fluoride Oral Solution, featuring a mint flavor label and text indicating it is for 1-minute gel treatments.</description>
      </img>
      <img order="2" bbox="516,361,685,487" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_761f3ec1a750dbca.webp">
        <description>Clinical photo showing a close-up of a person inserting a clear, custom-fitted dental tray (likely for fluoride application or whitening) over their upper teeth.</description>
      </img>
      <img order="3" bbox="782,337,888,507" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_dfc1c461e566c715.webp">
        <description>Product photograph of a box of McKenzie's Bi-Carb Soda (Baking Soda), showing the brand logo, product name, and '1kg NET' weight.</description>
      </img>
      <img order="4" bbox="47,582,169,804" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_21e2860caa3551ec.webp">
        <description>A product photograph showing the packaging box and tube of GC Tooth Mousse (Strawberry flavor), a topical cream containing bio-available calcium and phosphate.</description>
      </img>
      <img order="5" bbox="194,561,253,795" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_d6c42c62e615eca1.webp">
        <description>A product photograph of a tube of GC Tooth Mousse Plus, featuring mint leaves on the packaging and text indicating it contains sodium fluoride.</description>
      </img>
      <img order="6" bbox="310,630,402,795" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_4aaca459f2360d4b.webp">
        <description>A product photo of a green and white cylindrical container for Recaldent, a dental care product. The label prominently displays the brand name &quot;Re CAL DENT&quot; with a tooth icon, along with Japanese text indicating it is a dental clinic exclusive item containing 2x CPP-ACP.</description>
      </img>
      <img order="7" bbox="481,615,699,738" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_9f12b1cd37429f8d.webp">
        <description>A product photograph showing two tubes of Clinpro 5000 toothpaste, identified by the visible brand name and '1.1% Sodium Fluoride' text on the packaging.</description>
      </img>
      <img order="8" bbox="830,620,915,798" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_3862cb8d4c5ba334.webp">
        <description>A product photograph of a white plastic jar with a green label for 'LOTTE XYLITOL' sweetener, featuring a red 'New' banner and an image of green chewing gum pieces.</description>
      </img>
    </images>
  </page>
  <page number="70">
    <text>DIFFICULTIES WITH DENTURES

• Susceptibility to oral thrush
  • Denture hygiene
  • Well-fitting denture
• Ill-fitting dentures
  • Post-surgical change
  • Weight loss
  • Changes in sensation
• Dry mouth

![ORAL7 Helps Soothe &amp; Protect Gums! MOISTURISING MOUTH GEL ORALSEVEN](W1 HNC Patient Journey_figures/img_306a1a2a52d638b0.webp)
![fitty dent super The only waterproof Denture Adhesive Long-lasting extra firm hold Good value - only 1x per day fitty dent Adhesive for Dentures](W1 HNC Patient Journey_figures/img_588d73918e23a579.webp)</text>
    <formatted_text>- Susceptibility to oral thrush
  - Denture hygiene
  - Well-fitting denture
- Ill-fitting dentures
  - Post-surgical change
  - Weight loss
  - Changes in sensation
- Dry mouth</formatted_text>
    <images>
      <img order="0" bbox="739,349,858,471" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_306a1a2a52d638b0.webp" caption="ORAL7 Helps Soothe &amp; Protect Gums! MOISTURISING MOUTH GEL ORALSEVEN">
        <description>A close-up photograph of the packaging for an Oral7 moisturising mouth gel. The white and green box features a '24h HOLD' badge, an illustration of green olives, the size designation 'XL', and text indicating it is 'Swiss Made' and contains '75g'.</description>
      </img>
      <img order="1" bbox="735,504,896,651" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_588d73918e23a579.webp" caption="fitty dent super The only waterproof Denture Adhesive Long-lasting extra firm hold Good value - only 1x per day fitty dent Adhesive for Dentures">
        <description>A product photograph showing a tube and packaging box for Fitty Dent Super denture adhesive. The blue and white packaging displays marketing text claiming it is 'The only waterproof Denture Adhesive' with 'Long-lasting extra firm hold'.</description>
      </img>
    </images>
  </page>
  <page number="71">
    <text>TRISMUS

• Muscle and joint capsule stiffness (trismus)
  • Reduced jaw muscle movement
  • Exercises can help to maintain and improve mouth opening and movement

Temporal mandibular joint
Maxilla
Masseter
Mandible


![Temporal mandibular joint Maxilla Masseter Mandible](W1 HNC Patient Journey_figures/img_d8438212f307b2a5.webp)
![Orastretch](W1 HNC Patient Journey_figures/img_31d6d9b1afdb7ef0.webp)
![Therabite](W1 HNC Patient Journey_figures/img_2daceb43feab70f5.webp)
![Tongue Depressor](W1 HNC Patient Journey_figures/img_44b90d3dad2e2e6b.webp)
![Dynasplint](W1 HNC Patient Journey_figures/img_dd180f09609f73a0.webp)
![Manual Stretch](W1 HNC Patient Journey_figures/img_b050cfe2ffe4d103.webp)
![Trismus Screw](W1 HNC Patient Journey_figures/img_fe97734fcc74c084.webp)</text>
    <formatted_text>- Muscle and joint capsule stiffness (trismus)
  - Reduced jaw muscle movement
  - Exercises can help to maintain and improve mouth opening and movement

*Anatomy shown: temporal mandibular joint, maxilla, masseter, mandible.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:56:41" confidence="6" anchor="Anatomy shown: temporal mandibular joint, maxilla, masseter, mandible.">
- ==Trismus may also result from radiotherapy, fibrosis, cancer itself, surgical changes, or changes involving the jaw joint and facial muscles==
- ==Trismus can make oral hygiene, dental examinations, extractions, posterior access and prosthetic treatment more difficult==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="233,571,436,764" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_d8438212f307b2a5.webp" caption="Temporal mandibular joint Maxilla Masseter Mandible">
        <description>Labelled anatomical diagram of a human skull in lateral view, highlighting the muscles and bones involved in jaw movement. The Temporal mandibular joint, Maxilla, Masseter (shown as a red muscle), and Mandible are explicitly indicated with leader lines.</description>
      </img>
      <img order="1" bbox="559,427,678,577" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_31d6d9b1afdb7ef0.webp" caption="Orastretch">
        <description>A clinical photograph showing a woman in profile using an Orastretch device, which is inserted into her mouth to assist with jaw stretching and opening exercises.</description>
      </img>
      <img order="2" bbox="695,429,814,577" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_2daceb43feab70f5.webp" caption="Therabite">
        <description>A clinical photograph showing a woman using a blue Therabite device. She holds the handles of the tool between her teeth to stretch her jaw muscles, demonstrating an exercise for improving mouth opening.</description>
      </img>
      <img order="3" bbox="833,429,949,576" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_44b90d3dad2e2e6b.webp" caption="Tongue Depressor">
        <description>A clinical photograph showing a close-up of a patient's face with the mouth open. A wooden tongue depressor is inserted horizontally between the upper and lower teeth to measure or maintain jaw opening.</description>
      </img>
      <img order="4" bbox="559,609,677,756" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_dd180f09609f73a0.webp" caption="Dynasplint">
        <description>Clinical photo of a woman using the Dynasplint device, which consists of two handles connected by a tensioning mechanism placed between her teeth to stretch and mobilize the jaw muscles.</description>
      </img>
      <img order="5" bbox="704,608,806,755" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_b050cfe2ffe4d103.webp" caption="Manual Stretch">
        <description>A line drawing illustrates a manual stretching technique for trismus, showing a profile view of a head where two hands are positioned to passively open the mouth. One hand grips the chin and lower jaw while the other supports the upper teeth or cheek area to apply gentle separation.</description>
      </img>
      <img order="6" bbox="832,609,949,755" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_fe97734fcc74c084.webp" caption="Trismus Screw">
        <description>Clinical photo showing a wooden trismus screw device inserted between the teeth of a patient. The tool features a threaded central shaft connecting two spherical handles, which is being used to mechanically stretch the jaw muscles and increase mouth opening.</description>
      </img>
    </images>
  </page>
  <page number="72">
    <text>TRISMUS - ORAL HYGIENE
MAINTENANCE

![waterpik waterflosser ULTRA](W1 HNC Patient Journey_figures/img_02a46edc6f1202bc.webp)
![Brush size (IDC) Pink 0.4 mm Orange 0.45 mm Red 0.5 mm Blue 0.6 mm Yellow 0.7 mm Green 0.8 mm Purple 1.1 mm Grey 1.3 mm Black 1.5 mm](W1 HNC Patient Journey_figures/img_4294cb5d4d74731a.webp)
![](W1 HNC Patient Journey_figures/img_bcb064c68fc828a5.webp)
![EXTRA SOFT baby toothbrush 0-2 years Colgate EXTRA SOFT](W1 HNC Patient Journey_figures/img_1d755884ba7ed9cf.webp)
![](W1 HNC Patient Journey_figures/img_a81aded537a5afbe.webp)
![](W1 HNC Patient Journey_figures/img_ce62ea252ff8a681.webp)</text>
    <formatted_text>*Trismus — oral hygiene maintenance.*</formatted_text>
    <images>
      <img order="0" bbox="93,490,225,715" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_02a46edc6f1202bc.webp" caption="waterpik waterflosser ULTRA">
        <description>A product image showing the packaging for a Waterpik waterflosser ULTRA, featuring a hand holding the device with a visible stream of water.</description>
      </img>
      <img order="1" bbox="278,433,484,570" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_4294cb5d4d74731a.webp" caption="Brush size (IDC) Pink 0.4 mm Orange 0.45 mm Red 0.5 mm Blue 0.6 mm Yellow 0.7 mm Green 0.8 mm Purple 1.1 mm Grey 1.3 mm Black 1.5 mm">
        <description>This figure displays a lineup of ten interproximal dental cleaning (IDC) brushes, arranged by increasing size. Each brush is distinguished by a specific handle color and labeled with its corresponding diameter in millimeters, ranging from the smallest Pink 0.4 mm to the largest Black 1.5 mm.</description>
      </img>
      <img order="2" bbox="319,610,445,789" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_bcb064c68fc828a5.webp">
        <description>Clinical photo: Three mint-green dental floss picks arranged side-by-side, each featuring a curved head with taut white string and a long handle.</description>
      </img>
      <img order="3" bbox="545,408,605,794" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_1d755884ba7ed9cf.webp" caption="EXTRA SOFT baby toothbrush 0-2 years Colgate EXTRA SOFT">
        <description>A product photograph of a packaged Colgate baby toothbrush, featuring a yellow and white handle with a small head. The blister packaging displays the text 'baby toothbrush', an age recommendation of '0-2 YEARS', and branding for 'EXTRA SOFT' bristles.</description>
      </img>
      <img order="4" bbox="673,410,707,794" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_a81aded537a5afbe.webp">
        <description>A close-up photograph of a dental instrument with a light blue handle and a curved, angled tip featuring a white abrasive surface. The tool is positioned vertically against a plain background.</description>
      </img>
      <img order="5" bbox="750,499,920,647" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_ce62ea252ff8a681.webp">
        <description>A close-up photograph shows a blue toothbrush actively brushing the teeth of a dental model, illustrating oral hygiene maintenance.</description>
      </img>
    </images>
  </page>
  <page number="73">
    <text>OSTEORADIONECROSIS OF THE JAW
(ORN)

• “Radiation-induced bone death”
• Changes in the jaw bone’s healing ability following dental extractions and trauma
• Occasionally seen as a spontaneous condition
  • Typically within first 2 years post-RT

![](W1 HNC Patient Journey_figures/img_413a4bf6f3a63cfe.webp)
![](W1 HNC Patient Journey_figures/img_99d99832275c3ca6.webp)</text>
    <formatted_text>- &quot;Radiation-induced bone death&quot;
- Changes in the jaw bone's healing ability following dental extractions and trauma
- Occasionally seen as a spontaneous condition
  - Typically within first 2 years post-RT</formatted_text>
    <images>
      <img order="0" bbox="705,374,947,582" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_413a4bf6f3a63cfe.webp">
        <description>Clinical photo: An intraoral view of the mandibular alveolar ridge showing exposed, necrotic bone (sequestrum) protruding through an ulcerated area of the gingiva. The surrounding soft tissue appears erythematous and inflamed, illustrating the characteristic presentation of osteoradionecrosis following tooth extraction.</description>
      </img>
      <img order="1" bbox="705,613,948,812" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_99d99832275c3ca6.webp">
        <description>Clinical intraoral photograph showing the mandibular anterior region with exposed, necrotic bone and surrounding soft tissue inflammation. The image illustrates osteoradionecrosis of the jaw, characterized by non-healing tissue and visible sequestra following dental trauma or extractions.</description>
      </img>
    </images>
  </page>
  <page number="74">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
DEFINITIONS OF&lt;br&gt;
OSTEORADIONECROSIS
&lt;/div&gt;

**Traditional ORN:**

*   *“Exposed bone through overlying skin or mucosa that presents as a non-healing wound for three months or more, without residual or recurrent tumour, in those who have received radiation”* (Marx 1983)

*   However, this is not strictly correct since:
    *   ORN can be shown radiographically without any breach of the oral mucosa or cervicofacial skin, by virtue of its characteristic appearance
    *   Pathological fractures due to ORN have been described without evidence of bone exposure
        (He et al 2015, Owosho et al 2015, Lyons et al 2014, Store &amp; Boysen 2000, Van Merkesteyn et al 1994)

**Radiographic ORN:**

*   *“Radiographic evidence of bone necrosis (i.e. &lt;u&gt;bone sequestrum&lt;/u&gt; or &lt;u&gt;pathologic bone fracture&lt;/u&gt;) within the radiation field, where tumour recurrence has been excluded, and mucosa is still intact”*
    (Owosho et al 2015, Støre &amp; Boysen, 2000, Van Merkesteyn et al 1994)</text>
    <formatted_text>#### Traditional ORN

- *&quot;Exposed bone through overlying skin or mucosa that presents as a non-healing wound for three months or more, without residual or recurrent tumour, in those who have received radiation&quot;* (Marx 1983)
- However, this is not strictly correct since:
  - ORN can be shown radiographically without any breach of the oral mucosa or cervicofacial skin, by virtue of its characteristic appearance
  - Pathological fractures due to ORN have been described without evidence of bone exposure (He et al 2015, Owosho et al 2015, Lyons et al 2014, Store &amp; Boysen 2000, Van Merkesteyn et al 1994)

#### Radiographic ORN

- *&quot;Radiographic evidence of bone necrosis (i.e. bone sequestrum or pathologic bone fracture) within the radiation field, where tumour recurrence has been excluded, and mucosa is still intact&quot;* (Owosho et al 2015, Støre &amp; Boysen, 2000, Van Merkesteyn et al 1994)</formatted_text>
  </page>
  <page number="75">
    <text># CLINICAL FEATURES OF ORN

| **Signs** | **Symptoms** |
| :--- | :--- |
| • Non-healing ulcer or necrosis of oral mucosa | • Pain |
| • Exposed necrotic bone | • Paraesthesia / dysaesthesia / anaesthesia&lt;br&gt;• When IAN irritated or severed by the process |
| • Oral malodour | • Trismus |
| • In advanced stages:&lt;br&gt;• Ulceration of overlying skin&lt;br&gt;• Chronic drainage or orocutaneous fistula&lt;br&gt;• Pathologic fractures | • Difficulties chewing / speaking / swallowing |
| • Complications:&lt;br&gt;• Repeated episodes of superimposed bacterial infection and osteomyelitis | |

![](W1 HNC Patient Journey_figures/img_5a4775e70ddd9703.webp)
![](W1 HNC Patient Journey_figures/img_ff87cc7efc7c16e2.webp)</text>
    <formatted_text>| Signs | Symptoms |
| :--- | :--- |
| Non-healing ulcer or necrosis of oral mucosa | Pain |
| Exposed necrotic bone | Paraesthesia / dysaesthesia / anaesthesia — when IAN irritated or severed by the process |
| Oral malodour | Trismus |
| In advanced stages: ulceration of overlying skin; chronic drainage or orocutaneous fistula; pathologic fractures | Difficulties chewing / speaking / swallowing |
| Complications: repeated episodes of superimposed bacterial infection and osteomyelitis | |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:44:33" confidence="3" anchor="Complications: repeated episodes of superimposed bacterial infection and osteomy">

&gt; [!note] Lecturer — ORN Risk
&gt; Osteoradionecrosis is a major lifelong concern after high-dose radiotherapy.
&gt;
&gt; - The risk is particularly increased above approximately 50 grays and at doses exceeding approximately 66 grays.
&gt; - It is especially relevant in the posterior mandible and remains greater in the mandible than the maxilla.
&gt; - Risk remains even when teeth are extracted before radiotherapy and the mucosa appears to have healed.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="525,666,744,831" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_5a4775e70ddd9703.webp">
        <description>Clinical photo: A panoramic radiograph (orthopantomogram) of the maxillofacial region showing the mandible, maxilla, and dentition. The image reveals a distinct pathological fracture through the left angle/ramus of the mandible with displacement of the bone segments.</description>
      </img>
      <img order="1" bbox="747,645,871,830" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_ff87cc7efc7c16e2.webp">
        <description>Clinical photo showing a close-up of the lower face and chin with a visible lesion on the skin, illustrating an advanced stage complication such as ulceration or chronic drainage.</description>
      </img>
    </images>
  </page>
  <page number="76">
    <text>RADIOGRAPHIC CHANGES FOLLOWING H&amp;N RT

1. Widened Periodontal Ligament Space (WPLS):
Subclinical, increased width of PDL space &gt;0.5mm along entire length of tooth root without a specific epicentre and adjacent bone destruction

2. Bone sclerosis (BS):
Region of increased bone density resulting from an increased number of bone trabeculae

3. Bone resorption (BR):
Region of decreased bone density resulting from decreased number of bone trabeculae.

4. Periodontal disease- like bone loss (PDBL):
Vertical bone loss in the alveolar process as measured from the level of the CEJ of the adjacent tooth

A B A B

A B

Chan K. Jaw Bone Changes on Panoramic Imaging after Head and Neck Radiotherapy. In: Pharoah M, editor.: ProQuest Dissertations Publishing; 2012.
Chan KC, Perschbacher SE, Lam EWN, Hope AJ, McNiven A, Atenafu EG, et al. Mandibular changes on panoramic imaging after head and neck radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(6):666-72.

![Figure 1: Widened periodontal ligament space (WPLS)](W1 HNC Patient Journey_figures/img_8d631da04e35461d.webp)
![Figure 2: Bone resorption (BR)](W1 HNC Patient Journey_figures/img_5305fb4f1dbb00b1.webp)
![Figure 3: Bone sclerosis (BS - blue), and Periodontal disease-like bone loss (PDBL - orange)](W1 HNC Patient Journey_figures/img_918d65af7d68f3ec.webp)</text>
    <formatted_text>1. **Widened Periodontal Ligament Space (WPLS):** subclinical, increased width of PDL space &gt;0.5mm along entire length of tooth root without a specific epicentre and adjacent bone destruction
2. **Bone sclerosis (BS):** region of increased bone density resulting from an increased number of bone trabeculae
3. **Bone resorption (BR):** region of decreased bone density resulting from decreased number of bone trabeculae
4. **Periodontal disease-like bone loss (PDBL):** vertical bone loss in the alveolar process as measured from the level of the CEJ of the adjacent tooth

*Radiographic features shown as panels A and B.*

*Chan K. Jaw Bone Changes on Panoramic Imaging after Head and Neck Radiotherapy. In: Pharoah M, editor.: ProQuest Dissertations Publishing; 2012.*

*Chan KC, Perschbacher SE, Lam EWN, Hope AJ, McNiven A, Atenafu EG, et al. Mandibular changes on panoramic imaging after head and neck radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(6):666-72.*</formatted_text>
    <images>
      <img order="0" bbox="153,431,510,611" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_8d631da04e35461d.webp" caption="Figure 1: Widened periodontal ligament space (WPLS)">
        <description>Radiograph: A split-panel dental image comparing a baseline scan (A) with a post-treatment scan (B). The right panel features orange arrows pointing to the roots of teeth, highlighting the specific areas where the periodontal ligament space has widened.</description>
      </img>
      <img order="1" bbox="524,431,884,610" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_5305fb4f1dbb00b1.webp" caption="Figure 2: Bone resorption (BR)">
        <description>Radiograph: A side-by-side comparison of two panoramic dental images, labeled 'A' and 'B', illustrating bone resorption. Image 'B' features orange arrows pointing to a region of decreased bone density in the mandible, demonstrating the loss of bone trabeculae.</description>
      </img>
      <img order="2" bbox="389,651,636,806" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_918d65af7d68f3ec.webp" caption="Figure 3: Bone sclerosis (BS - blue), and Periodontal disease-like bone loss (PDBL - orange)">
        <description>A pair of dental radiographs (labeled A and B) showing a comparison between pre-treatment bone levels (A) and post-treatment changes in the mandible (B). The image uses color-coded arrows to highlight specific pathologies: blue arrows indicate regions of increased bone density, while orange arrows point to vertical bone loss along the tooth roots.</description>
      </img>
    </images>
  </page>
  <page number="77">
    <text>THE
IMPORTANCE
OF REGULAR
DENTAL
CHECKS

• After radiotherapy in particular, it is important to have regular dental monitoring
• This may be more often than normal
• Allows dental team to work with you to prevent and manage problems before they become severe

![](W1 HNC Patient Journey_figures/img_db35b00c964f3eb2.webp)</text>
    <formatted_text>- After radiotherapy in particular, it is important to have regular dental monitoring
- This may be more often than normal
- Allows dental team to work with you to prevent and manage problems before they become severe</formatted_text>
    <images>
      <img order="0" bbox="475,500,806,746" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_db35b00c964f3eb2.webp">
        <description>Clinical photo showing a close-up of a patient's mouth during a dental examination. Gloved hands are visible holding a dental mirror and an explorer probe to inspect the teeth.</description>
      </img>
    </images>
  </page>
  <page number="78">
    <text>&lt;h2&gt;POST-RADIOTHERAPY EXTRactions&lt;/h2&gt;

&lt;div style=&quot;display: flex; justify-content: space-between; align-items: flex-start;&quot;&gt;
  &lt;div style=&quot;flex: 1;&quot;&gt;
    
    &lt;p&gt;Radiation tissue injury vs time (Marx and Johnson 1987)&lt;/p&gt;
  &lt;/div&gt;
  &lt;div style=&quot;flex: 1; font-size: 0.9em; margin-left: 20px;&quot;&gt;
    &lt;p&gt;Marx RE, Johnson RP. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol. 1987;64(4):379-90.&lt;/p&gt;
    &lt;p&gt;Kanatas A, Rogers S, Martin M. A practical guide for patients undergoing exodontia following radiotherapy to the oral cavity. Dent Update. 2002;29(10):498&lt;/p&gt;
    &lt;p&gt;Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: a systematic review. Int J Oral Maxillofac Surg. 2011;40(3):229-43&lt;/p&gt;
  &lt;/div&gt;
&lt;/div&gt;

![Radiation tissue injury vs time (Marx and Johnson 1987)](W1 HNC Patient Journey_figures/img_1942aa05b421901d.webp)</text>
    <formatted_text>*Radiation tissue injury vs time (Marx and Johnson 1987)*

*Marx RE, Johnson RP. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol. 1987;64(4):379-90.*

*Kanatas A, Rogers S, Martin M. A practical guide for patients undergoing exodontia following radiotherapy to the oral cavity. Dent Update. 2002;29(10):498*

*Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: a systematic review. Int J Oral Maxillofac Surg. 2011;40(3):229-43*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:46:21" confidence="3" anchor="*Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental ">

&gt; [!note] Lecturer — Extraction Decisions
&gt; Decisions about post-radiotherapy extractions should consider several factors.
&gt;
&gt; - The radiation dose at the tooth site
&gt; - The location of the tooth
&gt; - The condition of the surrounding bone
&gt; - Patient comorbidities and healing ability
&gt; - The urgency of treatment
&gt; - Whether conservative management is possible
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="118,350,585,718" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="W1 HNC Patient Journey_figures/img_1942aa05b421901d.webp" caption="Radiation tissue injury vs time (Marx and Johnson 1987)">
        <description>A line graph plotting radiation tissue injury against time (in years), with the vertical axis divided into 'Subclinical Damage', 'Clinical Threshold', and 'Clinical Damage' zones. Two curves track damage progression, annotated with events such as 'Early [Type I] Trauma Induced ORN', 'Spontaneous ORN', and 'Late [Type III] Trauma Induced ORN', alongside arrows indicating triggers like surgical trauma, inflammatory trauma, and HBO therapy.</description>
      </img>
    </images>
  </page>
  <page number="79">
    <text># 3D-CRT VS IMRT RADIOTHERAPY

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th colspan=&quot;2&quot;&gt;3DCRT&lt;/th&gt;
      &lt;th&gt;vs.&lt;/th&gt;
      &lt;th&gt;IMRT&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;🎯&lt;/td&gt;
      &lt;td&gt;Target Conformity&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;Highly conformal&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;🌈&lt;/td&gt;
      &lt;td&gt;Uniform intensity beams&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;Intensity-modulated beams&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;🛡️&lt;/td&gt;
      &lt;td&gt;Higher dose to nearby OARs&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;Better sparing of OARs&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;⏱️&lt;/td&gt;
      &lt;td&gt;Shorter&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;Longer&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;🔧&lt;/td&gt;
      &lt;td&gt;Simple to moderate&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;Complex&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;📈&lt;/td&gt;
      &lt;td&gt;Dose dose gradient less sharp&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;Sharp dose fall-off&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;🎯&lt;/td&gt;
      &lt;td&gt;Basic&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;Advanced&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;💰&lt;/td&gt;
      &lt;td&gt;Suitable for simple-shaped&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;Best for irregular tumors&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

![](W1 HNC Patient Journey_figures/img_7903da1acd4f4203.webp)
![](W1 HNC Patient Journey_figures/img_18ec198bb938f00f.webp)
![](W1 HNC Patient Journey_figures/img_30cb8f88b11ab7cc.webp)
![](W1 HNC Patient Journey_figures/img_32ea6ab9a01c239e.webp)
![](W1 HNC Patient Journey_figures/img_2868cda91fb1420c.webp)
![](W1 HNC Patient Journey_figures/img_d69c6ddea7b6ceb7.webp)
![](W1 HNC Patient Journey_figures/img_542eaefa6e9219e1.webp)</text>
    <formatted_text>| 3DCRT | vs. | IMRT |
| :--- | :--- | :--- |
| Target conformity | | Highly conformal |
| Uniform intensity beams | | Intensity-modulated beams |
| Higher dose to nearby OARs | | Better sparing of OARs |
| Shorter | | Longer |
| Simple to moderate | | Complex |
| Dose gradient less sharp | | Sharp dose fall-off |
| Basic | | Advanced |
| Suitable for simple-shaped | | Best for irregular tumors |</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:41:14" confidence="4" anchor="Basic | | Advanced | | Suitable for simple-shaped | | Best for irregular tumors">

&gt; [!note] Lecturer — Radiotherapy Planning
&gt; Earlier three-dimensional conformal radiotherapy produced broader radiation fields and exposed more healthy tissue. Intensity-modulated radiotherapy allows more highly contoured fields and aims to minimise radiation to healthy tissues.
</insert>
      <insert timestamp="01:13:26" confidence="9" anchor="| | Dental health | | | | Speech and swallowing function | |">

&gt; [!note] Lecturer — Surveillance Imaging
&gt; Surveillance includes imaging as well as clinical review. FDG-PET or CT may be performed at approximately three months after treatment, alongside ongoing assessment by the cancer team, dental monitoring and communication with community healthcare providers.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="21,288,348,573" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_7903da1acd4f4203.webp">
        <description>A radiation treatment planning CT scan showing an axial slice of the head and neck with overlaid isodose curves. The colored contours represent different dose levels, ranging from 78.0 Gy down to 7.0 Gy as listed in the legend on the left.</description>
      </img>
      <img order="1" bbox="21,580,181,712" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_18ec198bb938f00f.webp">
        <description>A sagittal CT scan of the head and neck displaying a radiotherapy treatment plan with superimposed isodose lines. The image shows a high-dose region (red/orange) conforming to the target volume, surrounded by lower dose gradients (yellow/green/purple), illustrating the concept of target conformity and dose fall-off.</description>
      </img>
      <img order="2" bbox="188,579,348,712" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_30cb8f88b11ab7cc.webp">
        <description>A radiotherapy treatment planning image displaying a coronal CT scan slice overlaid with color-coded isodose curves (ranging from 78.5 Gy to 7.0 Gy) and target volume contours. The visual demonstrates the dose distribution and gradient characteristics relevant to comparing different radiation techniques.</description>
      </img>
      <img order="3" bbox="370,289,731,502" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_32ea6ab9a01c239e.webp">
        <description>Clinical CT Planning Image: An axial cross-section of a head displaying radiotherapy dose distribution isodose lines overlaid on the anatomy. The image illustrates target conformity and dose gradients, with a color scale on the right indicating radiation levels in Gy.</description>
      </img>
      <img order="4" bbox="369,509,547,714" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_2868cda91fb1420c.webp">
        <description>A sagittal computed tomography (CT) scan from a radiation treatment planning system, displaying a patient's head and neck region with multiple colored isodose lines overlaid on the anatomy. The image includes a dose scale in Gray (Gy) on the right side, illustrating the distribution of radiation intensity for a specific radiotherapy plan.</description>
      </img>
      <img order="5" bbox="550,507,731,714" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_d69c6ddea7b6ceb7.webp">
        <description>A screenshot of a radiation therapy treatment planning system displaying a coronal CT slice with superimposed isodose lines and target volume contours. A vertical color bar on the right indicates dose levels in Gray (Gy), ranging from 77.00 to 7.00, illustrating the spatial distribution of radiation intensity within the head and neck region.</description>
      </img>
      <img order="6" bbox="759,334,957,716" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_542eaefa6e9219e1.webp">
        <description>A cropped section of a comparison table detailing the differences between 3D-CRT and IMRT radiotherapy. The rows list specific criteria such as 'Target Conformity', 'Uniform intensity beams', and 'Higher dose to nearby OARs' in an orange column, paired with corresponding attributes like 'Highly conformal' and 'Intensity-modulated beams' in a purple column, each row accompanied by a small illustrative icon.</description>
      </img>
    </images>
  </page>
  <page number="80">
    <text>HYPERBARIC OXYGEN THERAPY

• Based on Marx’s “3H” theory of ORN: Hypocellularity, Hypovascularity and Hypoxia

![RADIATION Bone tissue cell death from direct irradiation damage HYPOCELLULAR Tissue breakdown Irreversible cell change and dysfunction Damage to other bone tissue components (OSB, OSCt, OSCl, fibroblasts) Loss of reparative and synthetic function Vascular damage 'Endarteritis obliterans' and thrombosis of vessels HYPOVASCULAR Gradual ischaemia HYPOXIA Chronic non-healing wound in previously irradiated bone i.e. OSTEORADIONECROSIS](W1 HNC Patient Journey_figures/img_7bd069acdb9f4096.webp)
![](W1 HNC Patient Journey_figures/img_4ba6c9ea16834e20.webp)
![](W1 HNC Patient Journey_figures/img_f9f549f8c2231da4.webp)
![](W1 HNC Patient Journey_figures/img_89ca67a0b38f3390.webp)</text>
    <formatted_text>- Based on Marx's &quot;3H&quot; theory of ORN: Hypocellularity, Hypovascularity and Hypoxia</formatted_text>
    <images>
      <img order="0" bbox="69,408,479,825" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_7bd069acdb9f4096.webp" caption="RADIATION Bone tissue cell death from direct irradiation damage HYPOCELLULAR Tissue breakdown Irreversible cell change and dysfunction Damage to other bone tissue components (OSB, OSCt, OSCl, fibroblasts) Loss of reparative and synthetic function Vascular damage 'Endarteritis obliterans' and thrombosis of vessels HYPOVASCULAR Gradual ischaemia HYPOXIA Chronic non-healing wound in previously irradiated bone i.e. OSTEORADIONECROSIS">
        <description>A flowchart illustrating Marx's '3H' theory of osteoradionecrosis, detailing how radiation leads to hypocellularity, hypovascularity, and hypoxia. The diagram traces the pathological progression from initial cell death and vascular damage (endarteritis obliterans) through tissue breakdown and gradual ischaemia, culminating in a chronic non-healing wound.</description>
      </img>
      <img order="1" bbox="567,390,713,640" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_4ba6c9ea16834e20.webp">
        <description>Clinical photo: The interior of a hyperbaric oxygen therapy chamber. Visible features include padded walls, ceiling-mounted lights and sensors, wall-mounted control panels with tubing, a circular viewing port, and a chair.</description>
      </img>
      <img order="2" bbox="728,390,874,640" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_f9f549f8c2231da4.webp">
        <description>Clinical photo: The interior of a hyperbaric oxygen chamber, featuring multiple black reclining seats arranged within a room-like space with medical gas outlets and monitoring equipment mounted on the walls.</description>
      </img>
      <img order="3" bbox="629,650,830,843" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_89ca67a0b38f3390.webp">
        <description>Clinical photo showing the exterior of a multi-place hyperbaric oxygen chamber facility. The image displays white cylindrical chambers with open vertical doors and circular viewing ports, along with wall-mounted intercom panels and control boxes.</description>
      </img>
    </images>
  </page>
  <page number="81">
    <text>PENTOCLO

• Based on Delanian and Lefaix’s radiation-induced fibroatrophic theory of ORN
    • Impaired healing results from endothelial injury, release of cytokines (inflammation) and abnormal fibroblast activity
    • End result is hypocellular bone and reduced bone matrix formation, compensated by fibrosis $\rightarrow$ bone and tissue necrosis

| Pentoxifylline | $\alpha$-Tocopherol (Vitamin E) | Clodronate |
| :--- | :--- | :--- |
| Vasodilator and antifibrotic | Antioxidant | Non-nitrogenous bisphosphonate |

![](W1 HNC Patient Journey_figures/img_0c50a34fc2f1158b.webp)
![](W1 HNC Patient Journey_figures/img_b7de050d9705a140.webp)
![Trental 400mg Modified Release Tablets Pentoxifylline](W1 HNC Patient Journey_figures/img_c8ac59043055409a.webp)</text>
    <formatted_text>- Based on Delanian and Lefaix's radiation-induced fibroatrophic theory of ORN
  - Impaired healing results from endothelial injury, release of cytokines (inflammation) and abnormal fibroblast activity
  - End result is hypocellular bone and reduced bone matrix formation, compensated by fibrosis → bone and tissue necrosis

| Pentoxifylline | α-Tocopherol (Vitamin E) | Clodronate |
| :--- | :--- | :--- |
| Vasodilator and antifibrotic | Antioxidant | Non-nitrogenous bisphosphonate |</formatted_text>
    <images>
      <img order="0" bbox="72,624,612,795" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_0c50a34fc2f1158b.webp">
        <description>A three-column table listing the components of PENTOCLO: Pentoxifylline (Vasodilator and antifibrotic), $\alpha$-Tocopherol/Vitamin E (Antioxidant), and Clodronate (Non-nitrogenous bisphosphonate).</description>
      </img>
      <img order="1" bbox="628,315,982,642" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="W1 HNC Patient Journey_figures/img_b7de050d9705a140.webp">
        <description>This labelled schematic illustrates the cellular mechanisms of radiation-induced fibrosis, contrasting normal healing with pathological responses to ionising radiation. It depicts the interaction between Fibroblasts and Myofibroblasts, highlighting pathways involving TGF-β1, ECM production, collagenases/TIMP, oxidative stress (ROS/Cytokines), and phenotypic reversion.</description>
      </img>
      <img order="2" bbox="712,664,877,825" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="W1 HNC Patient Journey_figures/img_c8ac59043055409a.webp" caption="Trental 400mg Modified Release Tablets Pentoxifylline">
        <description>A product photograph of a white pharmaceutical carton for Trental 400mg Modified Release Tablets (Pentoxifylline), displaying the brand name in red and blue text along with the Sanofi logo.</description>
      </img>
    </images>
  </page>
  <page number="82">
    <text>CONSERVATIVE ORN MANAGEMENT

*   Strict oral hygiene
*   Irrigation (saline)
*   Chlorhexidine rinses or gel
*   Cessation of tobacco and alcohol consumption
*   Analgesics
*   Antibiotic therapy
*   Minimal surgical debridement</text>
    <formatted_text>- Strict oral hygiene
- Irrigation (saline)
- Chlorhexidine rinses or gel
- Cessation of tobacco and alcohol consumption
- Analgesics
- Antibiotic therapy
- Minimal surgical debridement</formatted_text>
  </page>
  <page number="83">
    <text>CANCER SURVEILLANCE

| Follow-up Intervals | Regular follow-ups to assess | Increased risk of recurrence |
| :--- | :--- | :--- |
| • **Year 1:** every 1-2 months | • Symptoms | - Buccal cancers |
| • **Year 2:** every 2-6 months | • Possible tumour recurrence | • Ongoing smoking |
| • **Years 3-5:** every 4-8 months | • Health behaviours | • Immunosuppressants |
| • **&gt;5 years:** every 12 months. | • Nutrition | • Larger cancers |
| | • Dental health | • Long history of SCCs (“hot mouth” “field cancerisation”) |
| | • Speech and swallowing function | |</text>
    <formatted_text>| Follow-up intervals | Regular follow-ups to assess | Increased risk of recurrence |
| :--- | :--- | :--- |
| Year 1: every 1-2 months | Symptoms | Buccal cancers |
| Year 2: every 2-6 months | Possible tumour recurrence | Ongoing smoking |
| Years 3-5: every 4-8 months | Health behaviours | Immunosuppressants |
| &gt;5 years: every 12 months | Nutrition | Larger cancers |
| | Dental health | Long history of SCCs (&quot;hot mouth&quot;, &quot;field cancerisation&quot;) |
| | Speech and swallowing function | |</formatted_text>
  </page>
  <page number="84">
    <text>LONG-TERM COMMUNITY SUPPORT

| General medical practitioner | Social worker |
| :--- | :--- |
| Clinical nurse specialist (including tracheotomy care and wound management) | Psychologist |
| Speech and swallowing therapist | Psychiatrist |
| Dietician (enteral feeding and oral nutrition) | Counsellor |
| Dentist/Dental hygienist | Pain specialist |
| Physiotherapist | Smoking and alcohol cessation services |
| Occupational therapist (lymphedema management) | Audiology |

![](W1 HNC Patient Journey_figures/img_3a16a936ac0dba06.webp)</text>
    <formatted_text>| | |
| :--- | :--- |
| General medical practitioner | Social worker |
| Clinical nurse specialist (including tracheotomy care and wound management) | Psychologist |
| Speech and swallowing therapist | Psychiatrist |
| Dietician (enteral feeding and oral nutrition) | Counsellor |
| Dentist/Dental hygienist | Pain specialist |
| Physiotherapist | Smoking and alcohol cessation services |
| Occupational therapist (lymphedema management) | Audiology |</formatted_text>
    <images>
      <img order="0" bbox="116,335,913,770" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_3a16a936ac0dba06.webp">
        <description>A two-column table listing various healthcare professionals and support services on an orange background. The left column details clinical roles such as General medical practitioner, Clinical nurse specialist, Speech therapist, and Physiotherapist, while the right column lists psychosocial and specialized support roles including Social worker, Psychologist, Pain specialist, and Audiology.</description>
      </img>
    </images>
  </page>
  <page number="85">
    <text>&lt;div align=&quot;center&quot;&gt;&lt;b&gt;PSYCHOSOCIAL CONSIDERATIONS&lt;/b&gt;&lt;/div&gt;

*   Depression during and post treatment
*   Social support/isolation
*   Affect on family (children, spouses)
*   Quality of life impacts
*   Social adaptation
*   Occupation
*   Survivorship
    *   Treatment guiding your life – what next?
*   Fear of recurrence</text>
    <formatted_text>- Depression during and post treatment
- Social support/isolation
- Affect on family (children, spouses)
- Quality of life impacts
- Social adaptation
- Occupation
- Survivorship
  - Treatment guiding your life — what next?
- Fear of recurrence</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:16:28" confidence="11" anchor="- Fear of recurrence">

&gt; [!note] Lecturer — Psychosocial Effects
&gt; Head and neck cancer can have major psychosocial effects because treatment may be disfiguring and functionally disabling.
&gt;
&gt; - Patients may have difficulty eating and speaking.
&gt; - Depression and anxiety may occur.
&gt; - Challenges may be greater for patients with low health literacy or vulnerable backgrounds.
&gt; - The MDT may involve psychology, psycho-oncology, social work, supportive care and palliative care.
</insert>
    </audio_inserts>
  </page>
  <page number="86">
    <text>PROGNOSIS

• 5-year survival
    • Overall survival for oral cancer globally = 50%

| Stage I | Stage II | Stage III | Stage IV |
| :--- | :--- | :--- | :--- |
| 85% | 66% | 41% | 9% |

• Steady increase in HNC survivors
    • Advances in treatment
    • Decreased smoking rates
    • Improved prognosis of HPV-associated oropharyngeal cancers (80% long term survival)

![](W1 HNC Patient Journey_figures/img_3873fc8a7e0c5e40.webp)</text>
    <formatted_text>- 5-year survival
  - Overall survival for oral cancer globally = 50%

| Stage I | Stage II | Stage III | Stage IV |
| :--- | :--- | :--- | :--- |
| 85% | 66% | 41% | 9% |

- Steady increase in HNC survivors
  - Advances in treatment
  - Decreased smoking rates
  - Improved prognosis of HPV-associated oropharyngeal cancers (80% long term survival)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:13:13" confidence="11" anchor="| 85% | 66% | 41% | 9% |">

&gt; [!note] Lecturer — Prognostic Factors
&gt; Prognosis is influenced by tumour and patient factors as well as treatment response.
&gt;
&gt; - Tumour site and stage
&gt; - Regional lymph node involvement and distant metastases
&gt; - HPV or p16 status
&gt; - Pathological findings and treatment response
&gt; - Patient comorbidities, functional status and ability to complete treatment
&gt;
&gt; HPV-associated or p16-positive oropharyngeal cancers generally have a better prognosis than HPV-negative cancers associated with smoking and alcohol.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="166,460,832,538" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="W1 HNC Patient Journey_figures/img_3873fc8a7e0c5e40.webp">
        <description>Table: Displays 5-year survival rates for oral cancer categorized by disease stage, showing a decline from Stage I (85%) to Stage IV (9%).</description>
      </img>
    </images>
  </page>
  <page number="87">
    <text/>
  </page>
  <page number="88">
    <text>THANK YOU!
QUESTIONS?

Jeeyun.leung@uwa.edu.au

![](W1 HNC Patient Journey_figures/img_a14ea16c15dd0d5c.webp)</text>
    <formatted_text>THANK YOU!

QUESTIONS?

Jeeyun.leung@uwa.edu.au</formatted_text>
    <images>
      <img order="0" bbox="84,231,330,720" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="W1 HNC Patient Journey_figures/img_a14ea16c15dd0d5c.webp">
        <description>The image displays a simple text slide with the message 'THANK YOU! QUESTIONS?' in large, black capital letters against a white background.</description>
      </img>
    </images>
  </page>
  <page number="89" origin="cases">
    <text>## Case: Post-recurrence mandibular non-union and free flap complications

### Question

**Scenario:** A patient with a history of left tongue squamous cell carcinoma (SCC) who developed a recurrence and subsequently underwent further surgery. 

**What's shown:** A clinical image showing the result of the surgical intervention, highlighting the site of the previous surgery in relation to the adjacent canine tooth, as well as the presence of a free flap in the oral cavity.

**Consider:** What surgical complications occurred following the recurrence, what dental issues arise as a result of the surgical site, and what secondary complications are associated with the use of a free flap in the mouth?


### Answer

**Observations:**
- The image shows the site of a previous surgical resection, clearly visible next to the canine tooth.
- The patient developed a non-union despite the use of plating.
- The surgical team performed an ankylosis/ankyloectomy for the recurrence.
- There are teeth on either side of the surgical site.
- The free flap transferred into the mouth contains hair follicles.

**Reasoning:** 
- The non-union developed despite plating, necessitating further surgical management (ankylosis) for the recurrence.
- The teeth adjacent to the surgical cages/site are prone to developing periodontal issues, trauma, and occlusal problems as a result of the altered anatomy and surgical access.
- Because the free flap is taken from a hairy area (like an arm or leg), the hair follicles transfer into the mouth. This causes a tickling sensation, difficulty with saliva management, poor oral hygiene, gagging, and nausea.

**Outcome:** 
- The patient requires management of the dental issues adjacent to the surgical site.
- The hair growth from the free flap requires management, which may include radiotherapy to the hair follicles or the use of an eyebrow plucker to remove the hair.

**Takeaway:** 
- Extensive mandibular surgery for cancer recurrence can lead to non-union and adjacent tooth complications, while free flap reconstruction introduces secondary issues like intraoral hair growth that require specific management strategies.

## Case: Dental workup for a patient with oropharyngeal squamous cell carcinoma

### Question

**Scenario:** A gentleman presents for dental evaluation prior to head and neck radiotherapy for a left oropharyngeal T4N2Mx p16-positive squamous cell carcinoma, which will involve bilateral neck irradiation down to level 4.

**What's shown:** The patient's dental status, including carious teeth, teeth with significant periodontal pockets, teeth with large lost fillings, and lower anterior teeth (32, 31, 41, 42) that are grade 1 mobile.

**Consider:** How to manage the lower anterior teeth that are only grade 1 mobile, considering the planned radiation fields and the risk of osteoradionecrosis.

### Answer

**Observations:**
- The patient has multiple teeth with varying prognoses, including carious teeth, teeth with 6-7 mm periodontal pockets, and teeth with large lost fillings.
- The lower anterior teeth (32, 31, 41, 42) are grade 1 mobile.
- The anticipated radiation field includes these lower anterior teeth, with a planned dose of about 70 Gy.

**Reasoning:** The risk of osteoradionecrosis significantly increases at radiation doses above 50-60 Gy. Although grade 1 mobile lower anterior teeth would typically be retained in a patient not planned for radiotherapy, the high radiation dose (70 Gy) to this specific area changes the risk-benefit analysis.

**Outcome:** The decision was made to extract the lower anterior teeth (along with the other poor-prognosis teeth) prior to radiotherapy.

**Takeaway:** When planning dental extractions prior to head and neck radiotherapy, the anticipated radiation dose to specific teeth must be considered; teeth in fields receiving &gt;60 Gy may need to be extracted even if they are only mildly mobile and would otherwise be retained.
</text>
    <formatted_text>## Case: Post-recurrence mandibular non-union and free flap complications

### Question

**Scenario:** A patient with a history of left tongue squamous cell carcinoma (SCC) who developed a recurrence and subsequently underwent further surgery. 

**What's shown:** A clinical image showing the result of the surgical intervention, highlighting the site of the previous surgery in relation to the adjacent canine tooth, as well as the presence of a free flap in the oral cavity.

**Consider:** What surgical complications occurred following the recurrence, what dental issues arise as a result of the surgical site, and what secondary complications are associated with the use of a free flap in the mouth?


![](W1 HNC Patient Journey_cases_attachments/img_3eb8a566cc793dbe.webp)
### Answer

**Observations:**
- The image shows the site of a previous surgical resection, clearly visible next to the canine tooth.
- The patient developed a non-union despite the use of plating.
- The surgical team performed an ankylosis/ankyloectomy for the recurrence.
- There are teeth on either side of the surgical site.
- The free flap transferred into the mouth contains hair follicles.

**Reasoning:** 
- The non-union developed despite plating, necessitating further surgical management (ankylosis) for the recurrence.
- The teeth adjacent to the surgical cages/site are prone to developing periodontal issues, trauma, and occlusal problems as a result of the altered anatomy and surgical access.
- Because the free flap is taken from a hairy area (like an arm or leg), the hair follicles transfer into the mouth. This causes a tickling sensation, difficulty with saliva management, poor oral hygiene, gagging, and nausea.

**Outcome:** 
- The patient requires management of the dental issues adjacent to the surgical site.
- The hair growth from the free flap requires management, which may include radiotherapy to the hair follicles or the use of an eyebrow plucker to remove the hair.

**Takeaway:** 
- Extensive mandibular surgery for cancer recurrence can lead to non-union and adjacent tooth complications, while free flap reconstruction introduces secondary issues like intraoral hair growth that require specific management strategies.

## Case: Dental workup for a patient with oropharyngeal squamous cell carcinoma

### Question

**Scenario:** A gentleman presents for dental evaluation prior to head and neck radiotherapy for a left oropharyngeal T4N2Mx p16-positive squamous cell carcinoma, which will involve bilateral neck irradiation down to level 4.

**What's shown:** The patient's dental status, including carious teeth, teeth with significant periodontal pockets, teeth with large lost fillings, and lower anterior teeth (32, 31, 41, 42) that are grade 1 mobile.

**Consider:** How to manage the lower anterior teeth that are only grade 1 mobile, considering the planned radiation fields and the risk of osteoradionecrosis.

### Answer

**Observations:**
- The patient has multiple teeth with varying prognoses, including carious teeth, teeth with 6-7 mm periodontal pockets, and teeth with large lost fillings.
- The lower anterior teeth (32, 31, 41, 42) are grade 1 mobile.
- The anticipated radiation field includes these lower anterior teeth, with a planned dose of about 70 Gy.

**Reasoning:** The risk of osteoradionecrosis significantly increases at radiation doses above 50-60 Gy. Although grade 1 mobile lower anterior teeth would typically be retained in a patient not planned for radiotherapy, the high radiation dose (70 Gy) to this specific area changes the risk-benefit analysis.

**Outcome:** The decision was made to extract the lower anterior teeth (along with the other poor-prognosis teeth) prior to radiotherapy.

**Takeaway:** When planning dental extractions prior to head and neck radiotherapy, the anticipated radiation dose to specific teeth must be considered; teeth in fields receiving &gt;60 Gy may need to be extracted even if they are only mildly mobile and would otherwise be retained.
</formatted_text>
    <heading_path>Case: Post-recurrence mandibular non-union and free flap complications</heading_path>
    <images>
      <img order="0" type="figure" path="W1 HNC Patient Journey_figures/img_3eb8a566cc793dbe.webp" media="frame" source="slide" page="30" timestamp="00:34:24">
        <description>a Marginal mandibulectomy The figure shows a lateral view of a human mandible (lower jaw) with a section of the alveolar ridge removed. Dashed lines indicate the excised segment, which is displayed separately below to illustrate the extent of bone resection.</description>
      </img>
    </images>
  </page>
  <page number="90" origin="cases">
    <text>## Case: 19-year-old with tongue cancer and clear aligner orthodontics

### Question

**Scenario:** A 19-year-old female university student is diagnosed with a left lateral tongue squamous cell carcinoma (T3N0M0). Her treatment plan includes neoadjuvant chemotherapy, left hemiglossectomy, left selective neck dissection, tracheostomy, NG tube placement, left radial forearm free flap reconstruction, and post-operative radiotherapy. She is currently 90 days away from completing a one-year course of clear aligner orthodontic therapy, with clear attachments placed on teeth 1 to 5 in each quadrant.

**What's shown:** The clinical dilemma of managing active clear aligner orthodontic appliances in a patient about to undergo extensive oral surgery and radiotherapy.

**Consider:** How to manage her orthodontic appliances and retention in the context of her upcoming major surgery and anticipated post-treatment oral soreness.

### Answer

**Observations:**
- The patient has clear aligner attachments on teeth 1 to 5 in each quadrant.
- She is 90 days from completing her one-year orthodontic course.
- She requires extensive head and neck surgery and post-operative radiotherapy.

**Reasoning:** 
- The orthodontic attachments and aligners pose a risk of trauma to the healing surgical sites in the mouth.
- Therefore, the appliances must be removed partway through the orthodontic treatment.
- A removable retainer (similar to an Invisalign-style retainer, avoiding rigid acrylic and wires) is fabricated. This allows the patient the option of not wearing it if her mouth becomes too sore post-surgery or during acute radiotherapy side effects, while her mouth adapts to the new surgical and functional changes.

**Outcome:** 
- The clear aligner attachments were removed.
- A flexible, removable retainer was fabricated to maintain orthodontic results while accommodating post-surgical soreness and radiotherapy side effects.

**Takeaway:** 
- In patients undergoing major head and neck surgery and radiotherapy, orthodontic appliances that risk trauma to surgical sites should be removed, and flexible, removable retainers should be provided to allow for non-compliance during periods of severe oral soreness.

## Case: Crusted mucus on the palate after extensive head and neck surgery and chemoradiotherapy

### Question

**Scenario:** A patient who underwent extensive surgery (including partial maxillectomy, bilateral neck dissection, and tracheostomy) followed by post-operative chemoradiotherapy.

**What's shown:** Intraoral photographs showing profound, dried mucus crusted on the palate, and the underlying tissue after removal.

**Consider:** What is the nature of the palatal presentation, and how was it managed clinically?


### Answer

**Observations:**
- Profound, dried mucus sticking to the palate.
- A crusted layer on the top of the palate.
- Underlying tissue revealed after the thick mucus was removed.

**Reasoning:** The mucus becomes so thick and profound due to the dry mouth and altered anatomy that it dries up and sticks to the palate, forming a crust.

**Outcome:** The lecturer used tweezers to peel off the crusted mucus from the palate.

**Takeaway:** Severe mucus buildup and crusting can occur in the altered anatomy of the palate post-surgery and chemoradiotherapy, requiring careful mechanical removal.

## Case: Thick mucus and tongue debris three weeks into radiotherapy

### Question

**Scenario:** A patient three weeks into post-operative radiotherapy following surgery.

**What's shown:** Intraoral photographs showing thick, rosy, mucousy saliva and debris building up on the tongue.

**Consider:** What are the clinical findings regarding the saliva and oral cavity in this patient, and what are the contributing factors?

</text>
    <formatted_text>## Case: 19-year-old with tongue cancer and clear aligner orthodontics

### Question

**Scenario:** A 19-year-old female university student is diagnosed with a left lateral tongue squamous cell carcinoma (T3N0M0). Her treatment plan includes neoadjuvant chemotherapy, left hemiglossectomy, left selective neck dissection, tracheostomy, NG tube placement, left radial forearm free flap reconstruction, and post-operative radiotherapy. She is currently 90 days away from completing a one-year course of clear aligner orthodontic therapy, with clear attachments placed on teeth 1 to 5 in each quadrant.

**What's shown:** The clinical dilemma of managing active clear aligner orthodontic appliances in a patient about to undergo extensive oral surgery and radiotherapy.

**Consider:** How to manage her orthodontic appliances and retention in the context of her upcoming major surgery and anticipated post-treatment oral soreness.

### Answer

**Observations:**
- The patient has clear aligner attachments on teeth 1 to 5 in each quadrant.
- She is 90 days from completing her one-year orthodontic course.
- She requires extensive head and neck surgery and post-operative radiotherapy.

**Reasoning:** 
- The orthodontic attachments and aligners pose a risk of trauma to the healing surgical sites in the mouth.
- Therefore, the appliances must be removed partway through the orthodontic treatment.
- A removable retainer (similar to an Invisalign-style retainer, avoiding rigid acrylic and wires) is fabricated. This allows the patient the option of not wearing it if her mouth becomes too sore post-surgery or during acute radiotherapy side effects, while her mouth adapts to the new surgical and functional changes.

**Outcome:** 
- The clear aligner attachments were removed.
- A flexible, removable retainer was fabricated to maintain orthodontic results while accommodating post-surgical soreness and radiotherapy side effects.

**Takeaway:** 
- In patients undergoing major head and neck surgery and radiotherapy, orthodontic appliances that risk trauma to surgical sites should be removed, and flexible, removable retainers should be provided to allow for non-compliance during periods of severe oral soreness.

## Case: Crusted mucus on the palate after extensive head and neck surgery and chemoradiotherapy

### Question

**Scenario:** A patient who underwent extensive surgery (including partial maxillectomy, bilateral neck dissection, and tracheostomy) followed by post-operative chemoradiotherapy.

**What's shown:** Intraoral photographs showing profound, dried mucus crusted on the palate, and the underlying tissue after removal.

**Consider:** What is the nature of the palatal presentation, and how was it managed clinically?


![](W1 HNC Patient Journey_cases_attachments/img_3790d763a0fa7f84.webp)
![](W1 HNC Patient Journey_cases_attachments/img_b8b0cfdd230bd716.webp)
### Answer

**Observations:**
- Profound, dried mucus sticking to the palate.
- A crusted layer on the top of the palate.
- Underlying tissue revealed after the thick mucus was removed.

**Reasoning:** The mucus becomes so thick and profound due to the dry mouth and altered anatomy that it dries up and sticks to the palate, forming a crust.

**Outcome:** The lecturer used tweezers to peel off the crusted mucus from the palate.

**Takeaway:** Severe mucus buildup and crusting can occur in the altered anatomy of the palate post-surgery and chemoradiotherapy, requiring careful mechanical removal.

## Case: Thick mucus and tongue debris three weeks into radiotherapy

### Question

**Scenario:** A patient three weeks into post-operative radiotherapy following surgery.

**What's shown:** Intraoral photographs showing thick, rosy, mucousy saliva and debris building up on the tongue.

**Consider:** What are the clinical findings regarding the saliva and oral cavity in this patient, and what are the contributing factors?


![](W1 HNC Patient Journey_cases_attachments/img_ba4c958be18280aa.webp)</formatted_text>
    <heading_path>Case: 19-year-old with tongue cancer and clear aligner orthodontics</heading_path>
    <images>
      <img order="0" type="photo" path="W1 HNC Patient Journey_figures/img_3790d763a0fa7f84.webp" media="frame" source="slide" page="56" timestamp="01:09:31">
        <description>Clinical intraoral photograph showing the maxillary arch and hard palate. The image reveals extensive brownish-yellow necrotic tissue and plaque accumulation along the gingival margins and covering the anterior palate, with visible teeth exhibiting significant staining.</description>
      </img>
      <img order="1" type="photo" path="W1 HNC Patient Journey_figures/img_b8b0cfdd230bd716.webp" media="frame" source="slide" page="56" timestamp="01:09:31">
        <description>Clinical intraoral photograph showing the maxillary arch and palate. The image reveals extensive dark brown to black staining or decay on the cervical margins of the teeth, particularly affecting the anterior incisors and premolars.</description>
      </img>
      <img order="2" type="photo" path="W1 HNC Patient Journey_figures/img_ba4c958be18280aa.webp" media="frame" source="slide" page="56" timestamp="01:09:31">
        <description>Clinical photograph showing an intraoral view of the tongue, which exhibits a large, raised mass with distinct red and white patches on its surface.</description>
      </img>
    </images>
  </page>
  <page number="91" origin="cases">
    <text>### Answer

**Observations:**
- Saliva has become thick, rosy, mucousy, and clammy, rather than the normal watery consistency.
- Debris is building up on the tongue.

**Reasoning:** The lack of normal natural flow (saliva) in the dry mouth environment leads to the accumulation of debris on the tongue and the thickening of saliva.

**Outcome:** Management includes using jumbo swabs dipped in bicarbonate or chlorhexidine to clean the palate, and bicarbonate mouth rinses (half a teaspoon in a glass of warm water) to help break down and soften the mucus.

**Takeaway:** Radiotherapy can cause profound changes in saliva consistency and oral clearance, requiring specific mechanical and chemical interventions to manage mucus and debris buildup.

## Case: Full dental clearance and prosthodontic rehabilitation for a head and neck cancer patient

### Question

**Scenario:** A lady diagnosed in June 2024 with a head and neck cancer, planned for partial mandibulectomy, marginal alveolar bulectomy, bilateral neck dissection, free flap, and post-operative chemoradiotherapy.

**What's shown:** The significant alterations to the patient's anatomy following surgery, making denture fabrication challenging.

**Consider:** What was the dental treatment plan in conjunction with her surgery, and how was her prosthetic rehabilitation managed?


### Answer

**Observations:**
- Very poor dentition.
- Significant alterations to the anatomy following extensive surgery.

**Reasoning:** Due to the poor dentition, a full dental clearance was planned at the same time as the ENT surgery. The significant anatomical changes made conventional denture fabrication tricky.

**Outcome:** The patient was referred to prosthodontic colleagues, who undertook the process of making her a conventional full upper denture.

**Takeaway:** Patients undergoing extensive head and neck surgery with poor dentition may require full dental clearance at the time of surgery, and complex anatomical changes necessitate referral to prosthodontic specialists for denture fabrication.

## Case: Maxillofacial prosthesis for facial rehabilitation

### Question

**Scenario:** A case presented by a colleague demonstrating the rehabilitation of entire facial structures (eyes, ears, noses) by a maxillofacial prosthetist.

**What's shown:** A maxillofacial prosthesis featuring natural hairs.

**Consider:** What specific detail is highlighted regarding the construction of this prosthesis?

### Answer

**Observations:**
- A silicone prosthesis for facial structures.
- Natural hairs individually threaded into the silicon.

**Reasoning:** The rehabilitation of facial structures requires highly detailed, artistic work to match natural features, such as individually threading hairs into the silicone base.

**Outcome:** The prosthesis was successfully crafted to rehabilitate the patient's facial structures.

**Takeaway:** Maxillofacial prosthetics involves highly specialized, artistic techniques to rehabilitate facial structures, such as individually threading natural hairs into silicone.
</text>
    <formatted_text>### Answer

**Observations:**
- Saliva has become thick, rosy, mucousy, and clammy, rather than the normal watery consistency.
- Debris is building up on the tongue.

**Reasoning:** The lack of normal natural flow (saliva) in the dry mouth environment leads to the accumulation of debris on the tongue and the thickening of saliva.

**Outcome:** Management includes using jumbo swabs dipped in bicarbonate or chlorhexidine to clean the palate, and bicarbonate mouth rinses (half a teaspoon in a glass of warm water) to help break down and soften the mucus.

**Takeaway:** Radiotherapy can cause profound changes in saliva consistency and oral clearance, requiring specific mechanical and chemical interventions to manage mucus and debris buildup.

## Case: Full dental clearance and prosthodontic rehabilitation for a head and neck cancer patient

### Question

**Scenario:** A lady diagnosed in June 2024 with a head and neck cancer, planned for partial mandibulectomy, marginal alveolar bulectomy, bilateral neck dissection, free flap, and post-operative chemoradiotherapy.

**What's shown:** The significant alterations to the patient's anatomy following surgery, making denture fabrication challenging.

**Consider:** What was the dental treatment plan in conjunction with her surgery, and how was her prosthetic rehabilitation managed?


![](W1 HNC Patient Journey_cases_attachments/img_a18ea4ed9518da63.webp)
### Answer

**Observations:**
- Very poor dentition.
- Significant alterations to the anatomy following extensive surgery.

**Reasoning:** Due to the poor dentition, a full dental clearance was planned at the same time as the ENT surgery. The significant anatomical changes made conventional denture fabrication tricky.

**Outcome:** The patient was referred to prosthodontic colleagues, who undertook the process of making her a conventional full upper denture.

**Takeaway:** Patients undergoing extensive head and neck surgery with poor dentition may require full dental clearance at the time of surgery, and complex anatomical changes necessitate referral to prosthodontic specialists for denture fabrication.

## Case: Maxillofacial prosthesis for facial rehabilitation

### Question

**Scenario:** A case presented by a colleague demonstrating the rehabilitation of entire facial structures (eyes, ears, noses) by a maxillofacial prosthetist.

**What's shown:** A maxillofacial prosthesis featuring natural hairs.

**Consider:** What specific detail is highlighted regarding the construction of this prosthesis?

### Answer

**Observations:**
- A silicone prosthesis for facial structures.
- Natural hairs individually threaded into the silicon.

**Reasoning:** The rehabilitation of facial structures requires highly detailed, artistic work to match natural features, such as individually threading hairs into the silicone base.

**Outcome:** The prosthesis was successfully crafted to rehabilitate the patient's facial structures.

**Takeaway:** Maxillofacial prosthetics involves highly specialized, artistic techniques to rehabilitate facial structures, such as individually threading natural hairs into silicone.
</formatted_text>
    <heading_path>Case: Thick mucus and tongue debris three weeks into radiotherapy &gt; Answer</heading_path>
    <images>
      <img order="0" type="figure" path="W1 HNC Patient Journey_figures/img_a18ea4ed9518da63.webp" media="frame" source="slide" page="61" timestamp="01:13:24">
        <description>FOLL-A 2 OF 2 A flowchart illustrating follow-up recommendations for head and neck cancers after systemic therapy or radiation, detailing the decision pathway based on clinical assessment and imaging results (FDG-PET/CT, CT, MRI) to determine whether observation, biopsy, or resection is required.</description>
      </img>
    </images>
  </page>
  <footnotes>[^1]: Original PDF page 1: [[W1 HNC Patient Journey.pdf#page=1|W1 HNC Patient Journey, p.1]]
[^2]: Original PDF page 2: [[W1 HNC Patient Journey.pdf#page=2|W1 HNC Patient Journey, p.2]]
[^3]: Original PDF page 3: [[W1 HNC Patient Journey.pdf#page=3|W1 HNC Patient Journey, p.3]]
[^4]: Original PDF page 4: [[W1 HNC Patient Journey.pdf#page=4|W1 HNC Patient Journey, p.4]]
[^5]: Original PDF page 5: [[W1 HNC Patient Journey.pdf#page=5|W1 HNC Patient Journey, p.5]]
[^6]: Original PDF page 6: [[W1 HNC Patient Journey.pdf#page=6|W1 HNC Patient Journey, p.6]]
[^7]: Original PDF page 7: [[W1 HNC Patient Journey.pdf#page=7|W1 HNC Patient Journey, p.7]]
[^8]: Original PDF page 8: [[W1 HNC Patient Journey.pdf#page=8|W1 HNC Patient Journey, p.8]]
[^9]: Original PDF page 9: [[W1 HNC Patient Journey.pdf#page=9|W1 HNC Patient Journey, p.9]]
[^10]: Original PDF page 10: [[W1 HNC Patient Journey.pdf#page=10|W1 HNC Patient Journey, p.10]]
[^11]: Original PDF page 11: [[W1 HNC Patient Journey.pdf#page=11|W1 HNC Patient Journey, p.11]]
[^12]: Original PDF page 12: [[W1 HNC Patient Journey.pdf#page=12|W1 HNC Patient Journey, p.12]]
[^13]: Original PDF page 13: [[W1 HNC Patient Journey.pdf#page=13|W1 HNC Patient Journey, p.13]]
[^14]: Original PDF page 14: [[W1 HNC Patient Journey.pdf#page=14|W1 HNC Patient Journey, p.14]]
[^15]: Original PDF page 15: [[W1 HNC Patient Journey.pdf#page=15|W1 HNC Patient Journey, p.15]]
[^16]: Original PDF page 16: [[W1 HNC Patient Journey.pdf#page=16|W1 HNC Patient Journey, p.16]]
[^17]: Original PDF page 17: [[W1 HNC Patient Journey.pdf#page=17|W1 HNC Patient Journey, p.17]]
[^18]: Original PDF page 18: [[W1 HNC Patient Journey.pdf#page=18|W1 HNC Patient Journey, p.18]]
[^19]: Original PDF page 19: [[W1 HNC Patient Journey.pdf#page=19|W1 HNC Patient Journey, p.19]]
[^20]: Original PDF page 20: [[W1 HNC Patient Journey.pdf#page=20|W1 HNC Patient Journey, p.20]]
[^21]: Original PDF page 21: [[W1 HNC Patient Journey.pdf#page=21|W1 HNC Patient Journey, p.21]]
[^22]: Original PDF page 22: [[W1 HNC Patient Journey.pdf#page=22|W1 HNC Patient Journey, p.22]]
[^23]: Original PDF page 23: [[W1 HNC Patient Journey.pdf#page=23|W1 HNC Patient Journey, p.23]]
[^24]: Original PDF page 24: [[W1 HNC Patient Journey.pdf#page=24|W1 HNC Patient Journey, p.24]]
[^25]: Original PDF page 25: [[W1 HNC Patient Journey.pdf#page=25|W1 HNC Patient Journey, p.25]]
[^26]: Original PDF page 26: [[W1 HNC Patient Journey.pdf#page=26|W1 HNC Patient Journey, p.26]]
[^27]: Original PDF page 27: [[W1 HNC Patient Journey.pdf#page=27|W1 HNC Patient Journey, p.27]]
[^28]: Original PDF page 28: [[W1 HNC Patient Journey.pdf#page=28|W1 HNC Patient Journey, p.28]]
[^29]: Original PDF page 29: [[W1 HNC Patient Journey.pdf#page=29|W1 HNC Patient Journey, p.29]]
[^30]: Original PDF page 30: [[W1 HNC Patient Journey.pdf#page=30|W1 HNC Patient Journey, p.30]]
[^31]: Original PDF page 31: [[W1 HNC Patient Journey.pdf#page=31|W1 HNC Patient Journey, p.31]]
[^32]: Original PDF page 32: [[W1 HNC Patient Journey.pdf#page=32|W1 HNC Patient Journey, p.32]]
[^33]: Original PDF page 33: [[W1 HNC Patient Journey.pdf#page=33|W1 HNC Patient Journey, p.33]]
[^34]: Original PDF page 34: [[W1 HNC Patient Journey.pdf#page=34|W1 HNC Patient Journey, p.34]]
[^35]: Original PDF page 35: [[W1 HNC Patient Journey.pdf#page=35|W1 HNC Patient Journey, p.35]]
[^36]: Original PDF page 36: [[W1 HNC Patient Journey.pdf#page=36|W1 HNC Patient Journey, p.36]]
[^37]: Original PDF page 37: [[W1 HNC Patient Journey.pdf#page=37|W1 HNC Patient Journey, p.37]]
[^38]: Original PDF page 38: [[W1 HNC Patient Journey.pdf#page=38|W1 HNC Patient Journey, p.38]]
[^39]: Original PDF page 39: [[W1 HNC Patient Journey.pdf#page=39|W1 HNC Patient Journey, p.39]]
[^40]: Original PDF page 40: [[W1 HNC Patient Journey.pdf#page=40|W1 HNC Patient Journey, p.40]]
[^41]: Original PDF page 41: [[W1 HNC Patient Journey.pdf#page=41|W1 HNC Patient Journey, p.41]]
[^42]: Original PDF page 42: [[W1 HNC Patient Journey.pdf#page=42|W1 HNC Patient Journey, p.42]]
[^43]: Original PDF page 43: [[W1 HNC Patient Journey.pdf#page=43|W1 HNC Patient Journey, p.43]]
[^44]: Original PDF page 44: [[W1 HNC Patient Journey.pdf#page=44|W1 HNC Patient Journey, p.44]]
[^45]: Original PDF page 45: [[W1 HNC Patient Journey.pdf#page=45|W1 HNC Patient Journey, p.45]]
[^46]: Original PDF page 46: [[W1 HNC Patient Journey.pdf#page=46|W1 HNC Patient Journey, p.46]]
[^47]: Original PDF page 47: [[W1 HNC Patient Journey.pdf#page=47|W1 HNC Patient Journey, p.47]]
[^48]: Original PDF page 48: [[W1 HNC Patient Journey.pdf#page=48|W1 HNC Patient Journey, p.48]]
[^49]: Original PDF page 49: [[W1 HNC Patient Journey.pdf#page=49|W1 HNC Patient Journey, p.49]]
[^50]: Original PDF page 50: [[W1 HNC Patient Journey.pdf#page=50|W1 HNC Patient Journey, p.50]]
[^51]: Original PDF page 51: [[W1 HNC Patient Journey.pdf#page=51|W1 HNC Patient Journey, p.51]]
[^52]: Original PDF page 52: [[W1 HNC Patient Journey.pdf#page=52|W1 HNC Patient Journey, p.52]]
[^53]: Original PDF page 53: [[W1 HNC Patient Journey.pdf#page=53|W1 HNC Patient Journey, p.53]]
[^54]: Original PDF page 54: [[W1 HNC Patient Journey.pdf#page=54|W1 HNC Patient Journey, p.54]]
[^55]: Original PDF page 55: [[W1 HNC Patient Journey.pdf#page=55|W1 HNC Patient Journey, p.55]]
[^56]: Original PDF page 56: [[W1 HNC Patient Journey.pdf#page=56|W1 HNC Patient Journey, p.56]]
[^57]: Original PDF page 57: [[W1 HNC Patient Journey.pdf#page=57|W1 HNC Patient Journey, p.57]]
[^58]: Original PDF page 58: [[W1 HNC Patient Journey.pdf#page=58|W1 HNC Patient Journey, p.58]]
[^59]: Original PDF page 59: [[W1 HNC Patient Journey.pdf#page=59|W1 HNC Patient Journey, p.59]]
[^60]: Original PDF page 60: [[W1 HNC Patient Journey.pdf#page=60|W1 HNC Patient Journey, p.60]]
[^61]: Original PDF page 61: [[W1 HNC Patient Journey.pdf#page=61|W1 HNC Patient Journey, p.61]]
[^62]: Original PDF page 62: [[W1 HNC Patient Journey.pdf#page=62|W1 HNC Patient Journey, p.62]]
[^63]: Original PDF page 63: [[W1 HNC Patient Journey.pdf#page=63|W1 HNC Patient Journey, p.63]]
[^64]: Original PDF page 64: [[W1 HNC Patient Journey.pdf#page=64|W1 HNC Patient Journey, p.64]]
[^65]: Original PDF page 65: [[W1 HNC Patient Journey.pdf#page=65|W1 HNC Patient Journey, p.65]]
[^66]: Original PDF page 66: [[W1 HNC Patient Journey.pdf#page=66|W1 HNC Patient Journey, p.66]]
[^67]: Original PDF page 67: [[W1 HNC Patient Journey.pdf#page=67|W1 HNC Patient Journey, p.67]]
[^68]: Original PDF page 68: [[W1 HNC Patient Journey.pdf#page=68|W1 HNC Patient Journey, p.68]]
[^69]: Original PDF page 69: [[W1 HNC Patient Journey.pdf#page=69|W1 HNC Patient Journey, p.69]]
[^70]: Original PDF page 70: [[W1 HNC Patient Journey.pdf#page=70|W1 HNC Patient Journey, p.70]]
[^71]: Original PDF page 71: [[W1 HNC Patient Journey.pdf#page=71|W1 HNC Patient Journey, p.71]]
[^72]: Original PDF page 72: [[W1 HNC Patient Journey.pdf#page=72|W1 HNC Patient Journey, p.72]]
[^73]: Original PDF page 73: [[W1 HNC Patient Journey.pdf#page=73|W1 HNC Patient Journey, p.73]]
[^74]: Original PDF page 74: [[W1 HNC Patient Journey.pdf#page=74|W1 HNC Patient Journey, p.74]]
[^75]: Original PDF page 75: [[W1 HNC Patient Journey.pdf#page=75|W1 HNC Patient Journey, p.75]]
[^76]: Original PDF page 76: [[W1 HNC Patient Journey.pdf#page=76|W1 HNC Patient Journey, p.76]]
[^77]: Original PDF page 77: [[W1 HNC Patient Journey.pdf#page=77|W1 HNC Patient Journey, p.77]]
[^78]: Original PDF page 78: [[W1 HNC Patient Journey.pdf#page=78|W1 HNC Patient Journey, p.78]]
[^79]: Original PDF page 79: [[W1 HNC Patient Journey.pdf#page=79|W1 HNC Patient Journey, p.79]]
[^80]: Original PDF page 80: [[W1 HNC Patient Journey.pdf#page=80|W1 HNC Patient Journey, p.80]]
[^81]: Original PDF page 81: [[W1 HNC Patient Journey.pdf#page=81|W1 HNC Patient Journey, p.81]]
[^82]: Original PDF page 82: [[W1 HNC Patient Journey.pdf#page=82|W1 HNC Patient Journey, p.82]]
[^83]: Original PDF page 83: [[W1 HNC Patient Journey.pdf#page=83|W1 HNC Patient Journey, p.83]]
[^84]: Original PDF page 84: [[W1 HNC Patient Journey.pdf#page=84|W1 HNC Patient Journey, p.84]]
[^85]: Original PDF page 85: [[W1 HNC Patient Journey.pdf#page=85|W1 HNC Patient Journey, p.85]]
[^86]: Original PDF page 86: [[W1 HNC Patient Journey.pdf#page=86|W1 HNC Patient Journey, p.86]]
[^87]: Original PDF page 87: [[W1 HNC Patient Journey.pdf#page=87|W1 HNC Patient Journey, p.87]]
[^88]: Original PDF page 88: [[W1 HNC Patient Journey.pdf#page=88|W1 HNC Patient Journey, p.88]]</footnotes>
</document>
